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ABSTRACT 
 
TIMOTHY P. SHEAHAN: SARS CORONAVIRUS PATHOGENESIS AND THERAPEUTIC 
TREATMENT DESIGN 
(Under the direction of Dr. Ralph S. Baric) 
 
 
Through the study of the viral pathogenesis, the mechanisms of disease can be elucidated 
providing specific targets for therapeutic intervention intended to prevent the development of disease.  We 
conducted four studies to gain a better understanding of SARS-CoV disease pathogenesis and therapeutic 
design.  We conducted two studies to investigate SARS-CoV evolution and adaptation to the human host. 
We have also investigated the importance of the innate immunity in protection from SARS-CoV disease.  
Lastly, we evaluated the protective efficacy of vaccination in senescent populations. 
 The prototypic civet SZ16 spike (S) gene was engineered into our epidemic strain infectious clone 
(icSARS) to create the recombinant icSZ16-S virus. A mutant of icSZ16-S (icSZ16-S K479N) was 
passaged on human airway epithelial cells (HAE) and resultant “evolved” viruses contained mutations in S 
that enhanced interactions with the receptor (hACE2) though adaptive mutations differed from those seen 
during the epidemic.  icSARS grew equally well in cells expressing the civet or human receptor while 
icSZ16-S only grew within civet expressing cells. Dual species tropism is retained by the epidemic strain 
suggesting it evolved through repeated passage between human and civet hosts.  
 Mice deficient in MyD88 (MyD88-/-), an adapter protein that mediates Toll-like receptor (TLR), 
IL-1R, and IL-18R signaling, are far more susceptible to mouse adapted SARS-CoV (rMA15) infection.  
Despite increased viral loads, the expression of multiple proinflammatory cytokines and chemokines within 
lung tissue was significantly reduced in MyD88-/- mice compared to wild-type mice suggesting that 
MyD88-mediated innate immune signaling and inflammatory cell recruitment to the lung are required for 
protection from lethal rMA15 infection.   
 We have developed a senescent BABL/c mouse model of SARS-CoV pathogenesis where 
infection with the mouse adapted SARS-CoV bearing a GD03 S glycoprotein (rMA15 GD03-S) mortality 
in senescent mice. We vaccinated senescent mice with Venezuelan equine encephalitis virus replicon 
 iii 
particles (VRP) expressing Urbani-S, GD03-S, SZ16-S, a pool of all three S expressing VRPs  or control 
VRPs in a prime/boost regimen.  After rMA15 GD03-S infection, all mice in the VRP HA and SZ16-S 
groups died while Urbani-S, GD03-S and Pool-S groups demonstrated 11, 29, 33% survival rates, 
respectively.  
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CHAPTER I 
INTRODUCTION 
 
 The Global Disease Burden and Pathogenesis of Respiratory Infections.  Fifteen million 
deaths each year are caused by infectious diseases throughout the globe(139).  According to annual 
statistics published by the World Health Organization (WHO) in 2002, respiratory infections were the 
leading cause of mortality by infectious disease causing almost 4 million deaths world wide with a 
disproportionate amount of disease in children and the elderly (Fig. 1) (139, 229).  Each year in the United 
States (U.S), respiratory tract infections cause over 500,000 hospitalizations and 4 million emergency 
department visits at an estimated combined annual cost of $14.6 billion(93). Viral respiratory tract 
infections (RTIs) caused by influenza A, respiratory syncytial virus (RSV), parainfluenza virus type 3 
(PIV3), human metapneumovirus (hMPV) and human coronaviruses (OC43 and 229E) account for a 
considerable amount of this disease burden. For example, seasonal influenza is estimated to cause 500,000 
deaths globally each year and 90% of influenza related deaths in the U.S. (~36,000/yr) occur in people over 
the age of 65(138, 202). While seasonal influenza is more damaging to elderly populations, RSV and PIV3 
cause a significant amount of disease burden in children in the U.S. each year resulting causing 7 million 
cumulative cases (RSV 4 million/yr, PIV3 3 million/yr) and almost 140,000 cumulative hospitalizations 
(RSV = 113,000/yr, PIV = 29,000/yr)(112).  In addition to the more common influenza, RSV and PIV 
RTIs, human coronaviruses cause approximately 10-15% of upper respiratory tract infections and hMPV 
causes 2-12% of all pediatric lower respiratory tract infections(97).  Due to their ease of dispersion by the 
aerosol route, respiratory viruses can cause both epidemic and pandemic disease in immunologically naïve 
human populations.  One of the most devastating infectious disease pandemics occurred during 1918-1920 
when a zoonotic H1N1 influenza virus emerged to infect humans causing 20-50 million deaths world-
wide(139). 1918 H1N1 was a newly emerging strain of influenza A and as a result, human populations did 
not have appropriate immune memory to adequately fight infection.  In turn, the emergence of this 
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extremely virulent and transmissible virus into a immunologically naïve population contributed to the 
generation of the devastating pandemic. Since the 1918 pandemic occurred in a time when mass 
transportation and global air travel were not as widespread like they are today, the future emergence of 
pandemic influenza might have even more disastrous consequences. The SARS-CoV epidemic in 2003 
provided us with a current example of the rapidity of the global spread of a novel respiratory virus in 
immunologically naïve human populations causing over 8000 cases (~10 % mortality rate) in 29 countries 
in 5 of the 7 continents(139).  Moreover, the SARS-CoV epidemic serves as a current model of the rapidity 
of virus spread facilitated by air travel, mass transit and increased population density of today.  
Unfortunately, effective and approved vaccines and therapies for humans do not yet exist to prevent SARS-
CoV, RSV, PIV and many other respiratory viral diseases. Though there is a vaccine for seasonal influenza, 
vaccine efficacy in humans varies with age and with antigenic identity between the vaccine and circulating 
strains(17, 18, 64, 83, 136).  Since it is difficult to predict the identity of future emerging respiratory 
diseases, it is important that  new vaccines or therapeutics have broad efficacy. Below, we review current 
models of SARS-CoV evolution, host range, and pathogenesis. We also review current models of SARS-
CoV vaccination and passive immunization therapy focusing on efficacy in the immune senescent, SARS-
CoV immunopotentiation, and efficacy against antigenically divergent strains.  
 Respiratory Virus Disease Pathogenesis.  Infectious viral agents cause a wide array of diseases 
including cancer, destruction of immune system, arthritis and pneumonia(139, 140).  Pathogenesis is 
defined as the factors that contribute to the development of disease. Virulence is defined by the capacity of 
a pathogen to produce disease where increasing virulence is most often results in increasing disease 
pathogenesis. The clinical presentation of viral disease is oftentimes the result of an unintended 
collaboration of direct viral effects on cell viability and function and host mediated immune pathogenesis 
where immune responses intended to eradicate invading pathogens also cause direct damage to the host.  
For example, the unchecked growth of pandemic influenza 1918 H1N1 in the lungs of immunologically 
naïve human population is thought to have instigated a massively dysregulated innate and adaptive immune 
response synergistically producing deadly disease(99). Through the study of the viral pathogenesis, the 
mechanisms of disease can be elucidated providing specific targets for therapeutic intervention intended to 
prevent the development of disease.  Many successful therapies have been developed from knowledge of 
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viral pathogenesis like oseltimavir  for influenza and the many antiretrovirals for HIV underscoring the 
importance and potential utility of viral pathogenesis research(117, 139). 
 A multitude of diseases can result from virus infection of the respiratory tract and the disease 
presentation of the infection can vary depending on the location of the infection.  For example, infection of 
the upper respiratory tract (URT) with rhinovirus, human coronavirus 229E or OC43 produces common 
cold symptoms (nasal congestion, sneezing, pharyngitis, rhinorrhoea etc.) with more severe disease 
associated with high fever seen in children(97).  In contrast, infection of the lower respiratory tract (LRT) 
with RSV, hMPV or influenza can cause bronchiolitis or pneumonia characterized by mild hypoxia 
(depressed blood oxygen saturation), tachypnea (increased respiratory rate), non-productive cough, and 
wheezing(97).  In studies of community acquired pneumonia (pneumonia acquired outside of the hospital 
setting), virus infection was detected in 10-46% of cases and influenza A was the most commonly 
identified (4-19% of viruses detected)(54).  Abnormalities in lung function and bilateral lung infiltrates 
visible on chest radiography are hallmarks of both viral pneumonia and conditions of more severe 
respiratory distress like acute lung injury (ALI) and acute respiratory distress syndrome (ARDS)(13, 97). In 
both pneumonia and ALI/ARDS, lung function is compromised by the inflammatory response which 
disrupts the alveolar-capillary units responsible for gas exchange(33, 97). Histopathologically, ALI is 
characterized by the formation of hyaline membranes, the loss of alveolar integrity resulting in their 
flooding with protein rich edema fluid, deactivation of surfactant by serum proteins and infiltration of 
alveolar space by inflammatory cells (macrophages, and neutrophils)(33). The degree of lung dysfunction 
and resultant depression in blood oxygen saturation allows for the differentiation between pneumonia (mild 
hypoxia), ALI (severe hypoxia) and ARDS (most severe hypoxia) where ALI/ARDS often requires 
mechanical ventilation and supplemental oxygen(33, 54, 97).  Unfortunately, the exact mechanisms 
underlying the development of ARDS have not yet been elucidated(13).  For the resolution of ALI, lung 
inflammation subsides while alveolar integrity is repaired, transcapillary water transport commences to 
remove fluid from the airway, and surfactant function is restored(33).  In some cases, resolution of ALI is 
incomplete and inflammation continues, pulmonary edema is unresolved and alveolar fibrosis ensues 
causing permanent abnormalities in lung function and a reduction in the quality of life(33).   
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 Coronavirus as Emerging Infectious Diseases.  Zoonoses are defined as diseases that are 
transmitted from domestic or wild animals to humans(236).  Many diseases of great human historical 
significance in the ancient and recent past like plague, smallpox, HIV, and influenza A emerged from wild 
or domestic animal populations to cause devastating human disease(4, 123, 143, 150, 209, 230, 236). In 
2002, a novel coronavirus (SARS-CoV) emerged suddenly as the causative agent of Severe and Acute 
Respiratory Syndrome (SARS) and spread worldwide causing about 8000 cases and >700 deaths(29, 103, 
173).  Coronavirus belong to the order Nidovirales and within the past four years, newly emerging viruses 
of human relevance have been identified within several genogroups of the coronavirus family. The newly 
identified NL63 and HKU1 (genogroup I) and SARS-CoV (genogroup II) are newly emerging or newly 
recognized coronavirus that cause respiratory disease in humans with SARS being the most pathogenic of 
any known human coronavirus (Figure 2, Table 1) (48, 103, 173, 213, 233, 235).  Coronavirus genogroups 
1, 2 and 3 also contain viruses that cause disease in animals of economic and agricultural importance like 
avian infectious bronchitis virus (IBV, group 3), transmissible gastroenteritis virus (TGEV, group 1) and 
porcine epidemic diarrheal virus (PEDV, group 1) and bovine coronavirus (BCoV, group 2b) (Figure 2) 
(188). The ubiquity and diversity of coronavirus in nature coupled with innate virological factors such as a 
promiscuous RNA polymerase and high recombination rates make the generation of diverse and new 
coronavirus a reality(42, 161, 162, 248). In fact, human coronavirus OC43 (HCoV-OC43) provides us with 
an additional example to SARS-CoV where a zoonotic pathogen evolved to infect and cause disease in 
humans.  Using a molecular clock approach, Vijgen et. al. suggest that BCov crossed the species barrier 
and evolved to infect humans in the late 1800s creating HCoV-OC43 (Table 1)(219).  BCoV has also 
jumped into other ruminant species where a newly recognized water buffalo associated coronavirus 
(BuCoV) is thought to have emerged from BCoV (Table 1)(39).  There is also evidence of the emergence 
of new coronavirus diseases resulting from evolution within the current natural host.  For example, porcine 
respiratory virus (PRCV) causes respiratory disease in pigs and is thought to have evolved from a virus that 
causes gastroenteritis (TGEV) in the same host (Table 1)(216).  Similarly, the gastroenteritis causing BCoV 
is thought to have mutated to become respiratory bovine coronavirus (RBCV) the causative agent of bovine 
shipping fever (Table 1)(74, 193).  Up to and including the present time, we have been consistently 
provided with examples of newly emerging or recognized coronavirus and their associated diseases.  Given 
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the trends of coronavirus emergence in the past, novel coronavirus emergence and/or discovery of novel 
coronavirus will most likely continue in the future. 
 Within live animal markets in China, a wide range of common and exotic food animals like bats 
and civets are sold live or as fresh meat for human consumption in part to improve health and sexual 
performance (28, 69, 236, 238). In Southern China, the consumption of exotic animals is especially 
prevalent during the winter months when most respiratory tract infections are highly prevalent(236). Since 
many zoonotic viral pathogens are shed in stool, densely housed birds and mammals shedding excreta in 
the wet marketplace creates an atmosphere for zoonotic virus transmission to human consumer 
populations(236).  Most recently, wet markets in Southeast Asian have been associated with cultivating the 
cross species transmission of avian influenza H5N1 and the newly emerged SARS-CoV(69, 108, 236).  
Viruses similar to the epidemic strain were isolated from civets for sale within wet markets in China during 
the epidemic in 2003 and the reemergence of 2004(28, 69).  Genome sequences of viruses isolated from 
bats, civets and humans suggest that viruses circulating in bats crossed the species barrier to infect civets 
who then served as an amplification host for yet another host range shift generating a human tropic 
virus(28, 69, 108, 122).  In 2007, surveys of wild Asian leopard cats and Chinese ferret badgers revealed 
the presence of yet more novel and highly divergent coronavirus circulating in animals typically sold in wet 
markets in China(44).  Since viruses similar to the epidemic strain of SARS-CoV are currently circulating 
in zoonotic pools, the future emergence of a SARS-CoV like virus may occur in the future.  Therefore, it is 
imperative that we understand the pathogenic mechanisms of coronavirus lung diseases and that current 
vaccination and passive sero therapies be effective in protecting humans from infection by zoonotic SARS-
CoV.  Unfortunately, bat-SARS-CoV and the prototypic civet SARS-CoV strain, SZ16, have not yet been 
cultured in vitro hampering our ability to evaluate their epidemic potential and pathogenesis and their 
susceptibility to current therapeutic interventions. 
 SARS-CoV Virion and Genome Organization.  Viruses within the family Coronaviridae have 
the largest RNA genomes of any virus known today(51).  SARS-CoV is an enveloped RNA virus with a 
29,727 base pair message sense RNA genome that is tightly associated with the viral nucleocapsid 
protein(103, 173).  The SARS-CoV genome is organized in the classic coronavirus gene order of replicase, 
spike (S), envelope (E), membrane (M), and nucleocapsid (N) (listed in the 5’ to 3’ order) (Figure 3)(173). 
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Like other coronavirus, SARS-CoV has several virus specific open reading frames (ORFs) interspersed 
between the structural proteins in the 3’ end of the genome (Figure 3)(173).  The genomic 
RNA/nucleocapsid complex is contained within the viral envelope acquired by budding into the 
endoplasmic reticulum/golgi intermediate compartment (ERGIC)(35).  At least five SARS-CoV structural 
proteins (S, E, M, 3a and 7a ) are contained within the lipid belayed of the viral envelope (Figure 3)(154, 
173, 181).  When viewed by electron microscopy, the SARS-CoV virion is pleomorphic in shape with the 
club like protrusions of the spike protein emanating from the envelope giving the virion the classic crown 
appearance that contributed to the naming of the virus family (corona = latin for “crown”)(103). 
 SARS Spike Glycoprotein as Critical Component of Species Specificity, Pathogenesis and 
Protective Immunity.  Like gp160 of HIV, hemagglutinin of  influenza, and glycoprotein of Ebola virus, 
the spike (S) glycoprotein protein of coronavirus is a class I viral fusion protein that mediates virus binding 
and fusion allowing the virus to enter the host cell(240). Like other class I fusion proteins, the SARS S 
glycoprotein contains two functional domains, S1 and S2, joined by a protease cleavage site(240). The S1 
domain (17-756aa) contains the receptor binding domain (RBD) (318-510aa) while the S2 region (757-
1225aa) contains the two heptad repeat (HR) regions that facilitate viral fusion and a transmembrane 
domain (1189-1227aa) that anchors spike to the viral envelope(Figure 4)(239). SARS-CoV is thought to 
gain entry into cells by the following sequence of events: binding to the cellular receptor ACE2, entry into 
the cell by endocytosis, and cleavage of the SARS-CoV S by cellular protease cathepsin-L causing a 
rearrangement of S1 and S2 subunits instigating viral and host membrane fusion depositing the viral 
genome/nucleocapsid complex into the cytoplasm where replication ensues (Figure 5C) (118, 120, 121, 
184).  
 The coronavirus S glycoprotein is a critical component of species specificity which is also primary 
determinant of pathogenesis since a virus incapable of infection will most likely not cause disease (Figure 
5A).  Using reverse genetics, the substitution of the mouse hepatitis virus (MHV) S protein with the feline 
infectious peritonitis virus (FIPV) S protein alone was sufficient for the murine tropic virus to infect feline 
cells(107). In less extreme examples, host range of coronavirus can be modulated by few point mutations 
within the S glycoprotein which either focus within the RBD or in the fusogenic domain(34, 121, 137).  
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 Though previous coronavirus dogma suggests that host range expansion is mediated by S1 region 
mutation, McRoy et al recently reported host range expansion of MHV can also be mediated by amino acid 
changes in the  S2 region fusion machinery(137).  A prime and pertinent example of a coronavirus host 
range shift due to mutations in the S1 region was seen during the evolution of the SARS-CoV epidemic 
strain, SARS Urbani. The SARS-CoV spike gene (S) sequences isolated from human cases during the early 
phase of the epidemic in 2002-2003 and during the reemergence of 2003-2004 are very similar to the SZ16 
strain (Figure 6) (28, 69, 94). SZ16 was isolated from palm civets in live animal markets within the 
Guangdong region of China during the epidemic and its S protein differs from the epidemic strain, SARS 
Urbani, in 18 amino acids 16 of which reside in the S1 domain containing the RBD (Figure 6)(69). The 
crystal structure of the SARS-CoV RBD bound to the receptor ACE2 and biochemical experimentation 
have demonstrated critical amino acids (K479, T487) in the RBD of the civet SZ16 S inhibited its binding 
to the human ACE2 receptor (hACE2) thus providing a block in host range expansion and human 
pathogenesis (Figure 6) (119, 121). Using retrovirus pseudotyped with mutant or wild type versions of the 
zoonotic (SZ16) or epidemic strain (Urbani) S glycoprotein, Li et. al. demonstrated that K479 and T487 
were critical residues inhibiting the binding of the civet spike to the human ACE2 receptor(122).  
Unfortunately, the pseudotype system is able to assess the efficiency of binding and entry but not virus 
growth kinetics.   Using recombinant SARS-CoV bearing various zoonotic, intermediate and epidemic S 
glycoproteins in single step growth curve, data regarding binding, entry and growth can be elucidated 
(Figure 5B).  Moreover, infection of cells expressing the civet (cACE2) or human versions (hACE2) of the 
SARS-CoV receptor with recombinant SARS-CoV S glycoprotein variants allows for the investigation of 
growth fitness and receptor usage in both the amplification and epidemic host.  By assessing SARS S 
glycoprotein variant growth in cACE2 or hACE2 cell cultures, we deduced that the epidemic strain had 
retained growth fitness in cACE2 and hACE2 expressing cell cultures.   
 These data suggest that the epidemic strain evolved through repeated transmission from civet to 
human or human to civet.  An alternative hypothesis is that civets repeatedly transmitted SARS-CoV like 
viruses to humans but virus, host and environmental conditions were not ripe for human to human spread.  
But at some point in time, a single introduction of a civet virus variant into the human population resulted 
in virus spread and evolution in humans while coincidently retaining growth fitness in the civet host.  
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Though it is difficult to prove that either one of these SARS-CoV evolutionary hypotheses is correct, both 
are supported by serological data of wet market workers, hospital workers and healthy clinic volunteers 
where SARS specific IgG was detected in 13%, 2.9% and 1.2%, respectively(2).   It is important to note 
that the wet market workers, hospital workers and healthy volunteers that tested positive for SARS IgG did 
not present with SARS-CoV symptoms and if these populations are representative of the population in 
Guangdong (est. population 100 million), there were more than a million SARS-CoV cases in China that 
were not reported(2).  Nevertheless, the molecular epidemiology, biochemical and serological data suggest 
that within wet markets in China, the interaction of infected civets and workers within the market 
ultimately gave rise to a SARS-CoV that could spread between humans thus beginning the early phases of 
the epidemic(2, 28, 119).  Moreover, clinical and virological data isolated throughout the early, middle and 
late phases of the epidemic suggest that as the S glycoprotein adapted to the human host, the pathogenicity 
of the virus in humans increased (Figure 5)(2, 28, 69, 94, 121). Also, much of the variation seen in the S 
glycoprotein occurs within or in close proximity to the three known neutralizing epitopes suggesting that 
the adaptive immune response in humans played a role in driving SARS-CoV S evolution (Figure X)(171).  
These data suggest that virus host expansion, degree of pathogenicity and antigenicity/protective immunity 
can in part be mediated by the coronavirus S glycoprotein. 
 The SARS-CoV Receptor, Angiotensin I Converting Enzyme 2 (ACE2), in Virus Entry and 
Pathogenesis.  Virus entry into a cell through the interactions between viral attachment proteins, cellular 
receptors and/or co-receptors is required for successful virus infection. Cellular proteins required for virus 
binding, entry, replication, assembly and egress oftentimes have diverse cellular functions as well(22, 80).  
The cellular receptor for SARS-CoV infection, angiotensin I converting enzyme 2 (ACE2), serves as a 
prime example of a cellular protein strictly required for the virus to gain entry into the host cell while also 
serving an important function in host physiology and perhaps viral pathogenesis and disease.   
 ACE2 and angiotensin I converting enzyme (ACE) are key regulators of the rennin-angiotensin 
system (RAS), which helps control cardiovascular function by maintaining the body’s blood pressure and 
electrolyte balance(105, 145).  ACE and ACE2 are metalloproteases with differing vasoactive peptide 
substrate specificities and as a result have disparate and antagonistic roles in maintaining physiologic 
homeostasis (Figure 7A)(105).  ACE cleaves the peptide ANG I into ANG II which has vasoconstrictive 
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effects inducing hypertension while also inducing cell proliferation and fibrosis(105, 210).  In contrast, 
ACE2 processes ANG I into ANG 1-9 and further processes ANG II into the peptide ANG 1-7 which acts 
as a vasodilator while also being anti-proliferative and apoptotic(47, 105, 203, 218). Current in vitro data 
suggests that ANG II ligation and signaling through angiotensin receptor 1a (AT1aR) can result in the 
production of proimflammatory cytokines (TNFα, IL-1β, IL-6, MCP-1 etc.), fibrosis, and cell 
proliferation(135).  In vivo models of liver fibrosis or ALI support the above in vitro data suggesting that 
ANG II exacerbates pathology and this pathology is ameliorated by ACE2 related signals.  In an acid 
aspiration model of ALI/ARDS, Imai et. al. demonstrated that ACE2 protected mice from injury while 
ACE, ANG II and AT1aR promoted disease pathology(89).  Similarly, Herath et. al, demonstrated that 
ACE2 and ANG 1-7 counteracted the detrimental effects of ANG II in liver disease in rats(81).  These data 
suggest a duality of RAS contributing to both homeostasis and immumopathology. 
 Within a year of discovering SARS-CoV, ACE2 was identified as the chief virus receptor utilized 
to gain entry into the host cell though other attachment factors have also been proposed(90, 120).  A second 
human coronavirus, NL63, also uses ACE2 as a receptor for docking and entry(161).  Isolation and 
expression of ACE2 molecules from various species such as mouse, civet and human in vitro have also 
helped elucidate important facets of epidemic and zoonotic SARS-CoV S and ACE2 interactions, virus host 
range expansion and the evolution of the epidemic strain(121).  Perhaps the most interesting facet to the 
SARS-CoV and ACE2 relationship resides in the effect of virus infection on the local pulmonary disruption 
of RAS homeostasis.  Within a mouse model of acute lung injury (ALI), Kuba et al demonstrated that 
SARS-CoV infection or the administration of SARS S alone depressed levels of ACE2 within the 
lung(104). Furthermore, the administration of SARS S recombinant protein exacerbated ALI induced by 
acid aspiration(104).  It was proposed that SARS-CoV or SARS S decreased levels of ACE2 within the 
lung thereby removing a key regulator and processor of the proinflammatory ANG II peptide whose excess 
contributed to more severe disease (Figure 7B) (104).  These data provide an interesting insight into 
possible RAS involvement in SARS-CoV pathogenesis and the progression of ALI to acute respiratory 
distress syndrome (ARDS) seen in more severe cases of SARS-CoV. 
 Transmission, Clinical Course and Immune Response to SARS-CoV Infection of Humans.  
The intrinsic transmissibility of an infectious agent in a susceptible population can be mathematically 
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defined as R0 which represents the average number of new infections caused by an index case during their 
entire infectious period(45, 56).  If R0 is greater than 1, an infectious outbreak has the potential to establish 
an epidemic unless public health interventions are instituted that diminish R0(45, 56).  The estimates of R0 
during the global epidemic (R0 = 0.77-7.7) of SARS-CoV vary widely over time since public health 
interventions were absent during the beginning of the epidemic and applied with success as the epidemic 
slowed(45, 127, 221).  As compared to other highly infectious respiratory disease like measles (R0 = 7-45) 
and pandemic Influenza (1978 H1N1 R0 < 21), SARS-CoV is considered moderately transmissible(45, 56).  
SARS-CoV is thought to be transmitted by direct patient contact, airborne droplet nuclei, contact with 
fomites or urine/fecal contact with mucous membranes(152, 153).  The time between exposure and onset of 
symptoms is approximately 6 days after which patients enter the acute febrile phase of SARS-CoV 
infection.  The hallmark of the acute phase of infection is fever (>100 F˚) coupled with chills, malaise and 
myalgia(19, 124, 152).  During the acute phase of the infection patients develop a non-productive 
cough/shortness of breath (dyspnea) and bilateral pulmonary infiltrates are seen by chest radiography. 
Pulmonary lesions visible by radiography continue to worsen until 7 days after the onset of symptoms 
(AOS) after which most patients begin to improve.  Approximately 30% of patients show clinical 
improvement after the first week of illness while the remaining 70% present with recurring fever and 
shortness of breath(152, 153).  A case study of health care workers in Toronto (N = 14, age mean = 42yrs, 
age range 27-63yrs) provides a typical example of the course of SARS-CoV convalescence where a week 
after hospital discharge, all patients complained of dyspnea, weakness, lethargy and all suffered from 
significant weight loss (anorexia) from SARS-CoV disease(11).  Three weeks after discharge, the Toronto 
healthcare worker cohort were no longer weak and continued to gain weight but still suffered from dyspnea 
(14/14 patients) and a few still presented with an abnormal chest x-ray (5/14 patients)(11).  A case study in 
Hong Kong provides a detailed example of a non-convalescent cohort where lung damage continues to 
progress in a minority (20-30%) of patients where “diffuse ground glass” changes are seen in the chest X-
ray typical of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) (152).   ALI can 
progress to ARDS, which is characterized primarily by  an acute onset, bilateral infiltrates on chest 
radiograph, hypoxemia, fever and leukopenia(13).  Approximately 20% of SARS patients required 
intensive care unit (ICU) treatment due to ARDS symptoms and a majority of those admitted to the ICU 
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require mechanical ventilation and oxygen support(19, 152).  Though overall mortality rates of the global 
SARS-CoV epidemic approached 8%, the mortality rates for patients over the age of 65 ranged from 
approximately 25-55% as a result of comorbidities and immune senescence(19, 116, 124, 152).   
 Chest x-ray, serology and virological data suggest direct involvement of the adaptive immune 
response in viral clearance.  A detailed virological/immunological longitudinal analysis was performed on a 
cohort of SARS patients in Hong Kong(152).  Five days AOS, nasopharyngeal aspirates contained between 
3 and 7 log10 genomes/ml of SARS-CoV and by day 10 the range tightened to 5-7 log10 genomes/ml.  In 
most patients SARS-CoV specific IgG seroconversion begins near day 10 AOS (mean = 20 days AOS) 
after which virus titers begin to fall. Interestingly, 40% of the cohort (n=75) did not seroconvert until 24 
days AOS but 93% had serconverted by day 29 AOS.  Even after seroconversion viral genomes were 
detected in nasopharyngeal aspirate (47%), stool (67%) and urine (21%) as far as 21 days AOS.  Of note, 
many patients in the Hong Kong cohort were treated with corticosteroids and these drugs may have delayed 
the onset of seroconversion. In an animal model of coronavirus lung infection (PRCV) with similar 
pathologies to SARS-CoV, the administration of corticosteroids alleviated signs of PRCV pneumonia early 
(2 dpi) though exacerbated later stages of disease (4, 10, 21 dpi) probably due to the lack of a cell mediated 
response that created an environment for extended virus lung replication(92).  In another Hong Kong SARS 
cohort, seroconversion was detected as early as 4 days AOS with a median seroconversion occurring at 15 
days AOS(113). Nevertheless, these data suggest that as the adaptive immune response mounts, viral load 
is depressed paving the way for convalescence.   
 The primary target organs and cells of SARS-CoV infection of humans remains controversial.  
Several thorough pathological studies of post mortem tissues from SARS-CoV infection have identified the 
ciliated epithelial cells within the lung as the primary target of virus infection though virus antigen has also 
been found in macrophages (Mø), dendritic cells (DCs), T cells, B cells, NK cells, and putative lung 
stem/progenitor CD34+Oct-4+ cells (26, 68, 88, 144, 206, 245). Unfortunately, the in situ hybridization 
utilized in these pathological studies was unable to differentiate between active viral infection and uptake 
of virus by passive cellular means like phagocytosis.  Several in vitro studies have demonstrated that 
human Mø and DCs were unable to support active virus replication in vitro and instead instigated cell 
activation leading to upregulation of MHC II and secretion of inflammatory cytokines(27, 111, 207).  In 
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support of gross lung pathology seen by x-ray, microscopic evaluation of SARS-CoV lung pathology has 
repeatedly been described in various cohorts as showing various phases of exudative and proliferative acute 
lung injury (ALI)(68, 88, 144, 206).  Typical SARS-CoV lung pathology is characterized by inflammatory 
cell infiltration, pulmonary edema, hyaline membrane formation, mild to moderate fibrosis, alveolar 
epithelial hyperplasia, and alveolar/epithelial cell desquamination (i.e. sloughing)(68, 88, 206).   
 The Role of the Innate Immune Response in the Pathogenesis of SARS-CoV infection of 
Humans, Non-Human Primates and Rodents.  The innate immune response is thought to provide the 
first line of host defense against invading pathogens.  Specialized membrane bound or cytosolic pathogen 
recognition receptors (PRRs) such as Toll-Like Receptors (TLRs), RIG-I/Mda5, and Nod-like receptors 
(NLRs) sense pathogen-associated molecular patterns (PAMPs) and initialize the innate immune 
inflammatory response by activating the transcription of various proinflammatory genes (Figure 8)(147, 
175).  These PRRs are very specific in their pathogen component recognition (e.g. double stranded RNA, 
CpG DNA, LPS etc.) and the type of immune response generated as a result of activation(147, 175).  TLRs, 
NODs, RIG-I and Mda5 have been shown to be expressed within lung epithelial cells as well as in the more 
“professional” environmental sensing cells like conventional/plasmacytoid dendritic cells (cDCs/pDCs) and 
macrophages (Mø)(25, 96, 134, 211).   
 Important insights into the mechanisms of the innate inflammatory response of SARS-CoV 
infection has been gleaned from several clinical, in vitro and in vivo animal model studies yet a clear and 
concise model of this innate response and its relation to viral pathogenesis remains to be elucidated. 
Inconsistencies in experimental protocol, clinical treatment, cell type infected in vitro, and possible species 
specific effects within various animal models have created a confusing and complicated body of data 
making the generation of a comprehensive model of SARS-CoV pathogenesis difficult.  Nevertheless, 
concordant data between experimental systems has provided the coronavirus field with a great body of 
useful information and those data are summarized below. 
 A thorough evaluation of inflammatory gene expression in SARS-CoV patient peripheral blood 
mononuclear cell (PBMC) was performed by both Cameron et al and Regunathan et al. but described 
disparate conclusions.  Cameron et al concluded that a robust type I INF response was observed early in the 
progression of disease and was predicted to be essential for viral clearance and convalescence(21). In 
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addition to a strong INF response, genes typically induced by INF like CCL2 (MCP-1) and CXCL10 (IP-
10) were also upregulated in patients at early times during SARS-CoV disease(21).  Interestingly, Cameron 
and collaborators present data that suggests that the cytokine storm that serves to protect convalescent 
SARS-CoV patients can progress in an unchecked manner in severe cases contributing more severe disease 
and to the development of an inadequate adaptive immune response(21).  Reghunathan and collaborators 
also sampled SARS patient PBMCs for microarray analysis but did not find type I INF induced in their 
samples and instead found upregulation of several other tissue inflammation/remodeling, homeostasis and 
cell cycle genes(166).  Compounding the fact that Reghunathan did not discuss virological data and failed 
to mention when over the course of SARS-CoV disease these samples were extracted, the sample size (n = 
10) was small in comparison to the Cameron et al cohort (n = 50)(21, 166).  Of note, many cohorts of 
SARS patients, including the Cameron cohort discussed above, were treated with immunosuppressive 
corticosteroids making the resulting immunological and virological data more difficult to interpret and 
evaluate(192). 
 Since human clinical SARS data is complicated by host genetic variation, disease exacerbating 
comorbidities, age variation, and variable drug treatment regimens, animal models provide a more 
homogenous and controlled environment within which to ask questions related to the involvement of the 
host innate response to SARS-CoV infection.  In non-human primate (NHP, cynmolgous macaque) 
infection with SARS-CoV, Haagmans et al demonstrated the prophylactic administration of pegylated 
INFα controlled virus replication and lessened disease pathology(70).  Concordantly, transcriptional 
profiles of NHP infected lung tissue suggest that INFα, β, λ, γ and also IP-10, MCP-1, IL-6 and IL-8 genes 
were all upregulated in SARS-CoV infected NHPs(36). Since NHPs do not succumb to infection, it is 
proposed that the inflammatory response to virus infection described above aids in the control and 
clearance of this acute infection. 
 The development of mouse models that recapitulate components of human disease have been 
invaluable in viral pathogenesis research.  BALB/c and C57BL/6 strains of mice support virus SARS-CoV 
replication in the lung and experience lung pathologies similar to those seen in human cases of SARS(169, 
172).  Glass et al demonstrated SARS-CoV was cleared with similar kinetics in WT C57BL/6 mice or 
strains that lacked that T, B and NK cells suggesting that the innate immune response alone is sufficient for 
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viral clearance(62).  Like gene expression data from human samples, MCP-1, MIP1-α, and IP-10 are all 
upregulated in the lung during SARS-CoV infection of C57BL/6 mice suggesting a role for these 
chemokines in protection(62).  In support of Glass et al, Hogan et al demonstrated that  STAT1, a key 
modulator INF α/β, λ, γ signaling, was required for the resolution of SARS infection, once again 
implicating the importance of the innate response in the clearance of SARS-CoV(84).  The induction of 
INF in mice seems to be dependent on mouse strain where BALB/c mice induce type I INF following 
SARS-CoV infection as measured by microarray (Rockx et al manuscript in preparation) and ELISA while 
the induction of INF is undetectable in C57BL/6 mice(Sheahan et al published data)(168).  These 
immunologic and pathologic discrepancies between mouse strains are unfortunate caveats of animal models 
of viral disease. Moreover, no animal model of SARS-CoV pathogenesis to date has fully recapitulated 
both the acute and extended immunopathological aspects SARS-CoV disease.  Nevertheless, mouse models 
of SARS-CoV pathogenesis faithfully recapitulate many aspects of acute human disease like virus 
replication, the induction of inflammatory cytokines, migration of immune cells into pulmonary tissues, 
virus and immune cell mediated lung pathology, and weight loss. Also, unlike human and NHP in vivo 
models, transgenic “knock out” mice provide the opportunity to  evaluate the role of single genes in viral 
pathogenesis. 
 Perhaps the most simplified models within which to study SARS-CoV pathogenesis are in vitro 
models.  Though in vitro models are less complicated than in vivo models, the resultant data and relevance 
to SARS-CoV pathogenesis is hotly debated.  There is a seeming incongruity between in vivo human, 
primate and mouse data where the induction of INF is observed while the in vitro infection of various 
primary or immortalized interferon competent cell types fail to induce or produce INF. These in vitro 
experiments are further complicated by the notion that several viral genes have been implicated as active 
INF antagonists(57, 100, 257).  The in vitro data regarding SARS-CoV innate immune activation is 
reviewed below. 
 The infection of interferon competent primary human airway epithelial cells (HAE) with SARS-
CoV does not result in the induction or secretion of INF but does result in the secretion of inflammatory 
chemokines IL-6, MCP-1 and IP-10 (Sims unpublished data)(57).  Pathological evaluation of lung tissue 
from lethal SARS-CoV and in vitro data suggests that airway epithelial cells are the primary target for 
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SARS-CoV infection yet do not induce INF in vitro(185, 206, 245).  In NHP studies by Haagmans and 
colleagues, it was demonstrated that epithelial cells adjacent to infected epithelial cells stained positive for 
INFβ suggesting a possible bystander activation effect.  It may be that viral INF antagonists suppress the 
antiviral sensing network in the infected cell but eventually neighboring cells are activated through the 
sensing of viral proteins or genomic RNA released into the extracellular milleu as a result of viral induced 
cell lysis. 
 Several studies focusing on infection of professional antigen presenting cells like dendritic cells 
and macrophages have also produced controversial data.  Most studies utilize human PBMC derived 
macrophages or DCs where CD14+ cells are isolated and differentiated in the presence of cytokines (Mø = 
GM-CSF, DC = IL-4, GM-CSF) in vitro after which the cell populations resemble “macrophages” and 
“dendritic cells” by cell surface staining profiles(27, 57, 111).  When SARS-CoV is added to these Mø and 
DC populations, a productive infection does not ensue, INF is not induced but several other inflammatory 
cytokines are induced and secreted (MIP1-α, IP-10, MCP-1)(27, 57, 111).  A possible explanation for the 
disparity between the in vitro and in vivo data regarding INF induction in SARS-CoV infection is presented 
by Cervantes-Barragan and colleagues where they show key differences in conventional (cDC) and 
plasmacytoid dendritic cell (pDC) populations in response to SARS-CoV infection(25).  pDCs differ from 
cDCs in their surface characteristics (cDC = CD11c+, B220-, pDC = B220+, CD11c-low, PDCA-1+) and 
function where pDCs are the major source of INFα in both humans and mice(10, 23, 25, 183).  Unlike most 
investigators who artificially differentiate Mø and DC from CD14+ precursor cells isolated from PBMCs, 
Cervantes-Barragan and colleagues isolated cDC and pDC populations directly from human blood and 
were subsequently incubated with SARS-CoV and demonstrated that unlike cDC, pDC induced INFβ 
transcription and produced large amounts of INFα protein in the cell media(25).  In the assessment of both 
pDC and cDC populations side by side, Cervantes-Barragan provide a possible explanation as to why 
previous studies of SARS-CoV infection of dendritic cells failed to induce INF especially since the 
differentiation protocol used by Law, Tseng, and Cheung result in the differentiation of a more cDC like 
cell(25, 27, 111, 207).  Cervantes-Barragan also utilized in vitro differentiated mouse cDC and pDC that 
were used in mouse hepatitis virus experiments (MHV).  Interestingly, the cytokine used by Cervantes-
Barragan to generate cDC (GM-CSF only) from CD14+ cells was used by other investigators to create Mø 
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though the generation of the pDC using Flt3-L was not employed by either Law, Tseng or Cheung(25, 27, 
111, 207).  Though the work of Cervantes-Barragan helps clarify some of the discrepancies seen in studies 
the innate immune response to SARS-CoV, the body of work is deficient in demonstrating the generation 
of infectious virus through infection of cDC’s or suggesting a mechanism of SARS-CoV binding and entry 
since ACE2 expression in cDC’s was not addressed(25, 27, 111, 207).  Nevertheless, it will be interesting 
to see if future mouse/NHP studies definitively demonstrate a role for pDC’s in SARS-CoV pathogenesis. 
 The Effects of Immunosenescence in Innate and Acquired Immunity.  The general 
deterioration of the immune system regarded as “immunosenescence” is found in both short and long lived 
species and this phenomena occurs as a function of age relative to life expectancy rather than chronological 
time(61).  Describing the complex process of immunosenescence as a simple deterioration is not 
completely accurate as certain processes decline, others remain static and some are even enhanced with 
age(55, 61). Though the memory immune response may be unperturbed in the aged, the ability to mount 
effective primary immune responses to new antigens declines with age(61).  The inability to mount 
effective primary immune responses in the aged may affect susceptibility to infectious disease by new 
pathogens and vaccine efficacy may be limited. The potential deficiencies of the immunosenescent innate 
and adaptive immune system that may enhance viral pathogenesis are reviewed below. 
 Immunosenescence in Innate Immunity.  In the context of virus infection or vaccination, the 
innate immune system plays an integral role in the generation of the initial inflammatory response thought 
to be essential for the generation of an adaptive immune response of appropriate quality, quantity and 
longevity(160).  Macrophages (Mø), neutrophils (Nø), and dendritic cells (DCs) are phagocytic cells that 
drive the innate immune response providing both effector functions that mediate pathogen clearance and 
antigen (Ag) presentation that begins the adaptive immune response(176).  Ag acquisition and recognition 
by phagocytes is thought to be the first step in the innate immune activation cascade.  Residing on the cell 
membranes and within the cytosol are specialized receptors called pathogen recognition receptors (PRRs) 
that recognize molecular signatures of invading pathogens and signal to begin the inflammatory 
response(147, 175). In vitro and in vivo murine studies of Mø and DC activation and cytokine secretion 
have produced conflicting results where levels of PRR expression and activation are similar in young and 
aged animals but the magnitude of cytokine secretion in aged mice is reported as both similar and 
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dissimilar as compared to young mice(7).  Similarly conflicting results have been reported in the 
examination of PRR gene expression and cytokine secretion in monocyte derived DCs from young and 
aged human donors.  Some studies suggest a functional equivalency in both PRR gene expression and 
cytokine secretion in young and aged DCs while others report discrepancies in cytokine secretion in 
response to PRR stimulation in the aged with decreased IL-12 but increased IL-6 and TNF-α(6, 7, 40).  
Basal levels of the Mø recruiting IL-8 are depressed in the elderly but LPS stimulation of senescent Mø 
results in increased induction of IL-8 as compared to young controls and may contribute to increased 
pulmonary inflammation seen in the elderly(31).  Recent studies suggest a decline in the phagocytic and 
pinocytic abilities of DC and Mø impairing antigen capture and sensing which affects the induction of the 
inflammatory response and the activation of the adaptive immune response(6).  Also, several studies 
suggest that DC migration to lymph nodes is impaired in the aged hampering efficient adaptive immune 
activation(6, 32, 126).  Lastly, non-phagocytic innate natural killer cells (NK) migration and cytotoxic 
capabilities to not seem to be hampered with ageing(102). Taken together, current data suggests that 
multiple levels of the innate immune system may be compromised in the immunosenescent.  Deficiencies 
or delay in APC pathogen sensing could allow for unchecked replication of invading pathogens which may 
contribute to more severe disease. Moreover, since APC and T cell interaction drives the adaptive immune 
response, APC dysfunction could affect the kinetics and quality of the cell mediated immune response 
contributing to more severe disease. 
 Immunosenescence in Adaptive Immunity.  Like the innate immune compartment, the adaptive 
immune compartment experiences various functional deficiencies with ageing.  In general, primary 
adaptive immune responses are generated by the presentation of antigen by antigen presenting cells (APCs) 
on MHC class II to the cognate T cell receptor (TCR, CD3) on naive CD4+ helper cells (Th)(129).  For 
efficient Th cell activation, a second costimulatory signal between APC surface molecules (CD40, CD80, 
CD86) and CD28 on the T cell must occur(212). Depending on the antigen and mechanism of APC 
activation, a third signal (Th1 = IL-12, Th2 IL-4, IL-12) then triggers differentiation into either Th1 or Th2 
cells which each have unique helper functions(129).  In response to intracellular pathogens, Th1 cells 
produce IL-2, IL-12, IL-15 and INFγ to mediate activation of cognate cytotoxic CD8 T cells and the 
generation of IgG2a antibody(61, 160).  In response to extracellular pathogens like helminthes, Th2 cells 
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produce IL-4, IL-5, and IL-10 and promote a B cell mediated response inducing IgG1, IgE and IgA(61, 
160).  With ageing, there is a general and preferential shift from a Th1 to a Th2 type of immune response 
with an associated decrease in INFγ and increase in IL-4 production(61). Due to Th1 to Th2 skewing with 
age, elderly individuals may have a more difficult time generating a Th1 response that is necessary to 
combat viral infection contributing to the development of severe viral disease. 
 The T cell compartment plays a pivotal role in the development of the cell mediated response to an 
invading pathogen while also driving the development of immune memory for future protection from 
similar pathogens(129).  While the relative percentage of T cell subsets remains static over time, the 
absolute numbers of T cells decrease with age(61).  Due to thymic involution, the numbers of naive T cells 
in circulation decrease while the memory pool increases in size hampering immune responses to novel 
antigens(67).  Besides decreasing in frequency with immunosenescence, naïve T cells in aged individuals 
secrete lower amounts of IL-2 as compared to young cells after Ag stimulation by APCs.  Decreased IL-2 
output from newly activated Th cells results in diminished clonal expansion and reduced activation 
suggesting that Th effector cell differentiation is incomplete(77).  Interestingly, Haynes et. al. have 
demonstrated that these defects in Th expansion and activation can be overcome in vitro when exogenous 
IL-2 is provided(76).  Reduced activation of senescent Th cells has been shown to dramatically alter 
cognate helper function hampering B cell expansion and differentiation thereby reducing IgG 
production(50).  The reduction in B cell activation by Th cells was not due to age related effects on Th cell 
migration and Eaton et. al suggest a reduction in the expression of CD154 (CD40L), the ligand for the B 
cell CD40 molecule, causes a reduction B cell proliferation and antibody production(50).   
 The CTL response is thought to be important for the clearance of intracellular viral pathogens and 
unfortunately both primary and memory CTL responses are affected by immunosenescence(77).  Repeated 
challenge of the immune system through persistent viral infection with CMV can result in more than 10% 
of their CTLs targeted against a single CMV epitope(215).  CTL  activation in the immunosenescent is also 
affected through the loss of CD28 expression (CD28null) which is necessary for efficient T cell activation.  
In people over the age of 50 or 65, up to 70% and 95% of CD8 T cells are CD28null, respectively(212).  
With a significant portion of CTLs exhibiting a CD28null phenotype and a certain percentage targeted to 
chronic viral antigen, the CTL compartment in the immunosenescent is compromised and may affect the 
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pathogenesis of intracellular pathogens. Since CTLs have been implicated in clearance of influenza and 
West Nile virus infection, defects in the CTL compartment may contribute to the more severe disease seen 
in the elderly(1, 15, 142, 182). 
 Vaccination and Passive Immunization to Protect Against SARS-CoV Disease.  It is clear that 
vaccination and passive immunization technologies are among the most important public health 
interventions in the past 200 years contributing to the complete eradication of small pox(132, 157).  
Though vaccination campaigns have eradicated polio and measles in developed nations, those diseases and 
other vaccine preventable diseases continue to plague developing nations(226-228).  Rapidly and newly 
emerging infectious diseases like SARS-CoV provide unpredictable scenarios for the of field vaccinology 
where diseases never before seen in human populations arise and spread rapidly while reagents necessary 
for vaccine development do not yet exist.  As seen with SARS-CoV epidemic, isolation of the virus 
allowed for the rapid generation of “killed”, DNA and viral vectored vaccines within a year of the start of 
the epidemic(196, 199).  Like vaccination, the practice of passive immunization to prevent infection or 
curtail established disease was first shown by Robert Koch in the late 1800s where he demonstrated that 
sheep antisera against diptheria toxin could protect against death in humans(132).  More recently, 
technologies like phage display and memory B cell immortalization have been developed to produce 
sufficient quantities of human monoclonal antibodies (hu-mABs) directed against specific viral 
antigens(132).  These technologies allowed for the rapid development of neutralizing hu-mABs directed 
against SARS-CoV within a year of the beginning of the epidemic(196).  We will discuss the problems 
associated with SARS-CoV vaccination and passive immunization therapies which fall into three categories 
that include a) SARS-CoV antigenic variation and therapy efficacy b) the complications of 
immunosenescence  and SARS-CoV vaccine efficacy c) SARS-CoV vaccine immunopotentiation of lung 
pathology. 
 SARS-CoV antigenic variation and therapy efficacy.  The body of work attributed to SARS-
CoV vaccine development is astounding though many studies are limited to assessment of the immune 
response and fail to evaluate the vaccine platform of interest through the more powerful and pertinent 
SARS-CoV virus challenge(12, 91, 128, 251).  Inactivated whole virus and vectored SARS-CoV vaccine 
trials in a number of different animals models have demonstrated that the SARS-CoV spike glycoprotein 
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(S) is the critical component of protective immunity and the passive transfer of SARS-CoV S specific sera 
is sufficient to provide protection from infection and disease by a homologous SARS-CoV strain(20, 41, 
78, 95, 163, 190, 194, 224, 241, 253, 254).  However, current animal models universally display a very 
acute SARS-CoV like disease(30, 41, 70, 71, 167, 169, 170, 195).  As such, these models may under 
represent the importance of the cell mediated and humoral responses in controlling more prolonged 
infection and pathogenesis as seen in human cases of SARS-CoV.  In fact, the development of a SARS-
CoV animal model that recapitulates both acute and prolonged infection with the development of adaptive 
immunity would greatly benefit the study of SARS-CoV pathogenesis and SARS-CoV vaccine 
development.  Nevertheless, these acute animal models of SARS-CoV infection are currently the most 
effective systems within which to assess vaccine and passive immunization efficacy. 
 Animal models to assess vaccine and passive immunization therapy efficacy against 
divergent SARS-CoV antigens.  Since the epidemic strain may no longer exist in nature, vaccination with 
epidemic strain antigens followed by challenge with the epidemic strain may not be the most biologically 
and medically relevant design.  Due to the complications of designing a vaccine against future emergence 
of SARS-CoV whose antigenic identity is unknown, several difficult questions arise in the development of 
effective SARS-CoV therapies: Which SARS-CoV antigen or pool of antigens will provide the greatest 
degree of cross protection if the vaccination is to prevent disease from future emergence of SARS-CoV?  
Similarly, which cross neutralizing epitopes should be targeted by passive immunization therapies in order 
to effectively treat future emergence of SARS-CoV?  Lastly, which SARS-CoV strain(s) should be 
employed as challenge virus to assess vaccine efficacy? We can begin to answer these questions within 
current animal models of SARS-CoV pathogenesis. 
 In 2006, Deming et al demonstrated that a Venezuelan equine encephalitis virus replicon particle 
expressing SARS Urbani S (VRP-S) vaccine provided complete protection from replication of a SARS-
CoV bearing a zoonotic heterologous GD03 S but protection was variable in senescent mice(41). Due to the 
lack of significant morbidity and mortality in the SARS-CoV replication models, previous vaccine studies 
were unable to assess protection from disease or death and could only speculate that diminishing virus 
replication would diminish disease.  Nevertheless, heterogeneity between antigen and challenge virus 
provides a more stringent, thorough, biologically and medically relevant model within which to assess 
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vaccine efficacy.  Therefore, employing an antigenically diverse panel of SARS-CoV antigens for 
vaccination coupled with the use of a similarly diverse lethal challenge virus panel may represent the most 
pertinent and relevant strategy to assess vaccine efficacy (Table 2). In 2007, Subbarao et al created a mouse 
adapted SARS-CoV (MA15) through repeated passage of SARS Urbani in BALB/c mice(167).  Our 
laboratory created a molecular clone of MA15 (rMA15 ) by introducing the six amino acid changes found 
in MA15 into our infections clone for SARS Urbani (icSARS)(167).  When administered intranasally to 
BALB/c mice of most any age, rMA15  causes significant weight loss (~20 % of starting weight) most 
likely resulting from  an acute infection of the lung resulting in almost 100% mortality(167).  The 
robustness of the MA15 lethal BALB/c would allow for the assessment of vaccines to induce protection 
from not only replication but also disease and mortality. 
 Similar to vaccination, the most successful hu-mABs for passive immunization against SARS-
CoV should broadly neutralize all current and future SARS-CoV strains.  One of the first hu-mABs 
developed against SARS-CoV, 80R, was effective in neutralizing pseudovirus bearing epidemic (Tor2) and 
civet (SZ3) S proteins but was not as effective against pseudovirus bearing the civet-like GD03 S in 
vitro(197).  Using hu-mAB m396, Zhu et al reported complete neutralization of SARS Urbani and SARS-
CoV bearing GD03 S (icGD03-S) but was less effective at neutralizing the SARS-CoV bearing the SZ16-
K479N S (icSZ16-S K479N, 4 log reduction in virus lung titer as compared to control hu-mAB) in passive 
transfer experiments in young BALB/c mice(256).  In contrast to the m396 antibody, Zhu et al also 
reported complete protection from virus replication (day 2 post infection) against SARS Urbani, icGD03-S 
and icSZ16-S K479N using a similar doses of hu-mAB S230.15(256). Rockx et al also demonstrated the 
cross reactivity and potent neutralizing ability of the S230.15 and another novel hu-mAB(S227.14) in 
passive transfer studies in mice(171). 230.15 and 227.14 effectively neutralized SARS Urbani and 
recombinant SARS-CoV bearing the early epidemic phase GZ02 S though were both less efficacious 
against recombinant SARS-CoV bearing the civet HC/SZ/61/03 S glycoprotein (2 log reduction in virus 
lung titers on day 2 post infection as compared to control Ab)(171).  Though S230.15 and S227.14 did not 
protect against virus replication in HC/SZ/61/03 challenged mice, both antibodies protected Urbani, GZ02 
and HC/SZ/61/03 infected mice from clinical signs of disease(171). These data highlight the importance of 
using more than one strain of SARS-CoV when evaluating SARS-CoV therapies since the hu-mABs 
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discussed above provided varying degrees of protection from replication depending the SARS-CoV S 
variant that was employed in the in vitro or in vivo assay.  Also, these data suggest that the complete 
abrogation of replication may not be necessary to protect from clinical signs of SARS-CoV disease. 
 SARS-CoV vaccine efficacy in senescent populations.  As mentioned above, the 
immunosenescence that occurs with ageing can hamper both the innate and adaptive immune responses 
whose collaboration is necessary for efficient vaccination.  The SARS-CoV epidemic was particularly 
harsh on immune senescent populations where mortality ranged between 25-55% in people over the age of 
65(19, 116, 124, 152).  If a SARS-CoV like virus were to reemerge in the future, it is imperative that 
current vaccination strategies be successful in the most vulnerable populations.  Unfortunately, the 
successful vaccination of elderly populations is a difficult and unpredictable task due to 
immunosenescence(17, 18, 50, 53, 64, 65, 67, 77, 151, 212, 215). Much of this research related to 
vaccination of the immunosenescent was been performed with influenza.  Current models predict influenza 
vaccine efficacy in elderly populations ranges from 17-53% while the vaccine in young adults is 70-90% 
effective and the reason for the discrepancy seems to be a result of senescent immune system malfunction 
on multiple levels(64).  Defects in antigen presentation, T cell activation and cytokine secretion affect the 
generation of effective adaptive immune system helper (T helper or Th) cells and effector (B cells and 
cytotoxic T cells) cells resulting in diminished vaccine efficacy(50, 53, 58, 64, 65, 77, 136, 212, 223).  
Current research suggest that the some defects of the senescent immune system can be overcome through 
administration of cytokines (IL-2) or adjuvants (MF59, CpG DNA) during vaccination that effectively 
activate APCs/Th cells thereby increasing the probability of generating appropriate effector cells required 
for successful vaccination(75, 76, 83, 160, 201).  Since influenza, West Nile Virus and SARS-CoV 
infection all produce disproportionately more disease in the elderly, the development of successful vaccine 
strategies in the elderly has a broad public health application(1, 116, 142). 
 Like in humans, the infection of aged mice with SARS Urbani results in more severe disease as 
compared to similar infection of young adult mice.  In senescent mice, both virus replication and lung 
pathology is enhanced but virus is eventually cleared suggesting that components of the aged immune 
system are less effective at controlling virus replication.  Though the senescent mouse model does not fully 
recapitulate SARS-CoV acute and extended cell mediated pathogenesis seen in humans, it serves as a 
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useful model to study the effects of immunosenescence on vaccine efficacy.  Using VRP vectors expressing 
the Urbani S glycoprotein, Deming et al demonstrated complete protection of young adult mice from 
replication of a heterologous challenge virus bearing the GD03 S glycoprotein though protection in 
similarly vaccinated senescent mice was variable(41).  Not surprisingly, high titers of Urbani and GD03 
neutralizing antibody were found in young vaccinated mice while most senescent animals had very low 
Urbani specific neutralization titers and most GD03 titers below the limit of detection(41).  Using vesicular 
stomatitis virus vectors expressing Urbani S (rVSV-S), Vogel et. al. obtained similar results in aged mice 
where neutralization titers in vaccinated aged mice were low and did not provide protection from 
replication upon homologous SARS Urbani challenge(220).  Similar to what is seen in humans, these data 
suggest that vaccination of young mice induces a robust and cross protective IgG response while the IgG 
response in aged animals is depressed in both magnitude and cross reactivity.   
 SARS-CoV vaccine immunopotentiation.  Effective vaccination induces specific protective 
immunity that confers protection from future disease.  Unfortunately, vaccination can sometimes 
exacerbate disease upon natural infection with the pathogen the vaccine was designed to protect against. 
This phenomena where the vaccine induced “protective” immune response upon challenge promotes rather 
than protects from disease is called “immunopotentiation” of disease(225).  Both measles (MV) and RSV 
are paramyxovirus respiratory pathogens that cause significant morbidity and mortality in infants that might 
be prevented through the development of effective vaccines (158, 214). In the 1960s, two infamous 
examples of immunopotentiation of disease surfaced with formalin inactivated MV (FI-MV) and RSV (FI-
RSV) vaccines(158, 214).  Infants with no prior exposure to RSV were vaccinated with the FI-RSV 
vaccine, developed virus specific antibody but were not protected from subsequent natural RSV 
infection(49).  In fact, FI-RSV vaccinated children infected with RSV suffered from enhanced RSV disease 
requiring hospitalization and a few children died from infection(49).  The pathological hallmark of FI-RSV 
immunopotentiation was lung and peripheral eosinophelia which is absent during the natural course of RSV 
infection(49, 214). Similar to FI-RSV, protective immunity waned in infants shortly after vaccination with 
FI-MV and subsequent natural measles infection resulted in more severe disease with eosinophelia 
uncharacteristic of natural measles infection(158).  Due to these severe vaccine associated disease 
complications, both vaccines were withdrawn and work began to understand the biology of these flawed 
 24 
vaccines.  Within mouse and non-human primate animal models, both FI-RSV and FI-MV were found to 
induce an atypical Th2 adaptive immune response not seen in natural infection(37, 49, 158, 214).  The 
effects of the Th2 responses generated by FI-RSV and FI-MV differ.  FI-RSV vaccination induces a Th2 
allergic immune response with T cells secreting cytokines (IL-13, IL-5) that upregulate the production of 
the potent eosinophil chemotactic molecule eotaxin(37, 49, 214). Natural infection of vaccinated 
individuals is thought to have been exacerbated by this atypical allergic immune response in the lung(37, 
49, 214). Interestingly, similar results are achieved in macaques using formalin inactivated human 
metapneumovirus vaccines (FI-hMPV) followed by hMPV challenge(38).  With FI-MV vaccination, non-
human primate models suggest the associated allergic Th2 response generated after MV challenge recruits 
eosinophils to sites of virus replication with disease pathology in part mediated by immune complex 
deposition(158). 
 Vaccine induced immunopotentiation has also been observed in coronavirus with vaccinia virus 
vectored feline infectious peritonitis virus (FIPV) vaccines.  Vennema et. al. observed that vaccination with 
recombinant vaccinia virus expressing FIPV S (vFS) induced short lived immunity in kittens(217).  When 
challenged, vFS immunized animals suffered from much more severe disease than those receiving a control 
vaccine. vFS vaccine induced immunopotentiation was suspected to be a result of antibody dependent 
enhancement (ADE) of virus infection where subneutralizing antibody coating FIPV virions allowed for the 
entry and productive infection of cells (e.g. macrophages) not normally targeted during natural infection.   
 Vaccine induced immunopotentiation of disease has also been shown with vectored vaccines 
expressing SARS-CoV N.  Deming et. al. demonstrated that mice vaccinated with VRP based vaccines 
expressing the SARS-CoV N gene were not protected from infection and developed enhanced lung 
immunopathology upon challenge with eosinophelia not seen in control mice(41).  These data suggest that 
the N protein not only does not provide protection from disease in these acute replication models, it also 
promotes enhanced disease pathogenesis in the lung.  The evaluation of several formalin inactivated SARS-
CoV vaccines suggest these vaccines primarily induce a Th2 response while natural SARS-CoV infection 
of humans induces primarily a Th1 response(190, 208, 232).  Given the data from both FI-RSV and FI-MV 
vaccination where the alteration of the natural Th response induced more severe disease upon challenge, 
 25 
caution should be taken in developing vectored vaccines containing SARS-CoV N or formalin inactivated 
SARS-CoV vaccines which may promote rather than prevent disease.  
 
Figure 1: World Health Organization (WHO) on global mortality due to respiratory infections by 
age group. 
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Figure 2: Neighbor joining tree created from coronavirus S gene amino acid sequences. Numbers 
represent bootstrap values based on 1000 bootstrap replicates. 
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Table 1: Examples of past and newly emerging/discovered coronavirus. 
Virus Name Genogroup Host Disease 
Host range 
expansion 
New 
disease 
Newly discovered 
or emerging virus 
Sever acute respiratory 
syndrome coronavirus 
(SARS-CoV) 2a Human 
Respiratory 
disease X   X 
Human coronavirus 
OC43 (OC43) 2 Human 
Respiratory 
disease X     
Buffalo associated 
coronavirus (BuCoV) 2b Buffalo Gastroenteritis X     
Respiratory bovine 
coronavirus (RBCV) 2b Cows 
Respiratory 
disease   X   
Porcine respiratory 
virus (PRCV) 1 Pig 
Respiratory 
disease   X   
Human coronavirus 
NL63 (NL63) 1 Human 
Respiratory 
disease  ?   X 
Human coronavirus 
HKU1 (HKU1) 2 Human 
Respiratory 
disease  ?   X 
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Figure 3: Schematics of SARS-CoV virion and genome organization.  (A) Schematic of the SARS-CoV 
virion.  The virus genome is associated with the nucleocapsid protein and is contained within a lipid bilayer 
containing at least five structural proteins (membrane (M), spike (S), envelope (E), ORF 3a, and ORF 7a). 
(B) Schematic of the SARS-CoV genome organization. The SARS-CoV genome is 29,727bp of positive 
sense RNA.  The first two thirds of the genome contains genes encoding non-structural proteins while the 
last third contains genes encoding structural genes.  The SARS-CoV genome is layed out in the classic 
coronavirus gene order 5’-non-structural genes, S, E, M, and N-3’ with group specific open reading frames 
interspersed between the structural genes. 
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Figure 4:Schematics of the SARS Spike (S) glycoprotein domain organization. Like gp160 of HIV, 
hemagglutinin of  influenza, F protein of paramyxovirus, and glycoprotein of Ebola virus, the spike (S) 
glycoprotein protein of coronavirus is a class I viral fusion protein that mediates virus binding and fusion 
allowing the virus to enter the host cell. (A) Above view of S protein trimers situated in the viral envelope. 
(B) Side view of S protein trimer situated in the viral envelope.  (B) Close up side view of S trimer situated 
within the viral envelope. Putative locations of the receptor binding domain (RBD), S1, S2, fusion and 
transmembrane domains are noted.  (D) Linear layout (N-terminal to C-terminal) of the S protein domains.  
Like other class I fusion proteins, the SARS S glycoprotein contains two functional domains, S1 and S2, 
joined by a protease cleavage site. The S1 domain (17-756aa) contains the receptor binding domain (RBD) 
(318-510aa) while the S2 region (757-1225aa) contains the two heptad repeat (HR) regions that facilitate 
viral fusion and a transmembrane domain (1189-1227aa) that anchors spike to the viral envelope.
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Figure 5: SARS-CoV S protein interactions with the human receptor angiotensin I converting 
enzyme 2 (hACE2) mediate entry into the host cell.  (A) The coronavirus S glycoprotein is a critical 
component of species specificity which is primary determinant of pathogenesis since a virus incapable of 
infection will most likely not cause disease.  SARS-CoV S and ACE2 interactions affect efficiency of virus 
entry and infection where zoonotic viruses are incapable of binding hACE2, intermediate SARS-CoV are 
moderately capable of binding hACE2 and human epidemic strains are very capable of binding hACE2. 
These differences in binding efficiency affect infection efficiency and pathogenesis. (B) An example of a 
one step growth curve examining zoonotic, intermediate and human tropic SARS-CoV replication kinetics 
within cells expressing hACE2.  Cell cultures are infected at a high multiplicity of infection (MOI) and cell 
media is sampled over time to monitor virus growth. Since the cells are infected with a high MOI, only one 
cycle of virus growth is seen in the time allotted.  These experiments provide data regarding binding, entry 
and replication efficiency.  As virus titers of human tropic strains are superior to intermediate strains at 
early times post infection suggesting the human tropic strains appear to gain entry more quickly while 
zoonotic virus cannot gain entry and does not grow.  Since the slopes of the human and intermediate curves 
are similar, this indicates that these viruses replicate at similar rates.  Even though human and intermediate 
strains seem to replicate at similar rates, human tropic viruses achieve titers superior to those of the 
intermediate strains. Since human tropic S binding is to hACE2 is the most efficient, more cells are infected 
as compared to intermediate strains and as a result, more progeny virus is produced.  (C) SARS-CoV is 
thought to gain entry into cells by the following sequence of events 1. Binding to the cellular receptor 
ACE2 2. Entry into the cell by endocytosis 3. Cleavage of the SARS-CoV S by cellular protease cathepsin-
L causing a rearrangement of S1 and S2 subunits 4. Viral and host membrane fusion depositing the viral 
genome into the cytoplasm 5. Virus genomic and subgenomic replication ensues.
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Figure 6: Phylogenetic relationships of zoonotic and epidemic SARS-CoV. (A) Neighbor joining tree 
constructed from nucleotide sequences of various SARS-CoV S genes. The degrees of gray color indicate 
evolutionary relationships between zoonotic virus (white), early (light gray), middle (medium gray) and 
late (dark gray) phases of the epidemic. Numbers represent bootstrap values based on 1000 bootstrap 
replicates. (B) Spike amino acid differences between Urbani (late phase), CUHK-W1 (middle phase), 
GZ02 (early phase), HC/SZ/61/03 (zoonotic phase), GD03 (zoonotic phase) and SZ16 (zoonotic phase) 
viruses.  
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Figure 7: The SARS-CoV receptor, angiotensin I Converting Enzyme 2 (ACE2), in virus entry and 
pathogenesis. (A) ACE2 and angiotensin I converting enzyme (ACE) are key regulators of the rennin-
angiotensin system (RAS), which helps control cardiovascular function by maintaining the body’s blood 
pressure and electrolyte balance.  ACE and ACE2 are metalloproteases with differing vasoactive peptide 
substrate specificities and as a result have disparate and antagonistic roles in maintaining physiologic 
homeostasis.  ACE cleaves the peptide ANG I into ANG II which has vasoconstrictive effects inducing 
hypertension while also inducing cell proliferation and fibrosis.  In contrast, ACE2 processes ANG I into 
ANG 1-9 and further processes ANG II into the peptide ANG 1-7 which acts as a vasodilator while also 
being anti-proliferative and apoptotic. Current in vitro data suggests that ANG II ligation and signaling 
through angiotensin receptor 1a (AT1aR) can result in the production of proimflammatory cytokines 
(TNFα, IL-1β, IL-6, MCP-1 etc.), fibrosis, and cell proliferation. (B) Infection of the lung by SARS-CoV 
disrupts of RAS homeostasis. SARS-CoV infection or the administration of SARS S alone depresses levels 
of ACE2 within the lung. Furthermore, the administration of SARS S recombinant protein exacerbated ALI 
induced by acid aspiration.  Current data suggests that SARS-CoV infection or SARS S protein decreases 
levels of ACE2 within the lung thereby removing a key regulator and processor of the proinflammatory 
ANG II peptide whose excess contributes to more severe disease.  These data provide an interesting insight 
into possible RAS involvement in SARS-CoV pathogenesis and the progression of ALI to acute respiratory 
distress syndrome (ARDS) seen in more severe cases of SARS-CoV. 
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Figure 8: Schematic of membrane bound and cytosolic pathogen recognition receptors.  The innate 
immune response is thought to provide the first line of host defense against invading pathogens.  
Specialized membrane bound or cytosolic pathogen recognition receptors (PRRs) such as Toll-Like 
Receptors (TLRs), RIG-I/Mda5, and Nod-like receptors (NLRs) sense pathogen-associated molecular 
patterns (PAMPs) and initialize the innate immune inflammatory response by activating the transcription of 
various proinflammatory genes.  These PRRs are very specific in their pathogen component recognition 
(e.g. double stranded RNA, CpG DNA, LPS etc.) and the type of immune response generated as a result of 
activation.  TLRs, NODs, RIG-I and Mda5 have been shown to be expressed within lung epithelial cells as 
well as in the more “professional” environmental sensing cells like conventional/plasmacytoid dendritic 
cells (cDCs/pDCs) and macrophages (Mø).   
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Table 2: A panel of antigenically divergent recombinant SARS-CoV bearing various S glycoproteins 
for the assessment of vaccine efficacy.  
Recombinant 
Virus Name Description 
Spike AA Δ s 
from Urbani 
Pathogenic Phenotype in 
Young BALB/c 
Pathogenic Phenotype in 
Senescent BALB/c 
icSARS 
Molecular clone of the 
epidemic strain SARS 
Urbani 0 
No weight loss, high titer 
virus replication in lung 
Moderate weight loss, 
more virus replication 
than in young 
icCHUK-W1 
icSARS bearing a middle 
epimdemic phase virus 
spike 3 
No weight loss, high titer 
virus replication in lung 
Little weight loss,similar 
virus replication than in 
young 
icGZ02 
icSARS bearing an early 
epidemic phase virus 
spike 6 
No weight loss, high titer 
virus replication in lung 
Lethal, more virus 
replication in lung than in 
young 
icHC/SZ/61/03 
icSARS bearing a 
zoonotic SARS-CoV 
spike isolated from a 
palm civet  21 
No weight loss, high titer 
virus replication in lung 
Lethal, similar virus 
replication in lung than in 
young 
icA031G 
icSARS bearing a 
zoonotic SARS-CoV 
spike isolated from a 
racoon dog 23 
No weight loss, high titer 
virus replication in lung 
Moderate weight loss, 
similar virus replication 
than in young 
icGD03 
icSARS bearing a 
zoonotic SARS-CoV 
spike isolated from a 
sporadic human case 18 
No weight loss, high titer 
virus replication in lung 
Little weight loss, similar 
virus replication than in 
young 
icSZ16-S K479N 
icSARS bearing a 
zoonotic SARS-CoV 
spike isolated from palm 
civet mutated at residue 
479 17 
No weight loss, high titer 
virus replication in lung 
Little weight loss, similar 
virus replication than in 
young 
rMA15 
Molecular clone of the 
mouse adapted SARS-
CoV 1 
Lethal, high titer virus 
replication in lung 
Lethal, more virus 
replication in lung than in 
young 
rMA15-GD03 
rMA15 bearing the GD03 
spike 19 
Moderate weight loss, 
high titer  virus replication 
in lung 
Lethal, more virus 
replication in lung than in 
young 
 
Since the epidemic strain may not exist in nature, vaccination with epidemic strain antigens followed by 
challenge with the epidemic strain may represent a biologically irrelevant design.  Unfortunately, a difficult 
choice is presented in choosing SARS-CoV vaccine antigens in hopes of preventing disease by future 
emergents whose antigenic identity is unknown. Therefore, employing an antigenically diverse panel 
SARS-CoV antigens for vaccination coupled with the use of an similarly diverse lethal challenge virus 
panel may represent the most pertinent and relevant strategy to assess vaccine efficacy. 
 
 
  
 
CHAPTER II 
MECHANISMS OF ZOONOTIC SARS-CoV HOST RANGE EXPANSION IN HUMAN AIRWAY 
EPITHELIUM 
 
Abstract 
 In 2002, SARS Coronavirus (SARS-CoV) emerged and caused over 8000 human cases and 
greater than 700 deaths worldwide.  Zoonotic SARS-CoV likely evolved to infect humans by a series of 
transmission events between humans and animals for sale in China. Using synthetic biology, we engineered 
the spike protein (S) from a civet strain, SZ16, into our epidemic strain infectious clone creating the 
chimeric virus, icSZ16-S, which was infectious but yielded progeny viruses incapable of propagating in 
vitro.  After introducing a K479N mutation within the S receptor binding domain (RBD) of SZ16, the 
recombinant virus (icSZ16-S K479N) replicated in Vero cells but was severely debilitated in growth.  The 
in vitro evolution of icSZ16-S K479N on human airway epithelial cells (HAE) produced two viruses 
(icSZ16-S K479N D8 and D22) with enhanced growth on HAE and on DBT cells expressing the SARS-
CoV receptor (hACE2).  icSZ16-S K479N D8 (D8) and D22 (D22) virus RBDs contained mutations in 
ACE2 contact residues Y442F and L472F that remodeled S interactions with hACE2.  Further, these 
viruses were neutralized by a human monoclonal antibody (mAb), S230.15, while the parent icSZ16-S 
K479N strain was eight times more resistant. These data suggest that human adaptation of zoonotic SARS-
CoV strains may select for some variants that are highly susceptible to select mABs that bind to the RBD.  
Epidemic, icSZ16-S K479N and D22 viruses replicate similarly in the BALB/c mouse lung highlighting the 
potential use of these zoonotic spike SARS-CoV to assess vaccine or sero therapy efficacy in vivo. 
Introduction 
Emerging viral diseases such as HIV, Ebola, Influenza H5N1, West Nile and Dengue virus have 
had a profound impact on global public health(139).  In 2002, a novel coronavirus (SARS-CoV) emerged 
suddenly as the causative agent of Severe and Acute Respiratory Syndrome (SARS) and spread worldwide 
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causing about 8000 cases and >700 deaths(29, 103, 173).  SARS-CoV most likely evolved from viruses 
circulating within the Chinese horseshoe bat and other bat species that are believed to be the natural animal 
reservoirs(108). Within live animal markets in the Guangdong region of China, it is hypothesized that close 
cohabitation of bats and palm civets allowed for subsequent cross species transmission and amplification of 
bat strains in civets (69, 108). Palm civets then served as an intermediate host for subsequent viral 
evolution of strains that could infect and transmit between humans(108).  Clinical data suggests that the 
sporadic early human SARS-CoV infections were significantly less pathogenic and that a progressive series 
of adaptive mutations were necessary for increased human to human transmission and the expanding 
phases of the epidemic(28, 69, 173).  Despite initial reports that civet strains SZ16 and SZ3 could be 
propagated in cell culture, subsequent studies have indicated that these viruses could not be successfully 
maintained in culture thereby hampering our understanding of their pathogenicity  and mechanisms of cross 
species transmission in humans(110).   
Within the past four years, multiple newly emerging coronaviruses of human relevance have been 
identified highlighting the emerging disease potential of the coronavirus family(161, 173, 213, 235). 
SARS-CoV and human coronavirus HKU1 are newly emerging members of coronavirus genogroup II and 
both cause pneumonic disease in humans with SARS-CoV being the most pathogenic of the known human 
coronaviruses(48, 103, 173, 233, 235). Viruses related to the SARS-CoV epidemic strain have recently 
been found in Chinese horseshoe bats during surveillance of wild animals in Hong Kong(108). Since 
viruses similar to the epidemic strain have been found circulating within zoonotic pools, there is the 
potential for yet another reemergence(108). Moreover, a promiscuous RNA-dependent RNA polymerase 
coupled with high frequency recombination rates make the evolution of future human coronavirus 
pathogens a real possibility(42, 162, 248).   
The coronavirus spike glycoprotein (S) is a key determinant of host specificity and elucidating the 
molecular mechanisms of viral host expansion may help us understand the events that rendered SARS-CoV 
pathogenic to humans(94, 122).  Virus sequence data isolated throughout the course of the epidemic 
suggests that S gene was under heavy positive selection during the early phase of the epidemic but 
eventually stabilized as the epidemic progressed(28).  The S protein is 1225 amino acids in length and can 
be divided into two main functional domains S1 and S2.  The S1 region (17-756aa) contains the receptor 
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binding domain (RBD) (318-510aa) while the S2 region (757-1225aa) contains the two heptad repeat 
regions responsible for viral fusion and a transmembrane domain (1189-1227aa) that anchors S to the viral 
envelope. SARS-CoV entry into the host cell is mediated by a receptor, angiotensin I converting enzyme-2 
(ACE2), and perhaps other coreceptors(90, 120).  ACE2 has been detected on the apical surfaces of ciliated 
cells within the lung epithia as well as in kidney and colon(72).  After S and receptor binding, the virus 
enters the cell by receptor mediated endocytosis.  Cleavage of the SARS-CoV S by cathepsin L within the 
endosome is required for SARS-CoV infection and precedes fusion(184).  
Sequences isolated throughout the initial epidemic in 2002-2003 and during the reemergence of 
2003-2004 chronicle the mutations in S that may have allowed for host expansion. During the epidemic and 
reemergence, the early 2003 SARS-CoV animal isolate, SZ16, and the 2004 reemergent human isolate, 
GD03, were among the most divergent viruses isolated from civets and humans, respectively. SARS-CoV 
SZ16 was identified from palm civets in live animal markets within the Guangdong region of China during 
the epidemic and its S protein differs from the epidemic strain, SARS Urbani, in 18 amino acids 16 of 
which reside in the S1 domain. Using pseudotyped viruses, recent work has shown that mutation of residue 
479 within the SZ16 RBD was sufficient to allow for the host range expansion of zoonotic SARS-CoV 
spike bearing pseudovirus to infect human cells(119, 122). 
In this study, we describe the synthetic construction and characterization of a SARS-CoV chimera 
bearing a zoonotic SZ16 S protein.  Importantly, we find that the mutations acquired during the in vitro 
evolution of a zoonotic S bearing recombinant virus in human airway epithelial cells (HAE) can vary from 
those that occurred during the epidemic highlighting the adaptive plasticity of the zoonotic S protein. Also, 
these data suggest that HAE can be used as a model to evaluate the possible avenues of SARS-CoV 
zoonotic S evolution towards efficient infection of human cells. Lastly, recombinant viruses bearing 
zoonotic S proteins replicated efficiently in mice, and will serve as a valuable tool in assessing the efficacy 
of vaccines and therapies.  
Materials and Methods 
Viruses and Cells.  The recombinant epidemic strain virus “icSARS” (AY278741), icSZ16-S (AY304488) 
and icSZ16-S K479N, icSZ16-S K479N D8, and icSZ16-S K479N D22 were propagated on Vero E6 cells 
as described(249).  Virus stocks used throughout this study were grown and titered by plaque assay in Vero 
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E6 cells as described(249). Vero E6 and delayed brain tumor (DBT) cells were grown in MEM (Invitrogen, 
Carlsbad, CA) supplemented with 10% FCII (Hyclone, South Logan, UT) and gentamycin/kanamycin 
(UNC Tissue Culture Facility). Mink lung epithelial cells (Mv1lu) were grown in DMEM (Invitrogen, 
Carlsbad, CA) supplemented with 10% FCII (Hyclone, South Logan, UT) and gentamycin/kanamycin 
(UNC Tissue Culture Facility).  Human tracheobronchial epithelial cells (HAE) were obtained from airway 
tissues harvested from patients undergoing elective surgery under UNC Institutional Review Board-
approved protocols by the UNC Cystic Fibrosis (CF) Center Tissue Culture Core.  Briefly, primary cells 
were expanded on plastic to generate passage 1 cells and plated at a density of 250k cells per well on 
permeable Transwell-Col (T-Col, 12mm diameter) supports (59, 156).  HAE cultures were generated by 
provision of an air-liquid interface for 4-6 weeks to form well-differentiated, polarized cultures that 
resemble in vivo pseudo-stratified mucociliary epithelium (156). All virus work was performed in a Class II 
biological safety cabinet in a certified biosafety level 3 laboratory containing redundant exhaust fans while 
wearing Tyvek suits and PAPRs as described(247).   
Construction of Chimeric SARS-CoV bearing the SZ16 spike protein “icSZ16-S”.  The Baric 
laboratory’s infectious clone for the epidemic strain is divided into six subgenomic cDNA clones (A–F) 
that span the SARS-CoV genome. The first two thirds of the S gene is located within the icSARS E 
fragment (21492-24056) and the last third is located within the icSARS F fragment (nt 24057–25259). A 
synthetic DNA containing SZ16 nucleotides 21541-24056 was purchased from Blue Heron Technology 
(Bothell, WA).  The fragment was digested with AgeI and XbaI (NEB, Ipswich, MA), and cloned into the 
existing icSARS-E pSMART plasmid, replacing the Urbani S glycoprotein with the SZ16 variant sequence 
to create icSZ16-E pSMART.  Within the SARS-F fragment, the two remaining coding changes of the 
SZ16 S were introduced via PCR and the class II restriction enzyme AarI. Briefly, three amplicons A, B, 
and C were generated by PCR using Expand High Fidelity Polymerase (Roche, Indianapolis, IN). Primer 
pairs are as follows: Amplicon A (PasIF 5’-CTGTTTTCCCTGGGATCGC-3’, AarIM1NR 5’- 
NNNNNNCACCTGCTTTTGGGCAACTCCAATGCC -3’) Amplicon B (AarIM1NF 5’- 
NNNNNNCACCTGCAGTTGCCCAAAATGTTCTCTATGAGAAC -3’, AarIM2NR 5’- 
NNNNNNCACCTGCATTTCTTCTTGAATGTTGACGACAGAAG-3’), and Amplicon C (AarIM2NF 5’ 
NNNNNNCACCTGCTCAAGAAGAAATTGACCGCCTC-3’, BamHIR 5’- 
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CATAAATTGGATCCATTGCTGG-3’). A, B, and C amplicons were digested with AarI for 1.5hr at 37˚C 
(Fermentas, Burlington, Ontario, Canada), gel purified and ligated to create the fragment ABC. ABC 
ligation products were gel purified and TA cloned into TOPO-XL (Invitrogen, Carlsbad, CA) to create 
pTOPO-XL ABC.  The pTOPO-XL ABC subclones were sequence confirmed. pTOPO-XL ABC was 
BamHI digested at 37˚C for 1hr releasing a 2059nt fragment containing the icSZ16 F-fragment S sequence. 
icSARS F-pSMART was digested with BamHI at 37˚C for 1hr excising the epidemic strain S sequence 
while releasing a 5749bp vector fragment. The 2059bp SZ16 insert and the 5749bp vector fragments were 
gel purified using a QIAquick gel purification kit (Qiagen, Valencia, CA) and ligated (NEB, Ipswich, MA) 
to create icSZ16 F-pSMART. 
Construction of Chimeric icSZ16-S K479N mutant.  The icSZ16-E pSMART sequence for S residue 
479 was mutated from lysine (AAA) to an asparagine (AAT) using overlap PCR. Amplicon A (NcoIF 5’- 
TGTTTCTAAACCCATGGGTACACAG-3’, SZ16479R5’- CCATAATCATTTAATGGCCAATAAC-3’) 
and Amplicon B (SZ16479NF 5’- GTTATTGGCCATTAAATGATTATGG-3’, XbaIR 5’- 
GGGCCCTCTAGAGATCGAGC-3’) were generated using Expand High Fidelity Polymerase (Roche, 
Indianapolis, IN). To join the fragments, Amplicons A (1010bp) and B (1153bp) were used as template in 
overlapping PCR with primers NcoIF and XbaIR. The final AB amplicon was purified using a Qiagen PCR 
purification kit (Qiagen, Valencia, CA) and digested with NcoI and XbaI (NEB, Ipswich, MA) for 1 hour at 
37˚C. The digested amplicon (2.2KB) was gel purified using a QIAquick gel purification kit (Qiagen, 
Valencia, CA), ligated to the 5.3KB NcoI/XbaI fragment of icSARS SZ16-E pSMART and sequence 
verified. 
Isolation of Recombinant Viruses.  From the ligation of appropriate infectious clone fragments, icSZ16-S 
or icSZ16-S K479N full-length chimeric cDNA was generated, full-length transcripts were synthesized and 
mixed with polyadenylated N gene transcripts and then electroporated into cells as previously 
described(247). Clarified supernatants from the icSZ16-S or icSZ16-K479N electroporations were 
passaged onto naive Vero E6 cells to confirm the presence of replicating virus. If  CPE was not detected, 
viruses were passaged every 48 hours on Vero E6 cells until cytopathology was observed.  With icSZ16-S 
K479N, mild CPE was observed at passage 3 (p3) and more robust CPE was seen by passage 6 (p6). P3 
and p6 icSZ16-S K479N viruses were plaque-purified in Vero E6 cells. The S, 3a, E, and M genes of the 
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recombinant viruses were sequence verified, and stocks were grown in T75 flasks and stored at -80˚C for 
future use.  
RT-PCR to detect subgenomic leader containing transcripts.  RT-PCR to detect subgenomic leader 
containing transcripts was performed to demonstrate viral replication.  RNA from virus infected cells was 
isolated using TRIzol reagent (Invitrogen, Carlsbad, CA) according to protocol.  1-5µg of total RNA was 
used to generate cDNA by Superscript II (Invitrogen, Carlsbad, CA) using random hexamer primers 
(Invitrogen, Carlsbad, CA). cDNA was then used as template for PCR using Taq polymerase (NEB, 
Ipswich, MA) with a leader forward (CTCTTGTAGATCTGTTCTCTAAACGAAC) and reverse primer in 
the M gene (TTACTGTACTAGCAAAGCAATATTGTCG). Detection of GAPDH (GAPDHF 5’-
CATGGGGAAGGTGAAGGTCG-3’, GAPDHR 5’-TTGATGGTACATGACAAGGTGC-3’) messages by 
RT-PCR was done as a positive control.  PCR reactions were separated by gel electrophoresis on 1.8% 
agarose TAE gels and visualized by ethidium bromide staining. 
In vitro evolution of icSARS SZ16 K479N in human airway epithelial cell cultures for 22 days.  
Human airway epithelial cell cultures (HAE) were created as described(185). Cultures were infected with 
105 pfu of icSARS-S K479N in a 200ul volume. After a 2hr infection, the inoculum was removed, the cells 
were washed briefly with DPBS, and then maintained for 4 days. After 4 days of infection, the apical 
surfaces of the cultures were rinsed and supernatants were placed onto the apical surface of fresh cultures 
for 1 hr, washed and maintained for another four days.  Apical washes were then plaque purified to isolate 
icSZ16-S K479N D8 virus. 200µl of day 8 supernatants were used to infect naive HAE cultures as 
described above and the cultures were passaged two additional times at 4 day intervals and then 3 times 
every 48 hrs to preferentially enrich for more efficiently replicating virus variants.  After 22 days of 
selection for efficient growth in HAE, the apical surfaces were rinsed and supernatants were plaque 
purified to isolate icSZ16-S K479N D22 virus. Plaques were expanded on 60mm dishes and RNA was 
isolated using TRIzol (Invitrogen Carlsbad, CA). Amplicons spanning from S, 3a, E and M genes were 
generated by RT-PCR and directly sequenced. 
Generation of hACE2 expressing DBT cells.  Plasmid encoding an N-terminal myc tagged human 
angiotensin I converting enzyme-2 (hACE2) was kindly donated by M. Farzan at Harvard Medical School.  
The hACE2 gene was amplified by PCR using Expand High Fidelity polymerase (Roche, Indianapolis, IN) 
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(ACE2For 5’-CACCATGTCAAGCTCTTCCTGGCTCC-3’, ACE2Rev 5’- 
CTAAAAGGAGGTCTGAACATCATCAGTG-3’).  Amplicons were gel purified using the QIAquick gel 
purification kit (Qiagen, Valencia, CA) and cloned into pcDNA3.1/V5-His (Invitrogen, Calrsbad, CA) 
according to protocol to create pcDNA3.1/V5-His hACE2. The ACE2 gene plasmid was sequence verified.  
Delayed brain tumor cells (DBT) cells were transfected with 4µg of pcDNA3.1/V5-His hACE2 using the 
Fugene reagent (Roche, Indianapolis, IN). After 24 hours, cells were placed under drug selection using 
700µg/ml of G418 (Invitrogen, Carlsbad, CA) in complete growth media and remained under drug 
selection throughout all experiments.  Cells were passaged 4 times, sorted for high ACE2 expression by 
flow cytometry, and then expanded under drug selection before use.  
Growth curve analysis in HAE, Vero E6, DBT hACE2, or DBT cells.  HAE cells were infected with 
4.4x104pfu of the recombinant epidemic strain icSARS, icSZ16-S K479N p3, icSZ16-S K479N D8, or 
icSZ16-S K479N D22 for 2 hours at 37˚C after which the inoculum was removed and apical surface rinsed 
with DPBS. At times 0, 6, 12, 24, 36, 48 and 72 hr post infection, the apical surface of the HAE was rinsed 
with 200µl DPBS and the samples stored at -80˚C until titration by plaque assay.  Vero E6 and DBT 
hACE2 were infected with icSARS, icSZ16-S K479N p3, icSZ16-S K479N p6, icSZ16-S K479N D8, or 
icSZ16-S K479N D22 at an MOI of 0.01 for 1hr at 37˚C after which the inoculum was removed, the 
monolayer was rinsed with DPBS, and growth media was added.  DBT cells were infected in a similar 
manner and with the same panel of viruses as the Vero E6 and DBT hACE2 except icSZ16-S K479N p3 
was excluded from the experiment.  Cell media was sampled at 0, 6, 12, 24 and 36 hours post infection 
(hpi) and samples were stored at -80˚C until titered by plaque assay(247). Growth curve data presented are 
representative of two separate experiments. 
Immunohistochemistry of HAE infected cells.  To detect SARS-CoV antigens in HAE, infected or mock 
infected cultures were fixed in 4% paraformaldehyde (PFA) for 24 hours, transferred to 70% ethanol and 
prepared as paraffin-embedded histological sections by the UNC CF Center Morphology and 
Morphometrics Core.  After deparaffinzation, histological sections were incubated for 1 hour in PBS 
containing 3% bovine serum albumin (BSA).  Primary antibodies directed against SARS N or tubulin were 
applied at a 1:100 dilution in PBS with 1% BSA overnight and detected with FITC or Texas Red secondary 
antibodies (Jackson ImmunoResearch). Immunofluorescence was visualized with a Leica Leitz DMIRB 
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inverted fluorescence microscope equipped with a cooled-color charge coupled digital camera 
(MicroPublisher, Q-Imaging).  A tri-color filter cube set (GFP/Texas Red/DAPI) was used to show the 
morphology of the tissue section (by combining low level autofluorescence levels across the 3 filters) thus 
aiding determination of fluorescent antibody localization to specific regions of the cells.  
Plaque reduction neutralization assay (PRNT).  Neutralizing titers were determined by plaque reduction 
neutralization titer assay (PRNT) (172). 24hr prior to infection, 6-well plates were seeded with 5x105 Vero 
E6/well.   A human monoclonal antibody (mAb), S230.15, directed against the SARS-CoV RBD and an 
isotype control antibody directed against cholera toxin, D2.2, were kindly provided by A. Lanzavecchia.  
mAbs were serially diluted two-fold, and incubated with 100 pfu of either icSARS, icSZ16-S K479N p6, 
icSZ16-S K479N D8 or icSZ16-S K479N D22 for 1 hour at 37ºC. Virus and antibodies were then added to  
6-well plates of Vero E6 cells in duplicate and incubated at 37˚C for 1 hour after which the cells were 
overlayed with 3ml of 0.8% agarose in media. Plates were incubated for 48 hours at 37ºC, stained with 
neutral red for 3 hours and plaques were counted. The percentage of neutralization was calculated as: 1-
(number of plaques with antibody/number of plaques without antibody) x 100%.  
Infection of 6wk old and senescent BALB/c mice. Six week old (Charles River, Wilmington, MA) or 
twelve month old female BALB/c mice were anaesthetized with a ketamine and xylazine mixture 
administered intraperitoneally in a 50µl volume. Each mouse was inoculated with 1x105pfu/50µl of 
icSARS, icSZ16-S K479N p6, or icSZ16-S K479N D22 intranasally (n=10/virus in six week old animals, 
n=12/virus in twelve month old animals) and weight was monitored daily for four days post infection. On 
days two and four, three mice per group were sacrificed by isofluorane overdose and the lungs were 
removed for virus titer.  One half of the lung was frozen at -80˚C until titration by plaque assay.  Lungs 
were weighed, homogenized and PBS added to generate a 20% solution. The solution was then clarified by 
centrifugation and serially diluted for use in a standard plaque assay in Vero E6 cells(247). 
Phylogenetic Analysis of SARS-CoV spikes and Computer Modeling.  Nucleotide and protein sequence 
alignments of Urbani (GenBank Accession no. AY27841), HKU3 (GenBank Accession no. DQ022305), 
HC/SZ/61/03 (GenBank Accession no. AY515512), SZ16 (GenBank Accession no. AY304488), GD03 
(GenBank Accession no. AY525636), GZ02 (GenBank Accession no. AY390556), and CUHK-W1 
(GenBank Accession no. AY278554) were created using ClustalXv1.83(164). A neighbor joining tree was 
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generated from the ClustalX nucleotide sequence alignment, bootstrapped 1000 times, and exported into 
TreeView to create neighbor joining tree graphics(149). The numbers at each node represent the 
corresponding bootstrap value. 
 The crystal structure coordinates of SARS-CoV RBD interacting with the hACE2 receptor (PDB 
code 2AJF) were used as a template to generate each set of mutations using the Rosetta Design web server 
(http://rosettadesign.med.unc.edu/)(119).  In each case, the SARS-CoV RBD structure was analyzed using 
the molecular modeling tool, MacPyMol (DeLano Scientific), to determine which amino acids were 
proximal to the amino acid(s) being targeted for replacement.  Briefly, each amino acid to be altered was 
highlighted and all other amino acids within an interaction distance of 5 angstroms were identified.  Using 
the Rosetta Design website, the amino acid replacements were incorporated and all amino acids within the 
5 angstrom interaction distance were relaxed to allow the program to repack the side chains to an optimal 
energetic state.  This process was repeated with each mutation and series of mutations.  Ten models were 
generated for each set of mutations, and the best model, based on lowest energy score, was selected and 
further evaluated using Mac Pymol. 
Results  
Construction and characterization of icSZ16-S and icSZ16-S K479N viruses.  Public genetic databases 
and synthetic biology were harnessed to rapidly translate electronic S gene sequence information into S 
gene DNA fragments. The SZ16 virus was isolated in live animal markets in China and its sequence was 
published in 2003.  When comparing nucleotide sequences of S proteins isolated over the course of the 
epidemic, the SZ16 S is similar to viruses isolated from Chinese horseshoe bats (HKU3) and to the evolved 
human adapted strains (Figure 1A). The SZ16 S differs from the epidemic strain in 18 amino acid positions, 
16 of which reside in the S1 region and may well represent the progenitor strains for the 2003 human 
epidemic.  Much of the SZ16 sequence variability maps in and around the three known neutralizing 
epitopes marked as regions A, B, and C (Figure 1B) suggesting that human monoclonal antibodies derived 
from human SARS-CoV infections might be less efficacious against SZ16 early civet isolates.  As the SZ16 
virus could not be successfully maintained in culture, we used synthetic biology and reverse genetics to 
molecularly resurrect a recombinant and genetically modifiable SARS-CoV bearing the SZ16 S 
glycoprotein (icSZ16-S) (Figure 1C).  
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 Although icSZ16-S recombinant virus infection was not evident by cytopathology-based assays or 
by plaque assay, RT-PCR confirmed the presence of virus replication within the electroporated cell culture 
by detecting subgenomic leader containing transcripts for ORFs 3a, E, and M (Figure 2A). The transfer of 
icSZ16-S supernatants from the electroporated cell culture to naïve Vero E6 or a mink lung epithelial cell 
(Mv1Lu) cultures did not result in productive infection as leader containing transcripts were not detected 
(Figure 2B).  As a positive control, we passaged icSARS supernatants to Vero E6 and Mv1Lu cultures and 
both infections resulted in detectable wild type virus replication by RT-PCR (Figure 2B).  
 Since the icSZ16-S genomic RNA was capable of replicating in Vero E6 cells but progeny virions 
were incapable of re-infection and amplification, we hypothesized that infection was blocked due to 
inefficient S glycoprotein and ACE2 receptor interaction.  In 2005, Li et al crystallized the RBD of SARS-
CoV bound to ACE2 and proposed that residues 479 and 487 of the civet S inhibited efficient usage of the 
human ACE2 receptor(119). Using site directed mutagenesis, we changed residue 479 of the SZ16 S from 
lysine to the more human tropic asparagine (K479N), constructed and recovered the recombinant virus 
(icSZ16-S K479N).  Unlike icSZ16-S virus, icSZ16-S K479N infection could be passed in Vero E6 cell 
cultures by the transfer of supernatants to naive cell cultures (Figure 2C) providing direct support for the 
hypothesis that SZ16 infection of human and/or primate cells is blocked by civet S residue at position 479.  
In vitro evolution of icSZ16-S K479N virus in primary human airway epithelial cell cultures (HAE).  
Zoonotic reintroductions represent the most likely mechanism for reemergence of epidemic SARS-CoV 
strains in human populations.  The SZ16 S K479N mutation permitted binding and entry into primate cells 
but our preliminary data suggested that infections of HAE were inefficient (data not shown). To select for 
civet viruses with enhanced growth in HAE, cultures were apically infected with icSZ16-S K479N, 
maintained and passaged for a total of 22 days.  The virus isolated after 8 days in culture, icSZ16-S K479N 
D8 (D8), contained one mutation from tyrosine to phenylalanine at position 442 within the RBD (Y442F).  
The virus recovered after 22 days in culture, icSZ16-S K479N D22 (D22), contained the Y442F mutation 
as well as an additional mutation within the RBD from leucine to phenylalanine at position 472 (L472F). 
No other coding mutations were found in the S, 3a, E, or M genes.  Interestingly, both 442 and 472 are 
contact residues between S and ACE2 according to the reported crystal structure (119).  
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Evolved D8 and D22 viruses exhibit growth kinetics similar to the epidemic strain in various cell 
types.  The growth fitness of icSARS, icSZ16-S K479N p3 and the HAE evolved D8 and D22 viruses were 
assessed on HAE, Vero E6, murine DBT cells stably expressing hACE2 and on nonpermissive murine 
DBT cells. HAE cultures were infected with 4.4x104pfu virus for 2 hours, rinsed and apical wash samples 
were taken over 72 hours post infection (hpi) to monitor virus growth. The epidemic strain, icSARS, grew 
to peak titers approaching 107pfu/ml by 72 hpi (Figure 3A). icSZ16-S K479N p3 grew poorly in the HAE 
cultures with peak titers only approaching 103pfu/ml (Figure 3A).  As compared to the epidemic strain, the 
D22 virus grew with similar growth kinetics at early time points but peak titers were reduced by about 1 log 
and approached ~106pfu/ml by 72 hpi (Figure 3A). The D8 virus’ growth lagged at early time points but 
recovered to grow to peak titers similar to that of the D22 virus (Figure 3A). In Vero E6 cells, the epidemic 
strain and the D22 virus reached peak titers of 107pfu/ml 24hpi while icSZ16-S K479N D8, icSZ16-S 
K479N p3, and icSZ16-S K479N p6 grew to 105pfu/ml (Figure 3B).  
To model the SARS S and hACE interactions within the primary HAE cells and to prove that 
these mutations were influencing docking and entry via hACE2, we constructed DBT cells that stably 
express hACE2. In comparison to HAE, viral growth kinetics were more rapid in DBT-hACE2 although 
the overall trends in growth among viruses were more or less conserved.  In DBT-hACE2 cells, icSARS 
replicated to peak titers of 107pfu/ml by 24hpi and then diminished over time to 106pfu/ml by 36hpi (Figure 
3C).  Similar to the HAE model, early growth of the D22 virus was more rapid than the D8 virus in DBT-
hACE2, but the D8 virus never matched the D22 virus growth even after 36 hrs post infection (Figure 3C).  
Similar to the HAE, the icSZ16-S K479N p3 and the icSZ16-S K479N p6 viruses replicated poorly in 
DBT-hACE2 cells reaching titers of only 103pfu/ml by 36hpi (Figure 3C). DBT cells did not support the 
replication of any of the viruses within our panel supporting the hypothesis that the expression of ACE2 
within DBT-hACE2 cells is required for the growth of all viruses within our panel (Figure 3D).   
Immunohistochemistry of  infected HAE.  Host range expansion of other  coronaviruses resulted in a 
change in cell tropism that was oftentimes associated with a change in receptor usage (34, 137).  To 
determine the types of cells were infected by our panel of virus in HAE, infected cultures were fixed and 
sectioned for histological staining of SARS-CoV nucleocapsid antigen and tubulin for the staining of cilia.  
SARS N antigen was not detected in mock infected cultures though cilia on the apical surface of ciliated 
 46 
epithelial cells are stained brightly (Figure 4A). SARS N antigen is readily detected within the ACE2 
expressing ciliated cells of icSARS (Figure 4B) and D22 (Figure 4D) infected cell cultures but is only 
sporadically detected in icSZ16-S K479N p6 (Figure 4C) infected cell cultures.  Nevertheless, the HAE 
evolved D22 and parent zoonotic icSZ16-D K479N viruses encode ciliated cell tropisms that were similar 
to that seen in late phase epidemic strains. 
Plaque reduction neutralization assay using human monoclonal antibody S230.15.  Future outbreaks 
of SARS-CoV would most likely emerge from pools of zoonotic virus and it is imperative that vaccination 
or sero therapies be effective against both past and future emergent zoonotic strains.  S230.15 is a human 
monoclonal antibody (mAb) that is broadly neutralizing through the binding to the RBD though the specific 
location of the epitope is unknown(205, 256).  The epidemic strain and the evolved D8 and D22 viruses are 
equally neutralized by S230.15 (PRNT50 0.0625µg/ml) while the icSZ16-S K479N is eight times more 
resistant (PRNT50 0.5µg/ml) (Figure 5). Since icSZ16-S K479N and the evolved D8 virus only differ in 
one amino acid within the S protein, these data suggest that the S230.15 epitope resides near residue 442.  
Moreover, these data suggest that as SZ16-like zoonotic SARS-CoV adapt to the hACE2 receptor in the 
human airway, they may become more susceptible to S230.15 neutralization, especially if they evolve 
mutations at residue 442.  As an isotype control, an irrelevant cholera toxin specific antibody (D2.2) was 
used in a PRNT assay with the mutant virus panel and none of the viruses were neutralized at any 
concentration of antibody (Data not shown). 
icSZ16-S K479N and D22 virus replicate in lungs of young BALB/c mice but do not cause clinical 
signs in young or senescent BALB/c mice. Since the epidemic strain may no longer exist in nature and 
future epidemic SARS-CoV strains would most likely evolve from zoonotic pools of virus, it is prudent to 
employ an antigenically divergent panel of zoonotic challenge viruses to assess therapeutic efficacy and 
cross reactivity.  To this end, it is imperative that challenge virus behave similarly in current animal models 
used to assess vaccine efficacy.  Infection of young BALB/c mice with SARS Urbani typically does not 
cause clinical signs(41, 169).  Young mice that were either mock infected or infected with icSARS, 
icSZ16-S K479N or D22 viruses did not lose weight or present with other clinical signs (Figure 6A).  
Clinical outcomes in senescent mice infected with icSZ16-S K479N or D22 mirrored that of young mice 
with senescent mice losing little to no weight following infection (data not shown).  The icSZ16-S K479N 
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and D22 viruses replicated in the lungs of young BALB/c mice to similar titers as the epidemic strain on 
day two post infection (pi) (~3x106pfu/g) (Figure 6B). By day 4 pi, the titers of the SZ16 lineage viruses 
were about 1 log lower than the epidemic strain suggesting that the civet viruses might be cleared more 
rapidly (Figure 6B).  
Rosetta Design modeling of S RBD and ACE2 interactions.  Rosetta design was used to model hACE2’s 
interactions with the RBDs of SZ16, SZ16 K479N, D8 and D22 viruses.  In contrast to the epidemic strain 
N479 residue, the SZ16 K479 residue appears to electrostatically clash with ACE2 binding partners K31 
and H34. After a point mutation (K479N) is introduced in the civet S RBD, the repulsive forces of the civet 
K479 are eradicated allowing for S and ACE2 binding(Figure 7A, B and C).  The Urbani RBD residues 
442 and 479 are predicted to have single hACE2 binding partners (442 interacts with H34, 479 interacts 
with K31) (Figure 7A).  Though residues 442 and 479 of the SZ16 K479N RBD are identical to Urbani, 
residues 442 and 479 are predicted to compete for hACE2 binding partners H34 and 442 is also predicted 
to interact with H34 and K31 of hACE2 (Figure 7C).  The difference in binding efficiencies of seemingly 
similar Urbani and K479N RBD is likely due to subtle alterations of the RBD hydrogen-bonding network 
created by mutations at the peripheral RBD residue 487.  Residue S487 of SZ16 K479N RBD binds to one 
ACE2 residue while T487 of Urbani binds to three residues of ACE2 thereby enhancing S and ACE2 
binding interactions (Figure 7C).  The Rosetta Design model predicts that the Y442F mutation within the 
D8 S protein creates an RBD architecture similar to that of SARS Urbani where S residue F442 and N479 
have singular and unique hACE2 binding partners (442 binds K31 of hACE2 and 479 binds H34 of 
hACE2) while retaining the S487 and Y41 interaction and hydrogen bonding network (Figure 7C and D).  
Finally, while the D8 L472 residue is predicted to have only two potential ACE2 binding partners (L79 and 
M82), the L472F mutation of the D22 S protein is predicted to increase the numbers of possible binding 
partners of ACE2 to three residues (L79, M82 and Y83) thereby strengthening S binding (Figures 7D and 
E). 
Discussion 
 Past and present sporadic reemergence of Chikungunya, Ebola, and Nipah viruses highlight the 
severe pathogenic and epidemic potential of zoonotic viruses and the identification of the animal reservoir 
host is often elusive(85, 115, 125, 204, 222).  Live animal markets in China and elsewhere have been 
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proven to be an important factor in cultivating food borne illnesses and cross species transmission of 
SARS-CoV, avian influenzas and other pathogens(143, 243, 244).  Within the live animal markets of 
China, dense human and animal populations mix creating an environment ripe for the exchange of virus 
from animal to human and from human to animal.  During the SARS-CoV epidemic, the Himalayan palm 
civet was identified as a principle source of the SARS-CoV zoonosis though 1,107 civets on farms that 
supplied the markets tested negative suggesting that the civets were infected within the markets(94). 
Moreover, sequence analysis of bat and civet associated SARS-CoV has provided more definitive evidence 
that bat associated SARS-CoV jumped the species barrier to infect civets and that bat and civet viruses are 
similar yet distinct from late phase epidemic strain isolates(28, 69, 108, 133, 159, 173).  
 After the identification of ACE2 as the cellular receptor for SARS-CoV, several investigators have 
defined the molecular determinants of virus and receptor interactions that allowed for epidemic SARS-CoV 
host expansion. Prior to this report, key residues in the civet S gene responsible for changes in host range 
were identified using SARS-CoV S pseudotyped retrovirus, but these results had not yet been not 
confirmed in the context of wild-type SARS-CoV infection in vivo or in vitro.  In support of data from Li et 
al, we demonstrate that the civet spiked icSZ16-S virus was capable of a single round of replication 
following transfection of full length genomic RNA but was incapable of infecting naive Vero E6 cells in 
subsequent rounds of infection(119).  However, introduction of a single amino acid mutation (K479N) in 
the icSZ16-S virus S allowed for low level spread and passage in Vero E6 cells.  Both icSZ16-S K479N p3 
and p6 viruses grew similarly in Vero and DBT-hACE2 cells suggesting that the slight differences in their 
ability to cause CPE did not affect virus binding, entry or replication fitness during the time observed and at 
the MOI used in our assays.  Though we did not use icSZ16-S K479N p6 in our HAE growth studies, we 
would expect both p3 and p6 isolates to perform similarly since their growth kinetics in Vero and DBT-
hACE2 cells were similar.  Importantly, the K479N mutation did not result in a virus capable of efficient 
replication in HAE or DBT-hACE2 cells, supporting the argument that additional mutations are required to 
enhance the SZ16 S interaction with the human ACE2 receptor. The differences seen in icSZ16-S K479N 
growth in HAE and Vero E6 cells highlight the strength and relevance of the HAE model of the human 
airway.  Even though the contact residues of primate and human ACE2 are predicted to be similar, the 
differences in icSZ16-S K479N growth in HAE and Vero E6 cells suggest that differences in primate and 
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human ACE2 proteins (89% similar on the amino acid level) may affect binding efficiency or that the 
abundance of mucous and a unique extracellular matrix on the surface of HAE differentially antagonizes 
virus entry.  Thus, in order to study and model S protein and hACE2 interactions, HAE or DBT-hACE2 
cells should be used as a more relevant alternative to Vero E6 cells. Importantly, expression of hACE2 in a 
nonpermissive DBT cell line rendered these cells permissive for icSARS, icSZ16-S K479N, D8, and D22 
virus infection strongly supporting earlier hypotheses that ACE2 is the principle receptor required for 
docking and entry of both human and zoonotic strains(122).   
 In both canine parvovirus (CPV) and 1918 Spanish influenza H1N1, point mutations in viral 
structural proteins responsible for binding to the host cell were sufficient to catalyze host range 
expansion(86, 191). In 1978, two mutations in the capsid protein of feline parvovirus evolved that were 
sufficient to catalyze host expansion causing severe canine infection and a worldwide epidemic in CPV 
naïve canine populations(86, 150).  In 1918, the zoonotic H1N1 influenza virus acquired two mutations in 
HA changing the preferential binding from the avian to the human sialic acid receptor. When the HA 
mutations were coupled with a few additional mutations in the genome, a human pandemic ensued with 
estimated deaths of 20-40 million(150, 191).  Similar to CPV and H1N1 viruses, analyses of zoonotic and 
human SARS- CoV S sequences show a logical progression in S protein mutations that most likely fostered 
host range expansion and increased human pathogenesis(94). Of the 14 amino acids of S that contact 18 
amino acids of ACE2, mutations at positions K479N or S487T have been shown to be equally essential for 
civet S adaptation to human ACE2(119). The K479N mutation removed an electrostatic clash, allowing the 
S RBD to interact with human ACE2, while S487T appears to have subtly remodeled the RBD through 
hydrogen bonding differences that optimized hACE2 binding.  Considering our in vitro evolution data and 
sequence data from the SARS epidemic, we hypothesize that at least two independent mutational pathways 
can optimize hACE2 binding.  The first was observed during the epidemic, where the S487T mutation 
optimized binding as described above.  The second route occurred during our in vitro evolution, whereby 
the Y442F optimized hACE2 binding in the presence of the S487 variant.  
 ACE2 expressing ciliated epithelial cells in the airway are targets for SARS-CoV infection in 
humans, primate and rodent models making the HAE an important in vitro system to study molecular 
mechanisms of animal S adaptation to the human host(70, 71, 144, 168, 169). Since the icSZ16-S virus 
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could not be propagated in Vero E6 cells, we introduced the K479N point mutation in the virus S that was 
sufficient to allow multiple rounds of replication of the civet-spiked icSZ16-S K479N virus in cell culture. 
Passage of the icSZ16-S K479N recombinant virus in HAE resulted in the emergence of S variants that 
could replicate more efficiently. Surprisingly, S487T was not selected with the passage of SZ16 K479N but 
new mutations evolved within contact residues of the D8 and D22 virus RBDs (Y442F and L472F) that 
enhanced virus infection of HAE, Vero E6, and DBT-hACE2 cells. To rule out non-receptor specific cell 
culture adaptations that enhance entry into cells in vitro, we infected DBT cells and did not see evidence of 
virus growth with any of the viruses tested. Moreover, our immunohistochemistry of HAE infected cell 
cultures (Figure 4) suggests that in vitro evolved viruses and the epidemic strain infect similar cell types 
providing further support that non-receptor specific entry adaptations had not occurred in our model.  
Recent passage of a related coronavirus, mouse hepatitis virus (MHV), in cell lines resulted in variants with 
expanded host range due to the acquisition of a common non-receptor specific cell culture adaptation using 
heparin sulfate for virus entry into cells(34). Most recently, McRoy et al demonstrated that passage of 
MHV in cell lines resulted in expanded host range through mutations within the fusion peptide and heptad 
repeats demonstrating that host range can be governed by changes in spike fusogenicity(137).  From 
sequence analysis, we concluded that the in vitro evolved mutations of icSZ16-S K479N had not created a 
heparin consensus binding site (XBXBBX) and that our adaptive mutations were constrained to the RBD.  
 To determine the potential impact of the mutations acquired during HAE passage, we used Rosetta 
Design to generate structural models of the SZ16, K479N, K479N D8 or K479N D22 RBDs, and then 
superimposed these models onto the existing crystal structure of the SARS Urbani RBD bound to hACE2 
(PDB Accession no. 2AJF), (Figure 7A). Similar to Li et al, we observed that residue K479 of the SZ16 S 
inhibited binding to hACE2 by sterically clashing with residues K31 and H34 (Figure 7B). After the 
K479N mutation, the electrostatic repulsion at residue 479 is eradicated but Rosetta Design predicts that 
local remodeling within the RBD creates cross reactions whereby residues 442 and 479 of the K479N RBD 
compete with each other for interaction with partners H34, K31 and D32 of ACE2 (Figure 7C).  It appears 
that Y442 could interact with all three hACE2 residues while N479 is only predicted to interact with H34 
of hACE2.  We predict that this network of competing interactions reduces the avidity between the K479N 
RBD and the hACE2 receptor by misaligning other key residues in the RBD. Of note, the only difference in 
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the receptor binding domains of SZ16 K47N and Urbani occurs at position 487.  The fact that SZ16 K479N 
is compromised in growth compared to Urbani suggests that the hydrogen bonding differences between 
S487 of SZ16 K47N and Thr487 of Urbani influence the receptor interaction. During the 2003 epidemic, 
S487T likely evolved to eliminate this putative inhibitory effect.  Interestingly, the D8 Y442F mutation also 
restores an optimal RBD by allowing for favorable amino acid packing that recreated an RBD architecture 
similar to that of wild type (Figure 7A and 7D).  In this case, the D8 RBD residues 442 and 479 have 
distinct and unique interaction partners in hACE2, which likely restores avidity to near wild type levels, 
and may explain why D8 virus grows more efficiently than icSZ16-S K479N virus in cells expressing 
hACE2 (Figure 3C and 7D). Thus, at least two independent routes of evolution could increase S RBD and 
human ACE2 interactions.  Leucine 472 of the icSZ16-S K479N and the D8 RBD interacts with L79 and 
M82 of ACE2. The D22 virus RBD is mutated at position 472 from leucine to phenylalanine, which 
Rosetta Design predicts will induce strong hydrophobic interactions between F472 and partners  L79, M82 
and Y83 of ACE2 (Figure 7E).  The D22 virus F472 mutation likely strengthens the binding interface of the 
D22 virus over the D8 strain, which may explain why the D22 virus has a growth advantage over the D8 
virus in HAE, Vero E6 and DBT-hACE2 cells. Of note, it is possible that these viruses acquired replication 
enhancing mutations in structural or non-structural genes that we did not sequence. Nevertheless, these data 
demonstrate the plasticity of the RBD-ACE2 interface site and its ability to subtly remodel the RBD and 
hACE2 binding interface to promote efficient entry and growth.  Clearly, multiple genetic pathways likely 
exist to allow for zoonotic SARS-CoV host range expansion and it will be interesting to determine if other 
contact interface point mutations can enhance zoonotic virus infection of HAE cultures. 
 Since viruses similar to the epidemic strain are currently circulating in bats in China, we may see 
yet another emergence of human SARS-CoV from zoonotic pools of virus.  Therefore, it is imperative that 
current vaccination and passive sero therapies be effective against all known SARS-CoV zoonotic strains 
and their human adapted progeny.  Previous work by Deming et al has highlighted the value of using 
zoonotic strains as challenge virus to assess vaccine efficacy(41).  Deming et al demonstrated that sera 
from animals vaccinated with epidemic strain antigen were not as effective in neutralizing the zoonotic 
icGD03-S virus as compared to the epidemic strain(41).  Within this study, we demonstrated that two 
zoonotic spiked viruses, icSZ16-S K479N and icSZ16-K479N D22, grew to peak titers in the mouse lung 
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similar to that of the epidemic strain two days post infection. In contrast to recombinant SARS-CoV 
bearing early human (GZ02) or civet (HC/SZ/61/03) S proteins that were extremely pathogenic in aged 
animals, icSZ16-S K479N and icSZ16-S K479N D22 caused little to no disease in either young or 
senescent BALB/c mice(172).  Although the SZ16 and HC/SZ/61/03 viruses are both of civet origin, their 
S proteins differ by 18 amino acids(69, 246). The 7 month period of time in between the isolation of SZ16 
(May 2003) and HC/SZ/61/03(December 2003) isolation may help explain their sequence differences(69, 
246). Zoonotic SARS-CoV infection of humans is typically less severe than infection with human strains, 
but it is possible that the sequence differences between the SZ16 and the HC/SZ/61/03 S alter the structure 
of the S proteins such that the viruses bearing the HC/SZ/61/03 S are lethal in mice while our SZ16 lineage 
viruses are attenuated(28, 69, 110, 121, 172, 189). Nevertheless, icSZ16-S K479N and D22 viruses grow to 
similar levels as the epidemic strain in mice, and could be useful as challenge viruses to assess the efficacy 
of vaccines or sero therapies.  The human monoclonal antibody, S230.15, binds within the RBD although 
the specific epitope has yet to be defined(205, 256).  Recent data by Zhu et al have shown monoclonal 
antibodies S230.15 and to a lesser extent m396 are potent and cross neutralizing antibodies against human 
and zoonotic SARS-CoV isolates(205, 256). We have demonstrated that the “evolved” D8 and D22 viruses 
were equally susceptible to neutralization by the human monoclonal antibody S230.15 while the icSZ16-S 
K479N was eight times more resistant. In this instance, these data suggest that as zoonotic virus adaptation 
to the human ACE2 receptor may enhance susceptibility to neutralization by S230.15.  Since there was a 
dramatic difference in neutralization between icSZ16-S K479N and icSZ16-S K479N D8, these data 
suggested that the epitope of S230.15 is in close proximity to residue 442 of the S protein or was affected 
by structural changes associated with mutation of residue 442. Future efforts to revive the divergent wild 
type icSZ16-S virus in vitro will be especially helpful at mapping the S230.15 epitope since it is possible 
that the K479N mutation may contribute to enhanced S230.15 binding. Even though S230.15 is less 
effective at neutralizing icSZ16-S K479N in vitro, recently published passive transfer studies in mice have 
shown that the S230.15 antibody is extremely potent and broad neutralizing in vivo where replication of 
SARS Urbani, icGD03-S and icSZ16-S K479N were not detected in the mouse lung(256).  These data 
highlight the power and utility of zoonotic strains in assessing the efficacy of passive sero therapy both in 
vitro and in vivo.  
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 In conclusion, synthetic biology has been employed to rapidly construct and assemble a 
completely synthetic and infectious 5.3KB bacteriophage, poliovirus, 1918 influenza virus and a panel of 
SARS viruses bearing animal and human S glycoproteins(24, 41, 172, 186, 209). We provide yet another 
example of the utility of synthetic biology by resurrecting the civet SZ16 S.  We have shown that a single 
point mutation (K479N) in the SZ16 S facilitates host range expansion but additional mutations must occur 
for robust infection of human cells.  Mutation of residue 479 (K479N) and 487 (S487T) occurred during 
the early phase of the SARS-CoV epidemic to help facilitate host range expansion. Though we did not 
generate a mutant SZ16 S containing S487T, previous studies have shown that the inclusion of either 479 
or 487 in pseudotype virus bearing the civet S allowed for infection of human cells but this approach 
provides little information on growth efficiency and spread. Through our in vitro evolution of the icSZ16-S 
K479N virus, we discovered a novel evolutionary path by which SARS-CoV S can interface with hACE2 
to allow for efficient infection of human cells. When comparing S mutations acquired during our in vitro 
evolution to mutations that occurred during the evolution of the epidemic strain, the plasticity of the SARS-
CoV S protein becomes starkly apparent. Through the use of HAE cultures, synthetic biology, reverse 
genetics and animal models, we have created a system to isolate and characterize novel genetic pathways of 
zoonotic SARS-CoV S adaptation to the human ACE2 receptor. We have also generated antigenically 
divergent SARS-CoV zoonotic strains that might be useful in assessing SARS-CoV vaccine or sero therapy 
efficacy.  Since future emergence of SARS-CoV will most likely evolve from zoonotic pools of virus, it is 
imperative that current vaccination and passive sero therapies be effective against zoonotic virus, epidemic 
strain virus and all of the evolutionary permutations in between. 
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Figure 1: Phylogenetic relationships of zoonotic SARS-CoV and construction of zoonotic spike 
chimeras within the SARS-CoV infectious clone. Colors in panels A, B, and C denote the phase of the 
SARS-CoV epidemic at which the viruses or amino acid residues evolved. Blue = animal associated, 
yellow = early phase, orange = middle phase, and red = late phase.  (A) Neighbor joining tree constructed 
from nucleotide sequences of various SARS-CoV S genes. Numbers represent bootstrap values based on 
1000 bootstrap replicates. (B) Spike amino acid differences between Urbani, GD03 and SZ16. Known 
neutralizing epitopes are denoted as “A”, “B” and “C”.  (C) Schematic of infectious clone fragments A-F 
and the SARS-CoV genes contained therein.  Using synthetic biology and site directed mutagenesis, we 
reconstructed the SZ16 S that was then inserted into our infectious clone replacing the epidemic strain S. 
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Figure 2: SARS-CoV SZ16 spike chimera, icSZ16-S, replicates in Vero E6 cells but infection cannot 
be passed in culture until a point mutation (K479N) is introduced within the receptor binding 
domain. The expected sizes of the target RT-PCR products are as follows: 3a (1796bp), E (949bp), M 
(666bp) and GAPDH (235bp).  (A) RT-PCR for leader containing transcripts detects actively replicating 
genomic RNA. RT-PCR using RNA extracted from Vero E6 cells transfected with genomic icSZ16-S RNA 
(Passage 0) detects transcripts for the E and M gene of icSZ16-S. (B) Transfer of icSZ16-S supernatants 
from passage 0 to naïve Vero E6 or mink lung epithelial (Mv1Lu) cells does not result in a productive 
infection. As a positive control Vero E6 and Mv1Lu cells were successfully infected with epidemic strain 
supernatants as replication was detected by the presence of leader containing transcripts. (C) In contrast to 
wild-type icSZ16-S, a point mutation (K479N) in the icSZ16-S spike allows for passage of icSZ16-S 
K479N virus in Vero E6 cells.  
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Figure 3: Growth curve analysis of the mutant virus panel in HAE, Vero E6, DBT-hACE2 and DBT 
cells.  (A) HAE cultures were infected with 4.4x104pfu/200µl of with the indicated viruses for 2hr at 37˚C, 
the inoculum was removed and apical surface was rinsed with DPBS. Apical washes were taken at 0, 6, 12, 
24, 36, 48 and 72hr post infection. Virus titers were assessed on Vero E6 cells by standard plaque assay. 
(B-D) Vero E6, DBT-hACE2, or DBT cells were infected with the indicated viruses at an MOI of 0.01 for 
1hr at 37˚C, the inoculum was removed, cultures were rinsed with DPBS and growth media was added. 
Media was sampled at 0, 6, 12, 24, and 36 hr post infection and virus titer was assessed by plaque assay on 
Vero-E6 cells. Data presented are representative of two separate experiments. 
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Figure 4: Immunofluorescence staining of HAE cultures infected with the mutant virus panel.  At 
72hr post infection, mock and infected HAE cultures were PFA fixed and paraffin embedded for tissue 
sectioning. Sections were stained for SARS-CoV N (FITC) and tubulin within cilia (Texas Red) and 
viewed by fluorescence microscopy at a magnification of 100X. Mock (A), icSARS (B), icSZ16-S K479N 
(C), and icSZ16-S K479N D22 (D). 
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Figure 5: Plaque reduction neutralization assay of mutant panel virus using human monoclonal 
antibody S230.15. 100pfu of the indicated virus was incubated at 37˚C for 1 hr with 2-fold dilutions of 
antibody or DPBS in duplicate. After the incubation, the virus/antibody cocktails were used to infect Vero 
E6 cell monolayers for 1hr after which cultures were overlayed with growth media containing agarose. 
After 48 hr, plaques were enumerated. The percentage of neutralization was calculated as: 1-(number of 
plaques with antibody / number of plaques without antibody) x 100%. Error bars represent standard error of 
the mean.  
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Figure 6: Clinical signs and lung titer of 6wk old BALB/c mice infected with DPBS, icSARS, icSZ16-
S K479N or icSZ16-S K479N D22. (A) Mice were infected with 105pfu/50µl intranasally (n= 10 per virus) 
and weight was monitored daily.  (B) Lungs were removed on days 2 and 4 post infected (n=3 mice per 
group per day), homogenized and centrifuged to pellet debris. Supernatants were used in a standard plaque 
assay to determine lung titer (pfu/g).  
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Figure 7: Rosetta Design modeling of “evolved” mutations that enhance spike binding to ACE2. 
Rosetta Design was used to generate structural models of SZ16 and mutant RBDs that were then 
superimposed onto the existing crystal structure of the SARS Urbani RBD bound to ACE2. (A) Epidemic 
strain and hACE2 RBD architecture (B) SZ16 and hACE2 interaction is inhibited by steric clashing, shown 
as red dots, of K479 of S and residues K31 and H34 of hACE2 (C) Electrostatic repulsion at residue 479 is 
eradicated allowing S and ACE2 binding but local remodeling within the RBD due to hydrogen bonding 
differences at residue 487 create cross reactions whereby residues 442 and 479 of K479N compete with 
each other for interaction partners H34, K31 and D32 of hACE2 (D) Y442F mutation of icSZ16-S K479N 
D8 restores an optimal RBD allowing for favorable packing to create an architecture similar to that of wild 
type (E) Leucine 472 of the icSZ16-S K479N and D8 S interacts with L79 and M82 of ACE2. The icSZ16-
S K479N D22 L472F mutation is predicted to have hydrophobic interactions with three potential partners 
L79, M82 and Y83 of hACE2 that is predicted to increase stability of binding.  Green dots on the hACE2 
indicate residues which are within 4 angstroms and thus are predicted to interact with the S residues shown 
in red.
 
 
 
 
 
 
CHAPTER III 
 
PATHWAYS OF CROSS SPECIES TRANSMISSION OF SYNTHETICALLY RECONSTRUCTED 
ZOONOTIC SARS-CoV 
 
 
Abstract 
Zoonotic SARS Coronavirus (SARS-CoV) likely evolved to infect humans by a series of transmission 
events between humans and animals for sale in markets in China. Virus sequence data suggests the palm 
civet served as an amplification host where civet and human interaction fostered the evolution of the 
epidemic strain SARS Urbani (Urbani). The prototypic civet epidemic strain of SARS-CoV, SZ16, was 
isolated from a palm civet but has not been successfully cultured in vitro. In order to propagate a chimeric 
recombinant SARS-CoV bearing an SZ16 Spike (S) glycoprotein, we constructed cell lines expressing the 
civet ortholog (DBT-cACE2) of the SARS-CoV receptor (hACE2).  Zoonotic SARS-CoV were completely 
dependent on ACE2 for entry. Urbani grows with similar kinetics in both DBT-cACE2 and DBT-hACE2 
cells while icSZ16-S only grows within DBT-cACE2 cells.  In vitro “evolved” SZ16 S mutant viruses with 
enhanced affinity for hACE2 exhibited severe growth defects in DBT-cACE2 cells suggesting that 
evolutionary pathway that promoted efficient hACE2 interactions, simultaneously abolished efficient 
interactions with cACE2. Structural modeling reveals two distinct biochemical interaction networks by 
which zoonotic RBD architectures can productively engage hACE2. However only the Urbani mutational 
spectra promoted efficient usage of both hACE2 and cACE2 binding interfaces. Since dual species tropism 
is retained by Urbani, it is likely that it retained high affinity for cACE2/hACE2 receptors by evolving 
through repeated passage between human and civet hosts. Zoonotic SARS-CoV were variably neutralized 
by antibodies that were effective against the epidemic strain highlighting their utility to evaluate passive 
immunization efficacy. 
Introduction 
 Within wet markets in China, a wide range of common and exotic food animals like bats and 
civets are sold live or as fresh meat for human consumption in part to improve health and sexual 
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performance (28, 69, 236, 238). In Southern China, the consumption of exotic animals is especially 
prevalent during the winter months when most respiratory tract infections are highly prevalent(236). Since 
many zoonotic viral pathogens are shed in stool, densely housed birds and mammals shedding excreta in 
the wet marketplace creates a ripe atmosphere for zoonotic virus transmission to human consumer 
populations(236).  Most recently, wet markets in Southeast Asia have been associated with cultivating the 
cross species transmission of avian influenza H5N1 and the newly emerged severe acute respiratory 
syndrome coronavirus (SARS-CoV)(69, 108, 236). 
 In 2002, a novel coronavirus, SARS-CoV, emerged suddenly as the causative agent of severe 
acute respiratory syndrome (SARS) and spread worldwide causing about 8000 cases and >700 deaths(29, 
173, 236). Viruses similar to the epidemic strain, SARS Urbani, were isolated from animals for sale within 
wet markets in China during the epidemic in 2003 and the reemergence in 2004(28, 69).  Genome 
sequences of viruses isolated from bats, civets and humans suggest that viruses circulating in bats crossed 
the species barrier to infect civets who then served as an amplification host for yet another host range shift 
generating a human tropic virus(28, 69, 108, 122).  Recent surveys of animal populations in North 
America, Africa, and China implicate bats as reservoirs of a diverse group of coronaviruses including 
SARS-CoV like progenitors(43, 44, 108, 109, 141, 234, 236, 237).  As some bat species were found to be 
coinfected with more than one coronavirus lineage, recombination between and within genogoups and 
subsequent emergence of novel coronavirus is a real possibility(109).  In 2007, surveys of wild Asian 
leopard cats and Chinese ferret badgers revealed the presence of yet more novel and highly divergent 
coronavirus circulating in animals typically sold in wet markets in China(44).  Since viruses similar to the 
epidemic strain of SARS-CoV are currently circulating in zoonotic pools, the future emergence of a SARS-
CoV like virus may occur.  Therefore, it is imperative that current vaccination and passive immunization 
therapies be effective in protecting humans from infection by a wide range of epidemic and zoonotic 
SARS-CoV.  Unfortunately, bat-SARS-CoV and the prototypic civet SARS-CoV strain, SZ16, have not 
been able to be cultured in vitro hampering our ability to evaluate their epidemic potential, pathogenesis 
and susceptibility to current therapeutic interventions within in vitro and in vivo models(108, 110). 
 SARS-CoV spike gene (S) sequences isolated from human cases during the early phase of the 
epidemic in 2002-2003 and during the reemergence of 2003-2004 are very similar to the SZ16 strain(28, 
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69, 94). SZ16 was isolated from palm civets in wet markets within Guangdong region of China during the 
epidemic and its S protein differs from the epidemic strain in 18 amino acids 16 of which reside in the S1 
domain containing the receptor binding domain (RBD)(69). SARS GD03 was isolated from a sporadic 
human case during the reemergence in 2003-2004 and closely resembles those viruses isolated from civets 
and raccoon dogs within wet markets(28). SARS GD03 differs from the epidemic strain in 17 amino acids 
16 of which reside in the S1 domain(28). Recently we have shown that a recombinant SARS-CoV bearing 
the SZ16 S (icSZ16-S) was capable of replication within Vero E6 cells but progeny virions were unable to 
infect naïve cell cultures, supporting evidence that the binding of the civet S to the human SARS-CoV 
receptor (angiotensin I converting enzyme 2, hACE2) was inefficient(122). Since clinical SZ16 isolates and 
our recombinant chimeric icSZ16-S virus could not be successfully cultured in vitro, the biology of the 
SZ16 S and its effect on virus growth and pathogenesis remains elusive. 
 In this study, we describe the recovery and growth of icSZ16-S in culture using cells stably 
expressing the civet ortholog (cACE2) of hACE2. Like the epidemic strain, both icSZ16-S and icGD03-S 
are completely dependent on ACE2 for entry.  In DBT-cACE2 cells, icSZ16-S grows with similar kinetics 
to that of the epidemic strain but point mutations in the SZ16 S glycoprotein that enhance growth in hACE2 
expressing cells abrogate growth in cACE2 expressing cells.  The epidemic strain grows equally well in 
cACE2 or hACE2 expressing cells suggesting that epidemic strain evolution probably occurred through 
repeated exchange of virus between civet and human thus retaining dual host tropism.  icSZ16-S and 
icGD03-S are moderately susceptible to neutralization by the human monoclonal antibody (mAb) S230.15.  
Unlike the epidemic strain, zoonotic viruses are resistant to mAb S3.1 suggesting that therapeutics 
successful against directed against the epidemic strain may not work as well against zoonotic viruses. 
These data highlight the utility of employing antigenically diverse zoonotic S panel of SARS-CoV in the 
study of host range expansion and antiviral therapy efficacy. 
Materials and Methods 
Viruses and Cells.  The recombinant epidemic strain virus “icSARS” (GenBank accession no. 
AY278741), icSZ16-S (GenBank accession no. AY304488), icGD03-S (GenBank accession no. 
AY525636), icCUHK-W1 (GenBank accession no. AY278554), icGZ02 (GenBank accession no. 
AY390556), icSZ16-S K479N, icSZ16-S K479N D8, and icSZ16-S K479N D22 were propagated on Vero 
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E6 or DBT cells stably expressing cACE2 (DBT-cACE2) as described(41, 172, 179, 180, 247). icSZ16-S 
virus supernatant from the electroporated cell culture (passage zero), was passaged on DBT-cACE2 cells 
four times at 48hr intervals after which a robust cytopathic effect observed.  icSZ16-S was then plaque 
purified on DBT-cACE2 cells and plaques were expanded in 6-well dishes of DBT-cACE2 cells. 6-well 
dish supernatant was used to infect a T175 flask of DBT-cACE2 cells to generate a virus stock that was 
harvested after 20 hours post infection (hpi).  Viral RNA from the icSZ16-S virus stock was isolated using 
TRIzol (Invitrogen, Carlsbad, CA), cDNA was synthesized using SSII (Invitrogen, Carlsbad, CA) and 
amplicons spanning the S, 3a, E and M genes were generated by RT-PCR and directly sequenced.  Virus 
stocks used throughout this study were grown and titered by plaque assay in Vero E6 and/or DBT-cACE2 
cells as described(249).  Vero E6 and DBT cells were grown in MEM (Invitrogen, Carlsbad, CA) 
supplemented with 10% FCII (Hyclone, South Logan, UT) and gentamycin/kanamycin (UNC Tissue 
Culture Facility).  DBT-cACE2 and DBT-hACE2 were grown in Vero/DBT growth media supplemented 
with 700µg/ml G418 (Invitrogen, Carlsbad, CA).  All virus work was performed in a Class II biological 
safety cabinet in a certified biosafety level 3 laboratory containing redundant exhaust fans while wearing 
Tyvek suits and PAPRs as described(249).   
Generation of cACE2 expressing DBT cells.  Plasmids encoding N-terminal myc tagged human (hACE2) 
and civet (cACE2) angiotensin converting enzyme-2 (ACE2) were kindly provided by M. Farzan at the 
New England Primate Research Center. The construction of the DBT-hACE2 cell line is described in 
Sheahan et al(180). The cACE2 gene was amplified by PCR using Expand High Fidelity polymerase 
(cACE2F 5’-caccATGTCAGGCTCTTTCTGGCTCC-3’, cACE2Rh 5’- 
AAATGAAGTCTGAACGTCATCAG-3’).  Amplicon was gel purified and cloned into pcDNA3.1/V5-His 
according to protocol. The cACE2 reverse primer did not contain a stop codon allowing for read through 
and the inclusion of a 6X his tag on the 3’ end. pcDNA cACE2-His plasmids were sequenced and found to 
have two amino acid changes, G354D and R736Q, as compared to the published sequence (Genbank 
accession number AY881174) one of which (G354D) resides in a proposed interaction site with SARS S 
residues Y491 and G488 but these changes were also found in the parent gifted plasmid.  Delayed brain 
tumor cells (DBT) cells were transfected with 4µg of pcDNA3.1/V5-His expressing cACE2-His or GFP-
His using the Fugene reagent (Roche, Indianapolis, IN). After 24 hours, cells were placed under continuous 
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drug selection using 700µg/ml of G418 (Invitrogen, Carlesbad, CA).  DBT-cACE2-His, DBT-hACE2, and 
DBT-GFP-His cells were passaged 4 times under drug selection and then sorted for high ACE2 or GFP 
expression and expanded for future use.  
Cell sorting and FACS analysis of DBT expressing ACE2 stable cell lines.  106 DBT (control), DBT-
hACE2, and DBT-cACE2-His cells were blocked with DPBS/5% FBS and stained with a polyclonal goat 
anti human ACE2 (R+D Systems, Minneapolis, MN) followed by a secondary anti-goat IgG-FITC 
(Invitrogen, Carlsbad, CA) antibody. Stained DBT, DBT-hACE2, DBT-cACE2-His and unstained DBT-
GFP-His cells were sorted on a Cytomation Inc. MoFlo cell sorter (Dako, Denmark) for medium to high 
FITC or GFP expression and sorted cells were expanded in four passages after which stocks of DBT, DBT-
hACE2, DBT-cACE2-His, DBT-GFP-His were cyropreserved for future experiments. To assess transgene 
expression in post-sorted cell stocks, 5x105 DBT, DBT-hACE2, DBT-cACE2-His, DBT-GFP-His or Vero 
E6 cells were seeded into 6-well dishes. 24 hours later, media was removed and the cells were removed 
from the plate with Versene (UNC Tissue Culture Facility).  Cells were stained for FACS analysis as done 
above and analyzed for FITC/GFP expression by FACScan (BD Biosciences, San Jose, CA).  
Western blot analysis of DBT expressing ACE2 stable cell lines.  To assess transgene expression in post 
sorted cell stocks by Western Blot, DBT, DBT-hACE2, DBT-cACE2-His, DBT-GFP-His and Vero E6 
cells were seeded in 6-well dishes at 5x105 cells/well. 24 hours later, cells were lysed with protein lysis 
buffer (1% Triton X-100, 0.5% SDS, in 1X TBS). 20µl of cell lysates were heated at 70˚C in 1X Nupage 
buffer/4% BME, loaded on a Nupage 12% Bis-Tris SDS PAGE gel (Invitrogen, Carlsbad, CA) and 
separated at 150 volts for 2 hrs. Proteins were transferred to nylon membrane using the NuPage transfer 
apparatus according to the manufacturers protocol. Membranes were blocked with 5% milk and probed 
with either polyclonal goat anti-human ACE2 (R+D Systems, Minneapolis, MN) or mouse anti-penta-His 
antibody (Qiagen, Valencia, CA).  Membranes were washed with 1X TBS/0.1% Tween 20 and then probed 
with either rabbit anti-goat HRP (Invitrogen, Carlsbad, CA) or anti-mouse IgG-HRP antibody (Amersham, 
Piscataway, NJ).  Membranes were rinsed and then treated with ECL Plus reagent (Amersham) and then 
exposed to radiographic film (Amersham). 
RT-PCR to detect viral subgenomic leader containing transcripts, ACE2 and GAPDH transcripts. 
RT-PCR to detect subgenomic leader containing transcripts was performed to detect viral replication as 
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described in Sheahan et al(180).  DBT, DBT-GFP-His, DBT-cACE2, DBT-hACE2, or Vero E6 cells were 
seeded at 5x105 cells/well in a 24 well dish.  24hr later, cells were infected with 100µl of viral supernatant 
from the initial icSZ16-S transfection, icSARS supernatants or were mock infected.  24hpi, total RNA was 
isolated using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol.  1 µg of 
total RNA was used to generate cDNA by Superscript II (Invitrogen, Carlsbad, CA) using random hexamer 
primers (Invitrogen, Carlsbad, CA). cDNA was then used as template for PCR using Taq polymerase 
(NEB, Ipswich, MA). Evidence of SARS-CoV replication and subgenomic transcription (3a = 1796bp, E = 
947bp, M = 666bp) was detected using a leader forward (CTCTTGTAGATCTGTTCTCTAAACGAAC) 
and reverse primer in the M gene (TTACTGTACTAGCAAAGCAATATTGTCG). Detection of ACE2 
transcripts was performed using a conserved primer set capable of detecting primate, human and civet 
ACE2 (258bp) (ACE2RTF2 5’-AGCCTAAAATCAGCTCTTGG-3’,  ACE2RTR2 5’-
CCGGGACATCCTGATGGC-3’).  Detection of GAPDH (235bp) (GAPDHF 5’-
CATGGGGAAGGTGAAGGTCG-3’, GAPDHR 5’-TTGATGGTACATGACAAGGTGC-3’) messages by 
RT-PCR was used as a positive control.  PCR reactions were separated by gel electrophoresis on 1.8% 
agarose TAE gels and visualized by ethidium bromide staining. 
Growth curve analysis in Vero E6, DBT-cACE2, DBT hACE2, or DBT cells. Vero E6, DBT-cACE2, 
DBT-hACE2 or DBT cells were infected with icCUHK-W1, icGD03-S, icGZ02, icSZ16-S K479N p6, 
icSZ16-S K479N D22, icSARS, or icSZ16-S, at an MOI of 0.01 for 1hr at 37˚C after which the inoculum 
was removed, the monolayer was rinsed with DPBS, and growth media was added. Virus stock titers 
generated by plaque assay in DBT-cACE2 cells were used to calculate MOI for the DBT-cACE2 growth 
curve.  Virus stock titers generated by plaque assay in Vero E6 cells were used to calculate MOI for the 
Vero E6 and DBT-hACE2 growth curves.  25µl of cell media was removed at 0, 6, 12, 24 and 36 hpi and 
samples were stored at -80˚C until titered by plaque assay. For all growth curves except those performed 
within DBT cells, the cell type used for growth curve analysis was also utilized for the titration of growth 
curve samples by plaque assay. For example, samples generated from growth curves performed within 
DBT-cACE2 cells were titered on DBT-cACE2 cells.  All DBT cell growth curve samples were titered on 
DBT-cACE2 cells.  Since previous experiments suggested that Vero E6 and DBT-hACE2 cells were not 
permissive for icSZ16-S infection, icSZ16-S samples from DBT-hACE2 and Vero E6 growth curves were 
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titered on DBT-cACE2 cells.  Growth curves were performed in duplicate. Growth curves were performed 
on two independent occasions and data shown is one representative experiment. 
ACE2 blockade experiments in DBT-cACE2. DBT-cACE2 cells were seeded at 5x105cells/well in 6-well 
dishes.  The following day, cell media was removed and cells were incubated with 10, 5, 2.5, 1.25 or 
0.625µg/ml polyclonal anti-ACE2 or anti-ACE antibody (R+D Systems, Minneapolis, MN) or DBPS for 
1hr at 37˚C. After the 1hr pretreatment with antibody, 100pfu/50µl of icSARS, icSZ16-S, or icGD03-S, 
was added to the antibody mixture and incubated 1hr at 37˚C.  After the infection, the inoculum was 
removed, the monolayer was rinsed with 2 times with 1ml DPBS then overlayed with 0.9% agarose in 
complete growth media. After 48hpi, plates were stained with neutral red and plaques were counted. The 
average percent blockade was calculated by dividing the average number of plaques per Ab dilution by the 
average number of plaques in the DPBS no Ab controls.  Virus stock titers generated by plaque assay in 
DBT-cACE2 cells were used to calculate virus concentrations for the blockade experiment. Blockade 
experiments were performed in duplicate on two separate occasions. 
Plaque reduction neutralization assay (PRNT).  Neutralizing titers were determined by plaque reduction 
neutralization titer assay (PRNT) as described in Rockx and Sheahan et. al. (171, 172, 180). Briefly, 24hr 
prior to infection, 6-well plates were seeded with 5x105 DBT-cACE2 cells/well.   Human monoclonal 
antibodies (mAb) S230.15 and S3.1 directed against the SARS-CoV S and an isotype control antibody 
directed against cholera toxin, D2.2, were kindly provided by A. Lanzavecchia.  mAbs were serially diluted 
two-fold, and incubated with 100 pfu of either icSARS, icSZ16-S, or icGD03-S for 1 hour at 37ºC. Virus 
and antibodies were then added to 6-well plates of Vero E6 cells in duplicate and incubated at 37˚C for 1 
hour after which the cells were overlayed with 0.8% agarose in media. Plates were incubated for 48 hours 
at 37ºC, stained with neutral red for 3 hours and plaques were counted. The percentage of neutralization 
was calculated as: 1-(number of plaques with antibody / number of plaques without antibody) x 100%.  
Computer modeling of RBD interactions with cACE2 and hACE2.  Based on the reported crystal 
coordinates of SARS Urbani RBD interacting with the hACE2 receptor (PDB code 2AJF), we generated 
models of SZ16, SZ16-K479N, and SZ16 K479N D22 RBD interaction with either cACE2 or hACE2 using 
the Rosetta Design web server (http://rosettadesign.med.unc.edu/) as described(119, 180).  Briefly, each 
amino acid to be altered was highlighted and all other amino acids within an interaction distance of 5 
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angstroms were identified.  Using the Rosetta Design website, the amino acid replacements were 
incorporated and all amino acids within the 5 angstrom interaction distance were relaxed to allow the 
program to repack the side chains to an optimal energetic state.  This process was repeated with each 
mutation and series of mutations.  Ten models were generated for each set of mutations, and the best 
model, based on lowest energy score, was selected and further evaluated using Mac Pymol. 
Results 
Construction and Characterization of ACE2 expressing stable cell lines.  Since previous efforts to 
culture either wild-type SARS-CoV SZ16 or recombinant icSZ16-S were unsuccessful, we used a cell 
based approach to resurrect icSZ16-S(110, 180).  We constructed stable cell lines expressing cACE2-His, 
hACE2 and GFP-His in the DBT cell background.  The gifted cACE2 gene utilized to construct our stable 
cells varied in two amino acids (G354D and R736Q) as compared to the published sequence. The stable 
cells were sorted for medium to high ACE2 or GFP expression and cultivated master cell stocks were 
analyzed by flow cytometry and Western Blot (Figure 1).  By flow cytometry and Western Blot, hACE2 
expressing cells had the highest ACE2 protein expression as compared to Vero E6 and DBT-cACE2.  
Contrary to the Western Blot analysis that was performed under reducing conditions, cACE2 expression by 
flow cytometry appears to be lower than that of Vero E6 cells although this may be mediated by less 
efficient interactions between polyclonal hACE2 antibody and cACE2 in its natural conformation in flow 
cytometry.  In support of the hypothesis that polyclonal anti-hACE2 may not bind to cACE2 as efficiently 
in its natural conformation, the cACE2 and hACE2 proteins are only 83.5% similar.  Positive control GFP-
His exhibited a high level of GFP expression by flow cytometry and Western blot. ACE2 expression was 
not detected in untransfected DBT cells. 
Resurrection of icSZ16-S in DBT-cACE2 cells.  To assess virus replication and ACE2 transgene 
expression in our cell panel, we employed a highly sensitive RT-PCR based assay.  In the coronavirus 
model of discontinuous transcription, subgenomic messages all contain the same 5’ leader sequence(177). 
Thus, active SARS-CoV replication and mRNA synthesis can be detected by RT-PCR for viral subgenomic 
leader containing transcripts.  In our assay, we use a forward primer directed against the leader sequence 
and a reverse primer in the M gene allowing us to preferentially detect subgenomic transcripts encoding the 
ORF 3a, E, and M genes.  ACE2 transcripts were detected by RT-PCR in mock infected cell cultures of 
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DBT-hACE2, DBT-cACE2, and Vero E6 cell cultures (Figure 2).  ACE2 transcripts were not detected in 
DBT cells corroborating our flow cytometry and Western blot results.  As expected GAPDH positive 
control transcripts were detected at similar levels in all mock infected cell cultures while none of the mock 
infected cultures were positive for SARS-CoV replication (Figure 2).  In the icSARS infected cell panel, 
DBT-cACE2, DBT-hACE2 and Vero E6 cells were clearly capable of supporting efficient SARS-CoV 
replication. Under identical conditions, SARS-CoV leader containing transcripts were not detected in 
control DBT and DBT-GFP-His cells (Figure 2).  Interestingly, only cACE2 expressing cells efficiently 
supported the replication of icSZ16-S.  Importantly, icSZ16-S was successfully passaged and maintained in 
DBT-cACE2 cells in vitro producing a robust cytopathic after four passages at 48hr intervals.  Passage four 
virus was plaque purified, stocks were grown and the S, 3a, E and M genes were sequenced.  Only one 
coding mutation (Y107H) was found in the 3a gene. 
Assessment of virus growth in DBT, DBT-cACE2, DBT-hACE2, and Vero cells. Prior to this report, 
zoonotic SARS S and human/civet ACE2 interactions were evaluated using pseudovirus bearing GD03 and 
SZ16 S proteins but these assays were unable to address virus growth fitness(122, 242). Moreover, one 
study suggested that the GD03 S was not dependent on ACE2 for docking and entry(242).  Consequently, 
we assessed the growth fitness of recombinant virus bearing various S glycoproteins derived from the early, 
middle and late phases of the SARS epidemic in China.  We employed recombinant SARS-CoV bearing S 
genes isolated from humans during the early (icGZ02), middle (icCUHK-W1), and late (icSARS) phases of 
the epidemic and one isolate from a sporadic human case in early 2004 (icGD03-S).  The GD03, GZ02 and 
CUHK-W1 S glycoproteins differ from the epidemic strain in 17, 8 and 2 amino acids, respectively (Figure 
3D).  We also evaluated the growth of icSZ16 parent virus and two SZ16 mutants previously described in 
Sheahan et al that were selected for efficient growth in human airway epithelial cells (HAE)(180).  The 
SZ16, SZ16-K479N and SZ16-K479N D22 S glycoproteins differ from the epidemic strain in 18, 17, and 
19 amino acids, respectively.  The growth fitness of the virus panel was assessed within DBT, DBT-
cACE2, DBT-hACE2 and Vero cell cultures (Figure 3A, B, C). Cultures were infected at an MOI of 0.01 
for 1hr, subsequently washed to remove input virus, growth media was added and then sampled at various 
times post infection.  DBT cells not transfected with the SARS receptor, ACE2, were not permissive to 
infection by any of the viruses tested (Data not shown).  Within DBT-cACE2 cells, icSARS, icSZ16-S, 
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icGZ02, and icGD03-S grew to similar peak titers at 36 hpi (Figure 3A).  In DBT-cACE2 cells at 12 hpi, 
icSZ16-S titers were approximately one log higher than all of the other viruses tested (Figure 3A).  
Interestingly, CUHK-W1 had severely delayed growth kinetics within the cACE2 expressing cells.  
Similarly, icSZ16-S K479N and icSZ16-S K479N D22 exhibited little to no growth in the DBT-cACE2 
cells though their S proteins differ from SZ16 in 1 (K479N) and 3 (D22) amino acids (Figure 3A).  Within 
DBT cells expressing the hACE2, the epidemic strain exhibited superior growth fitness as compared to the 
other viruses tested with a 1-2 log titer advantage at 12 hpi. Within DBT-hACE2, icSARS, icCUHK-W1, 
icGZ02, icGD03-S and icSZ16-K479N D22 grew to similar peak titers 36hpi while icSZ16-K479N grew 
more poorly reaching titers less than 104pfu/ml and icSZ16-S did not grow at all (Figure 3B).  Vero E6 cell 
growth kinetics for icSARS, icCUHK-W1, icGZ02 and icSZ16-S K479N D22 were quite similar reaching 
titers around 107pfu/ml  at 36hpi while icSZ16-S K479N and icGD03-S grew much more poorly 
(~105pfu/ml at 36hpi) (Figure 3C).  As we had seen by RT-PCR, the Vero E6 cell was not permissive to 
infection by icSZ16-S (Figure 3C). 
icGD03-S and icSZ16-S are dependent on ACE2 for entry.  Using pseudotyped viruses, previous reports 
have suggested that some zoonotic SARS-CoV do not use ACE2 for entry(242).  In order to assess receptor 
dependence of the recombinant SARS-CoV strains bearing zoonotic S proteins, we utilized a receptor 
antibody blockade assay (Figure 4). Two-fold dilutions of antibody (pAb anti-ACE2) or control antibody 
(pAb anti-ACE) were used to block ACE2 within DBT-cACE2 cells that were subsequently infected with 
100pfu of icSARS, icGD03-S or icSZ16-S, rinsed and overlayed with media containing agarose.  All three 
viruses tested were equally dependent on ACE2 for entry exhibiting a dose dependent response to anti-
ACE2 receptor blocking antibody (Figure 4).  Control antibody (pAB anti-ACE) was not capable of 
blocking entry of any of the viruses tested in a dose dependent manner firmly establishing that ACE2 is a 
receptor for both epidemic and civet strains of SARS-CoV (Figure 4). 
mAb S230.15 and S3.1 neutralization profiles differ between epidemic, in vitro evolved and zoonotic 
strains of SARS-CoV.  S230.15 and S3.1 are human monoclonal antibodies (hu-mAb) that were isolated 
from a convalescent SARS patient’s B cells.  In order to assess neutralization efficacy of the above hu-
mAb, we employed a plaque reduction neutralization assay (PRNT) with the following challenge viruses: 
icSARS (epidemic strain S protein), icGD03-S (divergent human strain S protein), icSZ16-S (prototypic 
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civet strain), icSZ16-S K479N (SZ16 S protein mutated at residue 479 from lysine to asparagine), icSZ16-S 
K479N D22 (in vitro evolved mutant with enhanced growth within human cells whose S is mutated at 
Y442F and L472F).  The broadly neutralizing hu-mAb, S230.15, was able to neutralize 50% (PRNT50) of 
icSARS and the evolved icSZ16-S K479N D22 virus using less than 0.03125µg/ml of antibody while 
icGD03-S, icSZ16-S K479N and icSZ16-S were approximately four times more resistant (PRNT50 = 
0.125µg/ml) (Figure 5A).  The S3.1 hu-mAb was not as effective at neutralizing the viruses tested 
(PRNT50: icSARS, icSZ16-S K479N = 0.25µg/ml, icSZ16-S K479N D22 = 0.625µg/ml) (Figure 5B).  
Unlike the S230.15, hu-mAb S3.1 was weakly efficacious against icGD03-S (PRNT50 >1µg/ml) and 
completely ineffective against icSZ16-S (Figure 5B). 
Structure models provide insight into the retention of dual species tropism of SARS Urbani.  In order 
to gain a better understanding of the structural changes associated with mutation of both S and ACE2 
proteins, we developed predictive structure models of S and cACE2/hACE2 interactions within Rosetta 
Design.  Our models suggest additional methyl groups in E30 and Y34 of cACE2 likely create an enhanced 
protrusion from the binding interface as compared to hACE2.   The architecture of the Urbani RBD can 
accommodate this protrusion on the cACE2 binding interface thus retaining efficient binding to both 
cACE2 and hACE2 (Figure 6A and 6B).  We and others previously have published structure models that 
suggest that K479 of the SZ16 S inhibits binding to hACE2 because of electrostatic clashes with hACE2 
binding partners K31 and H34 but the SZ16 binding partners within cACE2 are mutated (Y34 and E30) and 
allow for efficient binding of SZ16 S(Figure 6C)(119, 122, 180).  Interestingly, the human ACE2 adaptive 
mutations in SZ16 K479N and SZ16 K479N D22, that progressively remodel the RBD binding interface to 
enhance binding to hACE2 (Figure 6D and 6F) create a steric clash between the RBD V404/F440 and 
E30/Y34 of cACE2 (Figure 6E and 6G).  Similar to what we had seen within in vitro growth analysis, the 
SZ16 K479N and D22 binding interface cannot accommodate the enhanced protrusion of cACE2 and are 
unable to bind efficiently.   
Discussion 
 Recent emergence of viruses like SARS-CoV, Ebola, Influenza H5N1, Marburg, and Nipah 
viruses highlight the pathogenic and epidemic potential of zoonosis in human populations(63, 85, 115, 204, 
236). The identification of zoonotic virus animal reservoirs are often unsuccessful hampering our ability to 
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understand the epidemiology of zoonotic diseases and the conditions required for zoonotic host range 
expansion.  Extensive virus sequencing efforts allowed for the identification of palm civets as a potential 
amplification host for SARS-CoV and the Chinese horsehoe bat as the potential SARS-CoV animal 
reservoir in a short span of 2 years(28, 69).  Though sequencing efforts have revealed much about the 
biology of zoonotic SARS-CoV, bat and civet isolates have not yet been cultured in vitro(108, 110).  Using 
synthetic biology and reverse genetics we constructed a SARS-CoV bearing an SZ16 civet S glycoprotein.  
In corroboration with Lau and Peiris, we have shown that icSZ16-S could not be maintained by passage in 
cell cultures that normally support SARS-CoV infection(110). Without the successful cultivation of 
zoonotic SARS-CoV, their mechanisms of host range expansion and pathogenic potential remain elusive 
and the efficacy of current therapies against zoonotic strains remains unknown.   
 Rather than mutate the SZ16 S glycoprotein in order to promote growth in cell culture, we 
constructed a stable cell line expressing the civet ortholog (cACE2) of the human SARS-CoV receptor 
(hACE2). As compared to the published sequence, the cACE2 gene utilized to construct our stable cells 
differed in two residues, G354D and R736Q, but only the G354 resides in a proposed interaction site with 
SARS S RBD (Y491 and G488)(119).  All of the viruses used within this study have the same amino acid 
at residues 491 (tyrosine) and 488 (glycine).  In turn, if the G354D mutation in our cACE2 protein has a 
deleterious effect on binding and entry, we predict all viruses would be affected equally.  As our data 
regarding Urbani and SZ16 binding to cACE2 and hACE2 is concordant with previously published data by 
Li et. al., we do not think the G354D mutation in cACE2 is altering our virus growth phenotypes(122).  
Within DBT-cACE2 cells, we have demonstrated that icSZ16-S can be grown, maintained and plaque 
purified.  In support of Li et al, we have shown that civet SARS-CoV utilizes cACE2 but cannot utilize 
hACE2 or Vero E6 ACE2 confirming that the civet SZ16 virus is restricted in its host range (Figure 2B).  
Using pseudotyped lentivirus, Li et al showed that the SARS Urbani S is capable of utilizing both cACE2 
and hACE2 and we confirmed these data showing that icSARS is capable of infecting both cACE2 and 
hACE2 expressing cells and replicating to high titer(Figure 2B, 3A, 3B). In support of our RT-PCR data 
that suggesting icSZ16-S was restricted in its host range (Figure 2B), icSZ16-S only grew within cACE2 
expressing cells and grew to titers similar to the epidemic, icGD03-S and icGZ02 strains (Figure 3 A, B, 
and C).  Interestingly, icSZ16-S exhibited a clear growth advantage at 12hpi suggesting that it gains entry 
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into cACE2 expressing cells more rapidly than the other viruses tested.  The icSZ16-S K479N and D22 
viruses were adapted for efficient growth on primary human airway epithelial cell (HAE) cultures known to 
be a robust and relevant model of the complex human airway epithelium.  Importantly, these viruses did not 
grow efficiently within DBT-cACE2 cells suggesting that mutations in the civet S that enhanced growth in 
HAE (K479N, Y442F and L472F) diminished binding of the icSZ16-S K479N/D22 S protein to cACE2.  
In hACE2 expressing cells, the epidemic strain displayed a clear growth advantage at 12hpi but most all 
viruses tested grew to similar peak titers by 36hpi.  In Vero E6 cells, the viruses bearing S proteins more 
similar to the epidemic strain (CUHK-W1, GZ02) grew to peak titers far greater than those viruses bearing 
S proteins more civet like (SZ16, GD03, SZ16 K479N).  As we had expected, icSZ16-S was not capable of 
growth within DBT-hACE2 or Vero E6 cells but mutations in the SZ16 S at select interaction sites with 
ACE2 (K479N, Y442F, L472F) rescue and promote growth in hACE2 or Vero E6 cells. These data suggest 
the SARS-CoV S and receptor interactions are quite specific and capable of restricting host range or 
limiting infection efficiency. Moreover, these data also suggest that very few mutations in the civet S can 
enhance infection of human cells (K479N, Y442F, L472F) but simultaneously abrogate infection of cACE2 
expressing cells.  A corollary is seen in the more human tropic strains.  icCUHK-W1, a middle phase 
epidemic isolate whose S differs from Urbani in 2 amino acids, is quite capable of infecting cells 
expressing hACE2 while it grows very poorly in cACE2 expressing cells as compared to the epidemic 
strain. These data suggest that G77 and/or I244 of the epidemic strain enhance growth in cACE2 expressing 
cells. Though G77 and I244 reside outside of the RBD (248-501aa), their close proximity to the RBD may 
either promote a rearrangement of the S protein subtly altering the S binding interface or somehow 
contribute to binding or entry by an unknown mechanism.  Through passage of zoonotic S bearing SARS-
CoV on Vero E6 cells, Rockx et al described mutations just outside of the RBD (HC/SZ/ 61/03, amino acid 
position 578, A031G, amino acid position 577) that seemed to enhance growth suggesting that mutations 
outside of the RBD influence the architecture of the binding interface or enhance binding and entry by an 
unknown mechanism(172).  All together, the growth curve data highlight the plasticity of both zoonotic and 
human tropic SARS-CoV S proteins where the subtle remodeling RBD can both enhance and abrogate 
binding to ACE2.   
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 Serological evaluation of workers in wet markets suggest that zoonotic SARS-CoV was 
transmitted to humans on occasion though these seropositive individuals did not clinically present with 
SARS(2).  These data support the hypothesis that repeated transfer of zoonotic SARS-CoV from civet to 
human and/or from human to civet fostered the evolution of the epidemic strain. Our growth curve analysis 
demonstrated that the epidemic strain is equally fit at growth within cACE2 or hACE2 expressing cells.  
Our predictive RBD and ACE2 structure model data provide a possible explanation of how the dual host 
tropism of SARS Urbani is retained.  The cACE2 molecule differs from hACE2 in two key residues (E30, 
Y34) that likely create a pronounced protrusion from the cACE2 binding interface.  The Urbani RBD is 
able to accommodate the varied binding interfaces of both cACE2 and hACE2 thus retaining dual host 
tropism.  These data suggest the epidemic strain’s dual host tropism and RBD architecture may have 
evolved over time for efficient transfer of virus from civet to human and from human to civet.  We also 
demonstrate that SZ16 lineage viruses passaged on HAE, in the absence of cACE2, evolved a mutant RBD 
that allowed for more efficient binding of hACE2 (icSZ16-S K479N, D22) but simultaneously lost the 
ability to efficiently infect cACE2 expressing cells.  Our predictive structure models suggest that the human 
adaptive RBD mutations in icSZ16-S K479N and D22 abrogate their ability to accommodate the protrusive 
cACE2 binding interface. Therefore, we hypothesize that in the absence of evolutionary pressure to retain 
the ability to grow within both cACE2 and hACE2 expressing cells, a series of mutations are acquired to 
enhance binding to only one of the two receptors.  We might have been able to generated a strain more 
similar to the dual tropic epidemic strain had we done repeated passage of icSZ16-S virus alternating 
between cACE2 and hACE2 expressing cells.  Nevertheless, these data suggest that the natural evolution of 
the epidemic strain probably occurred through repeated transfer of virus from civet to human and from 
human to civet over a long period of time and the evolutionary pressure due to the necessity to infect 
human and civet hosts fostered the retention of dual ACE2 tropism.  This hypothesis is supported by three 
serological surveys to determine the prevalence of SARS-CoV specific IgG  in healthy subjects in China.  
First, samples collected from volunteers in Guangdong province in China in May 2003 demonstrated that 
SARS specific IgG was found in animal traders (13%, n= 508), hospital workers (2.9% , n = 137), 
Guangdong CDC workers (1.6%, n = 63), and healthy adults at the clinic (1.2%, n = 84)(2).  The second 
study was a retrospective serological survey performed on 1,621 serum samples from March 2002 isolated 
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from healthy 18 year old male Chinese soldiers from 17 provinces including Guangdong(250).  Of these 
1,621 samples, 0.68% tested positive for SARS-CoV by ELISA though the province SARS-CoV IgG 
positive soldiers inhabited was not mentioned.  A third study retrospectively examined 938 serum samples 
collected in May of 2001 from healthy adults in Hong Kong.  Shockingly, 1.8% of these samples collected 
2 years prior to the epidemic tested positive for SARS-CoV by immunofluorescence assay(252). These data 
suggest less serious or asymptomatic cases of SARS-CoV existed at least 2 years prior to the beginning of 
the epidemic in various geographical locations in China.  If the sampled populations in the May 2003 
cohort are representative of the Guandong province population (est. population of 100,000,000), there were 
probably many more unreported or less serious cases (>1,000,000) of SARS-CoV prior to the evolution of 
the highly pathogenic 2002-2003 epidemic strain.   
 In 2005, Yang et al reported that pseudovirus bearing zoonotic S (GD03 and SZ3) were much less 
dependent on ACE2 for entry in 786-O cells(242). Using 786-O cells and similar pseudoviruses bearing 
Tor2, GD03 or SZ3 S proteins, both Yi et al and He et al were not able to infect 786-O cells with 
pseudoviruses(79, 122). To reevaluate these findings in the context of live SARS-CoV infection, we 
constructed viruses bearing zoonotic S proteins within the natural SARS-CoV genetic background.  The 
SZ3 S differs from SZ16 by one amino outside of the RBD (SZ3 F558, SZ16 I558).  Since our molecular 
and growth curve data suggested that icSZ16-S only efficiently infects cACE2 expressing cells, we 
performed receptor blockade experiments in DBT-cACE2 cells. We found that icSARS, icSZ16-S and 
icGD03-S were similarly blocked from entry in a dose dependent manner using an antibody directed 
against ACE2 while the control antibody had little effect.  Though we did not achieve 100% blockade with 
the highest concentration of antibody tested, we believe that polyclonal anti-hACE2 may interact less 
efficiently with native cACE2. Alternatively, we may not have completely saturated the available surface 
cACE2 which would result in an incomplete blockade.  At this time, we believe it is more likely that our 
inability to block 100% of infection was due the technical issues discussed above and less likely that 
zoonotic viruses gain entry into cells via alternative receptors. However, co-receptors (L-SIGN) have been 
reported for SARS-CoV but to our knowledge, the ability of zoonotic SARS-CoV to engage these receptors 
has not been rigorously examined(90).  Since the viruses we evaluated could not productively infect non-
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transfected DBT cells, it is unlikely that the incomplete block in entry with Ab was due to entry via 
alternative receptors.  We most likely did not block 20% of the surface ACE2 with 10µg/ml Ab.   
 Since it is impossible to predict the antigenic identity of future SARS virus emergents, the 
development of highly cross reactive antibody, drug or vaccination therapies would provide the greatest 
potential benefit to public health.  Recently, we have shown that mAb S230.15 was less effective in 
neutralizing icSZ16-S K479N in vitro but was very effective in passive transfer studies in mice lowering 
viral titers of both icGD03-S and icSZ16-S K479N below the detectable limit(256).  icSZ16-S and icGD03-
S are also more resistant to neutralization by S230.15 as compared to the epidemic strain.  Since icSZ16-S 
and icGD03-S are similarly neutralized by S230.15 in vitro, passive transfer studies by Zhu et al suggest 
that S230.15 would be effective against icSZ16-S in vivo as well(256). Yang et al described an antibody 
dependent enhancement (ADE) phenomenon using mAb S3.1 in neutralization assays in 786-O cells using 
GD03 and SZ16 pseudovirus(242).  We performed PRNT assays in cACE2 cells using icSARS, icSZ16-S 
and icGD03-S and found that S3.1 is moderately effective against icSARS, weakly effective against 
icGD03-S and ineffective against icSZ16-S.  Since there was such a dynamic range of neutralization 
efficacies using S3.1 against a panel of epidemic and zoonotic SARS-CoV, these data highlight pitfalls of 
using only the epidemic strain when evaluating passive immunization or vaccination therapies. Moreover, 
ter Meulen et al explored the possibility of ADE in human macrophages using SARS-CoV and 
subneutralizing concentrations of monoclonal antibodies and found that SARS-CoV is taken up by 
macrophages but does not productively infect the cells(200).  
 Coronavirus similar to SARS Urbani are currently circulating within bat species in China. 
Constant surveillance and biological evaluation of zoonotic pools of coronavirus is impractical making it 
quite difficult to predict the antigenic identity of SARS-CoV-like virus emergents in the future.  Therefore, 
it is imperative that current antiviral therapies be broadly cross reactive against all know SARS-CoV 
thereby maximizing the potential public health benefit.  We have constructed a SARS-CoV bearing the 
prototypic civet S protein from the SZ16 strain.  Prior to this publication, SARS-CoV bearing the SZ16 S 
were not able to be propagated in vitro hampering the study of the SZ16 biology and its pathogenic 
potential.  We have demonstrated that icSZ16-S can be propagated in vitro within DBT-cACE2 cell 
cultures, is dependent on ACE2 for entry and is incapable of using hACE2 for entry. We have also 
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demonstrated that point mutations in the SZ16 S protein that enhance virus growth in cells expressing 
hACE2 severely diminish growth in DBT-cACE2 cells while the epidemic strain retains dual ACE2 
tropism.  These data and retrospective serological surveys in China suggest that the natural evolution of the 
epidemic strain probably occurred through repeated transfer of virus from civet to human and from human 
to civet over a long period of time and the evolutionary pressure due to the necessity to infect human and 
civet hosts fostered the retention of dual ACE2 tropism . We have also demonstrated that both icGD03-S 
and icSZ16-S are neutralized by human mAb S230.15 and are more resistant to S3.1 highlighting the utility 
of using an antigenically diverse SARS-CoV panel to assess sero therapy efficacy. The icSZ16-S virus is 
yet another antigenically divergent zoonotic S bearing SARS-CoV that will prove useful in evaluating 
future sero or vaccination therapies. 
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Figure 1: Characterization of cACE2 and hACE2 expressing DBT cells by flow cytometry and 
Western Blot.  Transgene expression levels in cells stably expressing cACE2, hACE2 or GFP were 
assessed by flow cytometry and Western blot.  DBT cells were stably transfected with plasmids encoding 
cACE2-HIS, hACE2, or GFP-HIS were passaged 4 times after which cells were stained for ACE2 
expression (1˚ polyclonal anti-hACE2, 2˚ anti-goat-FITC) and sorted for mid/high ACE2 expression 
(FITC). GFP control cells were also sorted for mid/high expression.  (A) To assess transgene expression in 
expanded post-sorted cell stocks, cells were stained as done above and analyzed for FITC/GFP expression 
by flow cytometry. (B) To assess transgene expression in post sorted cell stocks by Western Blot, similar 
numbers of DBT, DBT-hACE2, DBT-cACE2-His, DBT-GFP-His were lysed and separated on a Nupage 
12% Bis-Tris SDS PAGE gel. After membrane transfer, blots were probed with either polyclonal goat anti-
human ACE2 or mouse anti-penta-His antibody. After washing, membranes were probed with either rabbit 
anti-goat HRP or anti-mouse IgG-HRP antibody.  Membranes were rinsed and then treated with ECL Plus 
reagent and to radiographic film. 
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Figure 2: Resurrection of icSZ16-S with DBT-cACE2 cells.  RT-PCR to detect subgenomic leader 
containing transcripts was performed to detect viral replication.  DBT, DBT-GFP-His, DBT-cACE2, DBT-
hACE2, or Vero E6 cells were infected with 100µl of viral supernatant from the initial icSZ16-S 
transfection, icSARS supernatants or were mock infected.  24hpi, total RNA was isolated, cDNA was 
generated and then used as template for PCR. Evidence of SARS-CoV replication and subgenomic 
transcription, ACE2 gene expression and control GAPDH gene expression was detected by the production 
of amplicons (SARS-CoV = 3a (1796bp), E (947bp), M(666bp), Control = 235bp GAPDH, ACE2 = 
258bp) visualized through electrophoresis within a 1.8% agarose TAE gel.  
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Figure 3: Assessment of virus growth in DBT, DBT-cACE2, DBT-hACE2, and Vero cells, spike 
variation in our recombinant virus panel, and ACE2 contact residues with the Urbani spike. (A) 
DBT-cACE2 (B) DBT-hACE2 (C) Vero E6 or DBT cells (data not shown) were infected with icCUHK-
W1, icGD03-S, icGZ02, icSZ16-S K479N p6, icSZ16-S K479N D22, icSARS, or icSZ16-S, at an MOI of 
0.01 for 1hr at 37˚C. 25µl of cell media was removed at 0, 6, 12, 24 and 36 hpi and samples were stored at -
80˚C until titered by plaque assay. Growth curves were performed in duplicate. Growth curves were 
performed on two independent occasions and data shown is one representative experiment. (D) Location of 
spike amino acid differences among the recombinant virus panel. (E) Urbani, cACE2 and hACE2 contact 
residues adapted from the crystal structure published by Li et. al. 2005.   
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Figure 4: icGD03-S and icSZ16-S are dependent on ACE2 for entry. DBT-cACE2 cells were seeded at 
5x105cells/well in 6-well dishes.  The following day, cell media was removed and cells were incubated 
with 10, 5, 2.5, 1.25 or 0.625µg/ml polyclonal anti-ACE2 or anti-ACE or DBPS for 1hr at 37˚C. After the 
1hr pretreatment with antibody, 100pfu/50µl of icSARS, icSZ16-S, or icGD03-S, was added to the 
monolayer and incubated 1hr at 37˚C.  After the infection, the inoculum was removed, the monolayer was 
rinsed with DPBS then overlayed with 0.9% agarose in complete growth media. After 48hpi, plates were 
stained with neutral red and plaques were counted. The average percent blockade was calculated by 
dividing the average number of plaques per Ab dilution by the average number of plaques in the DPBS no 
Ab controls.  Blockade experiments were performed in duplicate on two separate occasions. 
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Figure 5: mAb S230.15 and S3.1 neutralization profiles differ between epidemic, in vitro evolved and 
zoonotic strains of SARS-CoV.  Neutralizing titers were determined by plaque reduction neutralization 
titer assay (PRNT). 24hr prior to infection, 6-well plates were seeded with 5x105 DBT-cACE2 cells/well.   
Human monoclonal antibodies (mAb) S230.15 and S3.1 and an isotype control antibody directed against 
cholera toxin, D2.2, were serially diluted two-fold, and incubated with 100 pfu of either icSARS, icSZ16-S, 
or icGD03-S for 1 hour at 37ºC. Virus and antibodies were then added to 6-well plates of Vero E6 cells in 
duplicate and incubated at 37˚C for 1 hour after which the cells were overlayed with 3ml of 0.8% agarose 
in media. After 48 hr, plates were stained with neutral red and plaques were counted. The percentage of 
neutralization was calculated as: 1-(number of plaques with antibody / number of plaques without 
antibody) x 100%.  
 83 
 
 
Figure 6: Rosetta Design modeling demonstrating structural mechanisms of ACE2 tropism. Based on 
the reported crystal coordinates of SARS Urbani RBD interacting with the hACE2 receptor, we generated 
models of Urbani, SZ16, SZ16-K479N, and SZ16 K479N D22 RBD interaction with either cACE2 or 
hACE2 using Rosetta Design. Ribbon structures and “space filling” schematics of each RBD and ACE2 
combination are shown. Dotted spheres around RBD and ACE2 residues indicate they are within 4 
angstroms and thus are predicted to interact.  Red spheres around RBD and ACE2 residues indicate a steric 
clash.  (A) Urbani RBD and hACE2 architecture (B) Additional methyl groups of the E30 and Y34 cACE2 
mutations add a surface protrusion to the contact interface.  The Urbani RBD can accommodate the 
increased surface protrusion of cACE2 thereby retaining an efficient binding interface. (C) Similar to the 
Urbani RBD, the SZ16 RBD can accommodate the increased surface protrusion of cACE2 for efficient 
binding (D) The N479 mutation in SZ16 K479N remodels the SZ16 binding interface to promote binding 
to hACE2 (E) The remodeling of the SZ16 K479N binding interface by the N479 mutation creates a clash 
between S residues (V404 and F440) and cACE2 residues (E30 and Y34) blocking S and ACE2 binding.  
The SZ16 K479N RBD cannot accommodate the extended surface protrusion of the cACE2 RBD (F) In 
addition to the N479 mutation, the F442 and F472 mutations further remodel the SZ16 K479N D22 RBD 
further enhancing binding efficiency to hACE2 (G) Similar to the SZ16 K479N RBD interaction with 
cACE2, the SZ16 K479N D22 RBD cannot accommodate the protrusion of cACE2 abrogating binding. 
  
 
CHAPTER IV 
MYD88 IS REQUIRED FOR PROTECTION FROM LETHAL INFECTION WITH A MOUSE 
ADAPTED SARS-CoV 
 
 
Abstract 
A novel human coronavirus, SARS-CoV, emerged suddenly in 2003 causing ~8000 human cases and 
greater than 700 deaths worldwide.  Since most animal models fail to faithfully recapitulate the clinical 
course of SARS-CoV in humans, the virus and host factors that mediate disease pathogenesis remain 
unclear.  Recently, our laboratory and others developed a recombinant mouse-adapted SARS-CoV 
(rMA15).  Intranasal infection of C57BL/6 mice with rMA15 results in a nonlethal infection characterized 
by high titer replication within the lungs, lung inflammation, destruction of lung tissue, and loss of body 
weight, thus providing a useful model to identify host mediators of protection.  Here, we report that mice 
deficient in MyD88 (MyD88-/-), an adapter protein that mediates Toll-like receptor (TLR), IL-1R, and IL-
18R signaling, are far more susceptible to rMA15 infection.  The genetic absence of MyD88 resulted in 
greater than 90% mortality by day 7 post-infection.  MyD88-/-mice had higher viral loads in lung tissue 
throughout the course of infection.  Despite increased viral loads, the expression of multiple 
proinflammatory cytokines and chemokines within lung tissue was significantly reduced in MyD88-/- mice 
compared to wild-type mice.  Furthermore, the recruitment of inflammatory monocytes/macrophages to the 
lung was severely impaired in MyD88-/- mice. These data suggest that MyD88-mediated innate immune 
signaling and inflammatory cell recruitment to the lung are required for protection from rMA15 infection.   
Introduction 
In 2003, a novel coronavirus, SARS-CoV, emerged from zoonotic pools of virus in China to cause 
a global outbreak of Severe and Acute Respiratory Syndrome (SARS) affecting 29 countries, causing over 
8000 human cases and greater than 700 deaths(29, 103, 173).  The clinical course of SARS-CoV disease in 
humans is characterized by fever, non-productive cough, and malaise culminating in lung infiltrates visible 
by x-ray and an atypical pneumonia(11, 19, 114, 124, 152).  Immunologically, SARS-CoV infection of 
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humans generates a cytokine storm where elevated levels of IP-10, MIP1-α, and MCP-1 are detected 
within the blood(21).  Histological examination of lung tissue in terminal SARS-CoV cases revealed SARS 
antigen within macrophages in the lung suggesting a role for these cells in SARS-CoV pathogenesis(68, 
144).   
 Though clinical and epidemiological data from the epidemic and reemergence has provided insight 
in the molecular pathogenesis of SARS-CoV, thorough studies of virus and host interactions have been 
hampered by the lack of animal models that fully recapitulate human disease.  C57BL/6 mice infected with 
the epidemic strain, SARS Urbani, do not show any overt signs of disease but there is virus replication in 
the lung (107TCID50/g 3dpi), induction of MIP1α/MCP-1 and viral clearance even in the absence of T, B 
and NK cells suggesting that innate immunity alone is required for protection within this acute model of 
SARS-CoV replication(62).  MA15 is a mouse adapted SARS-CoV strain that was generated by fifteen 
serial passages of the epidemic strain, SARS Urbani, in the lungs of BALB/c mice(167).  Infection of 
young or senescent BALB/c mice with either MA15 or recombinant MA15 (rMA15) results in high virus 
titers in the lung, pulmonary pathology and mortality similar to those seen in severe and acute human cases 
of SARS-CoV disease(144, 152, 167).  
 Toll-like receptors (TLRs) are cellular receptors that recognize molecular signatures of pathogens 
and initiate an inflammatory signaling cascade that is key to the innate immune response(147).  Myeloid 
differentiation primary response gene 88 (Myd88) is key adaptor protein within the inflammatory signaling 
pathways of most all TLRs as well as IL-1R, IL-18R and INFγR1(147). In animal models of viral 
pathogenesis, Myd88 signaling has been shown to be protective oftentimes providing instructions to innate 
immune cells shown to be important for viral clearance(155, 174).  The role of Myd88 signaling in SARS-
CoV pathogenesis has not yet been described. 
 In this study, we describe a C57BL/6 mouse model of recombinant mouse adapted SARS-CoV 
(rMA15) acute pathogenesis characterized by high titers of virus replication within the lung with a 
concurrent induction of inflammatory cytokines and immune cell infiltration followed by viral clearance.  
WT mice show clinical signs of disease as manifested in 12-15% loss of body weight by 3 dpi but fully 
recover initial body weight by 7dpi.  We show a protective roll for Myd88 signaling events in our model of 
rMA15 pathogenesis.  Myd88-/- mice infected with rMA15 have significantly higher and prolonged virus 
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titers in the lung, exacerbated lung pathologies, defective induction of inflammatory cytokines, fail to 
recruit inflammatory macrophages to the lung and ultimately succumb to infection. These data suggest that 
a failure or delay in Myd88 inflammatory signaling or a failure to recruit inflammatory macrophages to the 
lung during acute infection results in exacerbated SARS-CoV disease. 
Materials and Methods 
Viruses and Cells. Vero E6 cells were grown in MEM (Invitrogen, Carlsbad, CA) supplemented with 10% 
FCII (Hyclone, South Logan, UT) and gentamycin/kanamycin (UNC Tissue Culture Facility).  Stocks of 
the recombinant mouse-adapted SARS-CoV (rMA15) were propagated and titered on Vero E6 cells and 
cryopreserved at -80˚C until use as described(247).  All viral and animal experiments were performed in a 
Class II biological safety cabinet in a certified biosafety level 3 laboratory containing redundant exhaust 
fans while wearing personnel protective equipment including Tyvek suits, hoods, and HEPA-filtered 
powered air-purifying respirators (PAPRs) as described(247). 
Mice.  C57BL/6 mice were obtained from The Jackson Laboratory (Bar Harbor, Maine) and bred in house.  
MyD88-/- mice were obtained from Shizou Akira (Osaka University) and backcrossed 11 generations to the 
B6 background.  Animal housing and care were in accordance with all UNC-Chapel Hill Institutional 
Animal Care and Use Committee guidelines.  10 week old WT or MyD88-/- mice were anaesthetized with a 
mixture of ketamine/xylazine and intranasally infected with 105pfu/50µl rMA15 in DPBS (Invitrogen, 
Carlsbad, CA).  Mice were monitored at 24 h intervals for virus-induced morbidity and mortality.   
Viral tissue titers.  To quantify the amount of infectious virus in tissues, lung tissue was weighed, placed 
in 0.5 ml DPBS, homogenized and titered via plaque assay on Vero E6 cells as previously described(180).   
 In situ hybridization.  35S-UTP-labeled riboprobes specific to the N gene of SARS-CoV (Urbani) or to 
the EBER2 gene from Epstein-Barr virus (negative control probe) were generated with an SP6-specific 
MAXIscript in vitro transcription kit (Ambion) and in situ hybridization was performed as described 
previously(41).  Briefly, deparaffinized tissue sections were hybridized with 5 x 104 cpm/µl of 35S-labeled 
riboprobes overnight.  Tissues were washed, dehydrated through graded ethanol, coated in NTB 
autoradiography emulsion (Kodak), and incubated at -80°C for 7 days.  Following development, sections 
were counterstained with hematoxylin and silver grain deposition was analyzed by light microscopy. 
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qRT-PCR.  To determine levels of inflammatory gene transcription within the infected lung, we employed 
a quantitative real-time PCR (qRT-PCR) approach.  Lungs from mock- or rMA15-infected mice were 
removed and homogenized directly in 1 ml of Trizol reagent (Invitrogen) and total RNA was isolated 
following the manufacturer’s instructions.  Complementary DNA was generated from 0.25-1 ug of total 
RNA using 250 ng random primers (Invitrogen) and superscript III reverse transcriptase (Invitrogen).  
Real-time PCR experiments were performed using Taqman© gene expression assays and an AB Prism 
7300 (Applied Biosystems).  18s rRNA was used as an endogenous control to normalize for input amounts 
of cDNA.  RNA levels of the target gene and the 18s endogenous control were quantitated by comparing 
the experimental signal with a standard curve generated from a DNA plasmid encoding the appropriate 
sequences.   
Flow cytometry.  Mice were inoculated as described above, sacrificed by exsanguination at 2 and 4 days 
post-infection, and lungs were perfused via cardiac puncture with 1X PBS.  Lungs were dissected, minced, 
and incubated for 2 hours with vigorous shaking at 37°C in digestion buffer [RPMI, 10% FBS, 15 mM 
HEPES, 2.5 mg/ml collagenase A (Roche), 1.7 mg/ml DNase I (Sigma)].  Cells were passed through a 40 
micron cell strainer, resuspended in RPMI media, layered on 5 ml lympholyte-M (Cedarlane), and 
centrifuged 30 minutes at 2500 rpm.  Banded cells were collected, washed in wash buffer (1X HBSS, 15 
mM HEPES), and total viable cells were determined by trypan blue exclusion.  Isolated cells were 
incubated with anti-mouse FcγRII/III (2.4G2; BD Pharmingen) for 20 min. on ice and then stained in 
FACS staining buffer (1X HBSS, 1% FBS, 2% normal rabbit serum) with the following antibodies from 
eBioscience: anti-F4/80-FITC, anti-Gr-1-PE, anti-CD11b-APC, anti-CD3-FITC, and anti-NK1.1-PE.  Cells 
were fixed overnight in 2% paraformaldehyde and analyzed on a Cyan cytometer (Dako) using Summit 
software.   
Statistical analyses.  Viral titers and inflammatory cell numbers were evaluated for statistically significant 
differences by unpaired t-tests using GraphPad InStat3 software.  P ≤ 0.05 was considered significant.   
Results 
MyD88-/-  mice are highly susceptible to rMA15 infection.   
 To assess the contribution of MyD88 to SARS-CoV-induced disease, wild-type (WT) and 
congenic MyD88-/- mice were infected intranasally with 105 pfu of recombinant mouse-adapted SARS-CoV 
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(rMA15) and monitored for virus-induced morbidity and mortality.  Infection of WT or MyD88-/- mice 
resulted in weight loss beginning at day 2 post-infection (Fig. 1A).  Infected WT mice lost 14±5% of 
starting body weight by 3 dpi and returned to starting body weights by 5-7 dpi, indicating that the mice 
recovered from infection.  In contrast, infected MyD88-/- mice continued to lose weight after 3 dpi.  
Additionally, 0% of WT mice succumbed to infection (n = 9) while 90% of MyD88-/- mice (n = 16) died as 
a result of rMA15 infection by 7 dpi (Fig. 1B).   These results indicate that MyD88 plays an important role 
in protection from SARS-CoV infection.  
Increased viral loads and viral spread in the lungs of MyD88-/-  mice 
To determine if lethal infection of MyD88-deficient mice to was due to increased virus replication 
and/or a lack of clearance, a kinetic analysis of rMA15 growth within the mouse lung was performed.   
Viral titers in WT mice peaked at 24 hpi (9x108pfu/g ± 7x108 (standard deviation)) and diminished by 6 dpi 
(5x105pfu/g ± 9x105) (Fig. 2).  Infectious virus was not recovered from the lungs of infected WT mice by 7 
dpi.  Lung titers in MyD88-/- mice were similar to WT mice at 24 hpi.  However, at 2 and 3 dpi, virus lung 
titers in MyD88-/- were significantly elevated as compared to WT mice (2 dpi, P = 0.0052; 3 dpi, P = 
0.0092) and remained elevated over  time as WT virus lung titers fell (Fig. 2).  
To assess the distribution of virus replication within the lung tissue of WT and MyD88-/- mice, in 
situ hybridization was performed on tissue sections using an 35S-labeled riboprobe complementary for the 
N gene of SARS-CoV.  rMA15-specific signal was determined by comparing silver grain deposition on 
parallel sections hybridized with an 35S-labeled riboprobe complementary for the EBER2 gene of Epstein-
Barr virus (data not shown).  As shown in Fig. 3, in situ signal was not observed in lung sections derived 
from mice that received intranasal administration of PBS alone.  At both 24 and 48 hpi, intense rMA15-
specific in situ signal was observed throughout the lung tissue, including lung airway epithelia, in rMA15-
infected WT and MyD88-/- mice.  At 72 and 96 hpi, the distribution and intensity of rMA15-specific in situ 
signal had greatly diminished in lung tissue of WT mice.  In contrast, rMA15-specific in situ signal in lung 
tissue of MyD88-/- mice was more intense and much broader in distribution at these time points.  By 6 dpi, 
though significantly diminished, rMA15-specific in situ signal was still readily detectable in lung tissue of 
MyD88-/- mice, whereas only very rare rMA15-specific in situ signal could be detected in lung tissue of 
WT mice.  These findings suggest that MyD88 is required for control of SARS-CoV replication in 
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pulmonary tissue at early times post-infection and the inability to control early replication is associated 
with increased lethality. 
Decreased expression of proinflammatory cytokines and chemokines in MyD88-/- mice.  Infection of 
WT mice with rMA15 results in a rapid inflammatory response in the lungs.  This virus-induced 
inflammatory response likely has both protective and pathologic consequences.  To investigate the 
importance of MyD88 in SARS-CoV-induced lung inflammation, we employed quantitative RT-PCR 
(qRT-PCR) to assess levels of proinflammatory cytokine and chemokine gene expression in the infected 
mouse lung at various times post-infection.  Infection of WT mice with rMA15 resulted in a significant 
induction of proinflammatory CCL2 and CCL3 transcription as compared to mock-infected control mice 
(Fig. 4A).  In contrast, induction of CCL2 and CCL3 transcripts were dramatically reduced in rMA15-
infected MyD88-/- mice.  In addition to proinflammatory chemokines, virus-induced expression of several 
proinflammatory cytokines, including TNF-α, IL-1β, and IL-6, was severely impaired in rMA15-infected 
MyD88-/- mice compared to infected WT mice (Fig. 4B).    Interestingly, induction if interferon-β 
transcripts within lung tissue of WT mice was not detected at any of the times during the course of viral 
infection we evaluated.  These data indicate that MyD88 is required for the induction of proinflammatory 
chemokines and cytokines within pulmonary tissues of SARS-CoV-infected mice and suggest that some 
aspect(s) of this inflammatory response is required for protection from lethal disease.    
Delayed recruitment of inflammatory monocytes to lungs of MyD88-/- mice 
The expression analyses of proinflammatory chemokine and cytokines indicated that MyD88 is 
critical for early immune/inflammatory responses in lung tissue following SARS-CoV infection.  To 
investigate whether the impaired chemokine and cytokine responses in MyD88-/- mice affected the cellular 
composition within the lung, total leukocytes were isolated from pulmonary tissue and analyzed by flow 
cytometry.  At 2 dpi, no significant differences were detected in natural killer cell (NK1.1+/CD3-) or T 
lymphocyte (CD4+/CD3+;CD8+/CD3+) populations isolated from the lung tissue of mock-infected or 
SARS-CoV infected WT mice (data not shown).  In contrast, a significant increase in inflammatory 
monocytes/macrophages (CD11b+/Gr-1+/F4/80+) was detected in lung tissue of SARS-CoV-infected WT 
mice compared to mock-infected WT control mice (Fig. 5A).  These results are consistent with previous 
findings demonstrating that rMA15-induced pulmonary inflammation is composed of a mononuclear 
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inflammatory infiltrate(167).  Strikingly, the CD11b+/Gr-1+/F4/80+ inflammatory monocyte/macrophage 
population was dramatically reduced in lung tissue of SARS-CoV-infected MyD88-/- compared to infected 
WT mice.  In fact, no significant increase in inflammatory monocytes/macrophages was observed in 
infected MyD88-/- mice compared to mock-infected control mice (5A). To determine if the failure to recruit 
inflammatory monocytes/macrophages is sustained at later times post infection in MyD88-/- mice, we 
performed similar cell isolation experiments at 4 dpi.  In contrast to 2 dpi, at 4 dpi a similar percentage and 
total number of inflammatory monocytes/macrophages (CD11b+/Gr-1+/F4/80+) were isolated from the lung 
tissue of WT and MyD88-/- mice.  Similar to 2 dpi, there were not significant numbers of CD3+ T 
lymphocytes detected within the lung tissue of rMA15-infected mice compared to PBS-inoculated control 
mice, indicating that T lymphocytes are not a major component of the inflammatory response at these times 
post-infection (data not shown).  These results indicate that MyD88 is critical for early host immune and 
inflammatory responses, which include the recruitment of inflammatory monocytes/macrophages to 
pulmonary sites, in response to SARS-CoV infection.   
Discussion 
 Since human clinical SARS data is complicated by host genetic variation, disease exacerbating 
comorbidities, age variation, and variable drug treatment regimens, animal models provide a more 
homogenous and controlled environment within which to ask questions related to the mechanisms of 
disease pathogenesis.  C57BL/6 mouse models of SARS Urbani replication demonstrated the importance of 
the innate response to clear virus but overt signs of disease similar to those seen in human cases of SARS-
CoV were not evident within this model(62).  We have developed a C57BL/6 mouse model for acute 
SARS-CoV disease through infection with mouse adapted SARS-CoV (rMA15).  Our model faithfully 
recapitulates many aspects of the acute phase of non-severe human SARS-CoV disease including high 
titers of virus growth within the lung, a viral induced inflammatory response, recruitment of inflammatory 
cells to the lung and a significant weight loss associated with the manifestation of viral disease(11, 21, 
152).   
 Serological and pathological data from the SARS-CoV epidemic suggests that the innate immune 
response plays a crucial role in the control of SARS-CoV infection while also potentially contributing to 
immune pathology.  Cameron et al describe inflammatory gene expression patterns and cytokine plasma 
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levels in the peripheral blood of severe and non-severe SARS patients in Toronto(21).  Non-severe and 
severe patients had similar amounts of IP-10 and MCP-1 in their serum during the early phase of infection 
but as disease progressed, cytokine levels in non-severe cases decreased while levels remained high in 
severe cases(21). In pathological evaluation of post mortem lung tissues from SARS-CoV cases, SARS 
antigen was frequently in macrophages suggesting an important role for these cells in SARS-CoV 
disease(68). In vitro data suggests that macrophages are not productively infected by SARS-CoV and 
instead secrete inflammatory cytokines like IP-10 and MCP-1(27). The above data suggests a dual role of 
inflammation and the innate immune response in both the prevention and progression of severe SARS-CoV 
disease.  Within our model of SARS-CoV acute disease, we see a protective role for inflammatory 
cytokines and chemokines and their recruitment of inflammatory cells to the infected lung to help clear 
infection. We have yet to determine the cell type responsible for the induction of this protective 
inflammatory response though we have demonstrated the recruitment of  inflammatory monocytes occurs 
even if alveolar macrophages are depleted (data not shown). In the future,  bone marrow chimeras between 
WT and MyD88-/-  mice may help us deduce if myeloid derived cells are responsible for the initial 
induction of the protective inflammatory response. 
 MyD88 is a key signaling adaptor protein for most all TLRs, IL-1R, IL-18R and INFγ-R1(147).  
Though MyD88 mediated proinflammatory signaling events have been implicated in the protection from 
numerous bacteria and parasitic infections, few in vivo studies have implicated MyD88 in protection from 
viral diseases(5, 52, 155, 174, 178, 198).  Moreover, the few studies implicating a protective roll for 
MyD88-/- in the context of viral infection suggest type I interferon induction is important for protection 
from disease(101, 155, 255).  In contrast, we show that WT C57BL/6 mice are protected from lethal SARS-
CoV infection independent of type I interferon induction.  It is possible that the induction of either type II 
interferon (interferon gamma) or type III interferon (IL-28/29, interferon lambda) may be instigating the 
protective signal in WT mice that seems to be absent in MyD88-/- mice contributing to their mortality from 
rMA15 infection.   Within mouse models of RSV infection,  MyD88 dependent induction of Th1 cytokines 
like INF-γ and IL-12 were demonstrated to decrease the severity of disease(174).  The signaling of INFγR1 
through MyD88 activates p38, a mitogen-activated protein kinase (MAPK), which is known to induce 
inflammatory mediators like IL-1 and TNF(106, 147).  Recent mouse models of HSV-2 pathogenesis have 
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demonstrated that type III interferon (IL-28/29, interferon lambda) is crucial for the control of infection and 
complete prevention of disease(8).  Furthermore, recent studies suggest that lambda interferon can be 
activated in a TLR/MyD88 dependent manner(148).  Currently, we are investigating the mechanism of 
protective signal induction that is present in WT animals and absent in MyD88-/- mice.  Our preliminary 
data suggests that our MyD88 lethal phenotype is not mediated by IL-1R or IL-18R and in the future we 
will investigate the possible roll of TLRs in protection from lethal infection of rMA15.  We will also 
investigate the contribution of both type II and type III interferon induction in the protection from lethal 
rMA15 infection. 
 Viral pathogenesis is a complex process where the virus and host engage in an unintended 
collaboration to generate the clinical presentation of disease.  Being a newly emerged infectious disease, 
many of the pathogenic mechanisms of SARS-CoV disease remain unknown.  We have developed a mouse 
model of acute non-severe SARS-CoV pathogenesis characterized by a high titer virus replication in the 
lung followed by a robust innate immune response resulting in the recruitment of inflammatory 
macrophages to the lung that mostly likely responsible for viral clearance and convalescence.   We also 
demonstrate a key role for MyD88 dependent signaling events and associated inflammation/cell 
recruitment that serves to protect WT mice from death while Myd88-/- mice succumb to infection.  These 
data suggest an important role for innate immunity in the control of SARS-CoV and prevention of virus 
induced mortality. 
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Fig. 1. MyD88-/-  mice are highly susceptible to rMA15 infection. WT (n = 9) or MyD88-/- (n = 16) mice 
were infected intranasally with 105 pfu rMA15 after which virus induced morbidity and mortality was 
monitored every 24 hpi.  Error bars represent one standard deviation. 
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Fig. 2. rMA15 replicates to significantly higher levels in the lungs of MyD88-/- mice as compared to 
WT.  WT or MyD88-/- mice were infected intranasally with 105 pfu rMA15. Lung tissues from 3 mice per 
strain were harvested on 1, 3, 4, 6, and 7 dpi, while lung tissue from 6 mice per strain were harvested on 2 
dpi.  Lung tissues were homogenized in DPBS and virus titer within clarified supernatants were assess by 
plaque assay. Mean titers  are displayed and error bars represent 1 standard deviation. 
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Fig. 3. Virus distribution is more widespread within the lungs of MyD88-/- mice as compared to WT 
mice. 5 µM paraffin-embedded sections derived from the lung tissue of WT and MyD88-/- mice were 
hybridized with an 35S-UTP-labeled riboprobe complementary to either the N gene of SARS-CoV (Urbani) 
or to the EBER2 gene from Epstein-Barr virus (data not shown).  Two images per strain per time point are 
presented (magnification, X 100) and are representative of at least three mice. 
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Fig. 4. Proinflammatory cytokine and chemokine transcription is depressed in MyD88-/- mice infected 
with rMA15 as compared to WT mice. To evaluate levels of proinflammatory cytokine and chemokine 
transcription, quantitative real-time PCR was employed.  We evaluated levels of CCL3, CCL2, TNFα and 
IL-6 transcription. cDNA was generated from 0.25-1µg lung RNA using superscript III reverse 
transcriptase.  Real-time PCR experiments were performed using Taqman© gene expression assays and an 
AB Prism 7300.  18s rRNA was used as an endogenous control to normalize for input amounts of cDNA.  
RNA levels of the target gene and the 18s endogenous control were quantitated by comparing the 
experimental signal with a standard curve generated from a DNA plasmid encoding the appropriate 
sequences.   
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Fig. 5.  Recruitment of inflammatory monocytes/macrophages to the SARS-CoV infected lung is 
delayed in MyD88-/- mice as compared to WT mice. 10 wk old B6 WT or MyD88-/- mice were 
inoculated intranasally with PBS or 105 pfu rMA15.  (A) At 2 dpi, lung leukocytes were isolated as 
described in Materials and Methods and analyzed by flow cytometry.  Histograms are representative of 
three mice.  Two independent experiments gave similar results. (B) Percent inflammatory 
monocytes/macrophages of total lung leukocytes isolated from mock (□), rMA15-infected WT (■), or 
rMA15-infected MyD88-/-n (■) mice at 2 dpi.  (C) Total numbers of inflammatory 
monocytes/macrophages isolated from mock (□), rMA15-infected WT (■), or rMA15-infected MyD88-/-n 
(■) mice at 2 dpi.  (D) Percent inflammatory monocytes/macrophages of total lung leukocytes (left panel) 
and total numbers of inflammatory monocytes/macrophages (right panel) isolated from mock (□), rMA15-
infected WT (■), or rMA15-infected MyD88-/-n (■) mice at 4 dpi. 
 
 
  
 
CHAPTER V 
VACCINE FAILURE IN SENESCENT BALB/C MICE CHALLENGED WITH MOUSE ADAPTED 
SARS-COV BEARING A ZOONOTIC SPIKE 
 
Abstract 
Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged suddenly within Guangdong 
province of China in 2002 causing over 8000 cases and >700 deaths in 29 countries throughout the world.  
The disease severity associated with SARS-CoV infection of humans was directly linked to increasing age 
with mortality rates exceeding 50% in people over 65 years of age. The successful vaccination of elderly 
populations is a difficult and unpredictable task due to immunosenescence with ageing and robust models 
are needed to evaluate and improve vaccines targeting infections that cause a disproportionate disease 
burden in the elderly.  In this manuscript, we have developed a senescent BABL/c mouse model of SARS-
CoV pathogenesis where infection with the mouse adapted SARS-CoV bearing a GD03 S glycoprotein 
(rMA15 GD03-S) causes morbidity in young mice and both morbidity and mortality in senescent mice 
mimicking the distribution of disease seen in human populations.  Our group has previously demonstrated 
that vaccines were inefficient at preventing SARS-CoV replication in senescent mice but it is unclear 
whether the vaccines protect senescent mice from lethal disease.  To address this issue, we vaccinated 
senescent mice with Venezuelan equine encephalitis virus replicon particles (VRP) expressing Urbani-S, 
GD03-S, SZ16-S, or a pool of all three S expressing VRPs in a prime/boost regimen. As a control, we also 
vaccinated a group with VRP expressing influenza HA.  Two months post boost, mice were intranasally 
challenged with 105 pfu rMA15 GD03-S after which morbidity and mortality were monitored daily.  All 
vaccine groups experienced significant morbidity with weight loss exceeding 20% of their starting weight 
by 5 days post infection (dpi).  All mice in the VRP HA and SZ16-S groups died while Urbani-S, GD03-S 
and Pool-S groups demonstrated 11, 29, 33% survival rates, respectively.  GD03-S specific IgG antibody 
responses in the serum predicted mortality and very low neutralizing antibody titers protect against 
mortality. We postulate that the apparent failure to successfully vaccinate senescent mice might be due to 
either intrinsic vaccine or senescent immune factors or a complex mixture of the two. 
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Introduction 
 Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged suddenly in Guangdong 
province of China in 2002 causing over 8000 cases and >700 deaths in 29 countries throughout the 
world(139). In 2004, SARS-CoV reemerged in the Guangdong province of China causing a more mild 
sporadic human disease and there were also several laboratory acquired cases and fatalities(28, 69, 146). 
Zoonotic SARS-CoV similar to the epidemic strain, SARS Urbani, have been found in the putative animal 
reservoir, the Chinese horseshoe bat, as well as in other exotic species like raccoon dogs and palm 
civets(108). Molecular epidemiology suggests that within wet markets in the Guangdong province, 
zoonotic SARS-CoV evolved to efficiently infect and transmit among humans through repeated animal to 
human or human to animal transmission events(28, 69, 108, 236). SARS-CoV disease is characterized by 
an atypical pneumonia where approximately 20% of cases progressed to acute respiratory distress 
syndrome (ARDS) requiring mechanical ventilation(19, 114, 124, 152, 153). The disease severity 
associated with SARS-CoV infection of humans was directly linked to increasing age with mortality rates 
exceeding 50% in people over 65 years of age(46, 73). Due to travel restrictions and associated hysteria, 
the SARS-CoV epidemic had a profound global economic impact with estimates between 30-100 billion 
dollars lost world wide(187).  Given the impact of the SARS-CoV epidemic on the global economy and 
public health and the potential for another reemergence, the development of therapeutic vaccines and 
passive sero therapies to combat future SARS-CoV emergence or laboratory acquired infection is highly 
desirable.   
 The successful vaccination of elderly populations is a difficult and unpredictable task due to the 
senescence of the immune system associated with ageing(17, 18, 50, 53, 64, 65, 67, 77, 151, 212, 215).  
Current models predict that influenza vaccine efficacy in elderly populations ranges from 17-53% while the 
vaccine in young adults is 70-90% effective(64).  Current research suggests that the senescent innate and 
adaptive immune system is defective on multiple levels making successful vaccination of the elderly a 
difficult task.  Defects in antigen presenting and T cell activation/cytokine secretion affect the generation of 
effective adaptive immune system helper (T helper or Th) cells and effector (B cells and cytotoxic T cells) 
cells resulting in diminished vaccine efficacy(50, 53, 58, 64, 65, 77, 136, 212, 223).  Interestingly, some of 
the senescent immune system deficiencies can be overcome through administration of cytokines or 
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adjuvants during vaccination that effectively activate APCs/Th cells thereby increasing the probability of 
generating appropriate amounts of effector cells required for successful vaccination(75, 76, 83, 160, 201).  
Since influenza, West Nile Virus and SARS-CoV infection all produce a disproportionate amount of 
disease burden in the elderly, the development of robust model systems for the design of successful vaccine 
strategies in the elderly has a broad public health application especially given the increasing age of global 
human populations(1, 116, 142). 
 Inactivated whole virus and vectored SARS-CoV vaccine trials in a number of different animals 
models have demonstrated that the SARS-CoV spike glycoprotein (S) is the critical component of 
protective immunity and the passive transfer of SARS-CoV S specific sera and select human monoclonal 
antibodies is sufficient to provide protection from lethal and nonlethal infection by a homologous and select 
heterologous SARS-CoV strains(20, 41, 78, 95, 163, 171, 190, 194, 224, 241, 253, 254, 256).  Since the 
epidemic strain may not exist in nature, vaccination with epidemic strain antigens followed by challenge 
with the epidemic strain may represent a biologically irrelevant design.  Unfortunately, a difficult choice is 
presented in choosing SARS-CoV vaccine antigens in hopes of preventing disease by future emergents 
whose antigenic identity is unknown. Therefore, employing an antigenically diverse panel of SARS-CoV 
antigens for vaccination coupled with the use of an similarly diverse lethal challenge virus panel may 
represent the most pertinent and relevant strategy to assess vaccine efficacy.  In 2003, Deming et al 
demonstrated that a Venezuelan equine encephalitis virus replicon particles expressing SARS Urbani S 
(VRP-S) vaccine provided complete protection in young mice from replication of a SARS-CoV bearing a 
zoonotic heterologous GD03 S but protection was variable in senescent mice(41). Due to the lack of 
significant morbidity and mortality in the SARS-CoV replication models, previous vaccine studies were 
unable to assess protection from disease or death and could only speculate that diminishing virus 
replication might result in reduced disease severity.   
 In 2007, Subbarao et al created a mouse adapted SARS-CoV (MA15) through repeated passage of 
SARS Urbani in BALB/c mice(167).  We then constructed a molecular clone of MA15 (rMA15 ) by 
introducing the six amino acid changes found in MA15 into the infectious clone for SARS Urbani 
(icSARS)(167).  When administered intranasally to young BALB/c mice, rMA15  causes significant weight 
loss by 4 days post infection (dpi) (~20 % of starting weight) and is uniformly lethal by 5 dpi(167).  
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Unfortunately pathogenesis of rMA15 in senescent animals has not yet been evaluated.  Nevertheless, if 
applied as a challenge virus in vaccine studies, the robust rMA15 lethal BALB/c model would allow for the 
assessment of protection from not only replication but also disease and mortality. 
 In this study, we have developed a lethal mouse adapted recombinant SARS-CoV bearing a 
zoonotic GD03 S glycoprotein (rMA15 GD03-S) testing the hypothesis that the mouse adapted gene set 
will universally enhance pathogenesis of variant S glycoproteins.  In contrast to the parent rMA15 virus, 
the recombinant rMA15 GD03-S is only lethal in senescent BALB/c mice.  We vaccinated senescent 
BALB/c mice with VRP vaccines expressing human (Urbani S), civet (SZ16 S) or zoonotic sporadic 
human (GD03-S) S glycoproteins or a pool or all three VRP vaccines and challenged them with the lethal 
rMA15 GD03-S.  The homologous VRP GD03-S and pooled VRP-S cocktail provided the most robust 
protection from mortality(GD03-S 29% and Pool-S 33% survival) however, all vaccines failed to protect 
animals from morbidity and mortality. In the future, this model will be useful in evaluating the design and 
efficacy of vaccines targeting elderly populations and in elucidating the molecular mechanisms by which 
senescent immune systems attenuate vaccine efficacy. 
Materials and Methods 
Viruses and cells. The recombinant epidemic strain virus “icSARS” (AY278741), rMA15, icGD03-S 
(AY525636), and rMA15 GD03-S were titered and propagated on Vero E6 cells as described(247). Vero 
E6 cells were grown in MEM (Invitrogen, Carlsbad, CA) supplemented with 10% FCII (Hyclone, South 
Logan, UT) and gentamycin/kanamycin (UNC Tissue Culture Facility). All virus work was performed in a 
Class II biological safety cabinet in a certified biosafety level 3 laboratory containing redundant exhaust 
fans while wearing Tyvek suits and PAPRs as described(249).   
Construction of rMA15 GD03-S.  The SARS Urbani infectious clone genome is divided across 6 
plasmids (icSARS-A to icSARS-F) and the spike gene is split between plasmids icSARS-E and icSARS F 
pSMART.  Recently we have introduced the GD03 S into the SARS infectious clone resulting in the 
creation of a recombinant chimeric SARS-CoV bearing a GD03 S. Using an infectious cDNA clone for the 
mouse adapted SARS (MA15) genome, which contains 6 amino acid changes from the epidemic strain 
sequence (H133Y nsp5, E269A nsp5, T67A nsp9, A4V nsp13, Y436H Spike, E11K M protein), we used 
overlapping PCR to mutate the icSARS GD03-E subclone to encode the Y436H mutation. Briefly, the 
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icSARS-GD03-E pSMART fragment DNA was amplified by PCR using Expand High Fidelity Polymerase 
(Roche, Indianapolis, IN) with the following primer sets: Amplicon A (NcoIF 5’- 
TGTTTCTAAACCCATGGGTACACAG-3’ and MA15spkR 5’- 
GATACCTATATTTATAATTATGATTACCAG-3’ ) and Amplicon B(XbaIR 5’- 
GGGCCCTCTAGAGATCGAGC-3’, and  MA15spkF 5’- 
CTGGTAATCATAATTATAAATATAGGTATC-3’). A second round of high fidelity PCR was 
performed using amplicons A and B as template and the NcoIF and XbaIR primer set creating an AB 
amplicon containing GD03 spike sequences and the Y436 mouse adaptive mutation. The final AB 
amplicon was purified using a Qiagen PCR purification kit (Qiagen, Valencia, CA) and digested with NcoI 
and XbaI (NEB, Ipswich, MA) for 1 hour at 37˚C. The target vector, icSARS GD03-E pSMART, was 
digested with NcoI and XbaI (NEB, Ipswich, MA) for 1 hour at 37˚C.  The digested AB amplicon (2.2KB) 
and vector fragments (5.3KB) were gel purified using a QIAquick gel purification kit (Qiagen, Valencia, 
CA), ligated to create rMA15 GD03-E pSMART and sequence verified. To generate rMA15 GD03 F 
pSMART, the 5’ end of the GD03 spike contained in the icSARS GD03-F plasmid was shuttled into the 
rMA15 F TOPO-XL plasmid. icSARS GD03 F pSMART  was digested with BamHI (NEB, Ipswich, MA) 
while rMA15-F TOPO-XL was digested with BamHI and CIP (NEB, Ipswich, MA).  icSARS-GD03 F 
pSMART (2059bp) and rMA15-F TOPO-XL (7260bp) fragments were gel purified and ligated to create 
rMA15 GD03-F TOPO-XL. Full length rMA15 GD03-S cDNA was constructed, in vitro transcripts were 
generated and electroporated into Vero E6 cells to create recombinant virus as described. rMA15 GD03-S 
virus supernatant from the electroporated Vero E6 cell culture (passage zero), was passaged 2 times after 
which robust cytopathic effect was seen.  rMA15 GD03-S was then plaque purified and isolated plaques 
were expanded in 6-well dishes. 6-well dish supernatant was used to infect a T175 flask of Vero E6 cells to 
generate a virus stock that was harvested after 20 hours post infection (hpi).  Viral RNA from the rMA15 
GD03-S virus stock was isolated using TRIzol (Invitrogen, Carlsbad, CA), cDNA was synthesized using 
SSII (Invitrogen, Carlsbad, CA) and amplicons spanning the S, 3a, E and M genes were generated by RT-
PCR and directly sequenced. One conserved coding change was found outside of the receptor binding 
domain of S at residue 623 from serine to tyrosine. 
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Growth curve analysis. Vero E6 cells were infected with icSARS, icGD03-S, rMA15, or rMA15 GD03-S 
at an MOI of 0.01 for 1hr at 37˚C after which the inoculum was removed, the monolayer was rinsed with 
DPBS, and growth media was added.  Media was sampled at 0, 6, 12, 24 and 36 hpi and samples were 
stored at -80˚C until titered by plaque assay as described(247). 
Infection of young and senescent BALB/c mice. Animal housing and care were in accordance with all 
University of North Carolina Institutional Animal Care and Use Committee guidelines. All BALB/c mice 
were purchased from Harlan Sprague Dawley (Indianapolis, IN).  Ketamine anaesthetized 10 week (n = 
10/virus) or 12 month old BALB/c (n = 6/virus) mice were intranasally infected with 105pfu/50µl of 
rMA15 or rMA15 GD03-S after which clinical signs of disease (weight) were monitored every day post 
infection (dpi). On 2 and 4 dpi, groups of animals were sacrificed and lungs were removed for histology 
and virus lung titer. For virus titer, portions of the lung weighed, placed in 0.5ml DPBS, and frozen until 
titered via plaque assay. Briefly, lungs were homogenized, clarified by centrifugation, and virus titer within 
lung supernatants were assessed via plaque assay in Vero E6 cells as described(180).  For lung histology, 
portions of the lungs were fixed in 4% PFA in PBS for 7 days before paraffin embedding, sectioning at 5 
µm thickness, and hemotoxylin and eosin staining at the Histopathology Core Facility (UNC, Chapel Hill).   
Vaccination and challenge of senescent BALB/c mice. 12 month old Harlan Sprague Dawley 
(Indianapolis, IN) BALB/c mice were vaccinated with 106 infectious units (IU)/10µl of either HA, SARS-
S, GD03-S, SZ16-S VRP or a Pool of SARS S containing VRPs (Pool-S, 106 IN/antigen) in the left rear 
footpad. Three weeks post primary vaccination, animals were bled to assess SARS S specific serum IgG.  
At 13 months of age, mice received a secondary vaccination of equal dose and identity of their primary 
vaccination.  At 15 months of age, mice were bled to assess post-boost SARS S specific serum IgG. A 
week later, mice were intranasally infected with 105pfu/50µl rMA15 GD03-S. Mice were monitored daily 
for clinical signs (weight). At 2 dpi, three animals per group were sacrificed to assess virus lung titer and 
histology as described above.  
Serology of vaccinated senescent BALB/c mice by ELISA.  Antibodies to the SARS S protein were 
quantitated by enzyme-linked immunosorbant assay (ELISA).  Purified recombinant SARS S proteins (BEI 
Resources, Manassas VA)  were coupled to high-binding plastic plates (NUNC Immunlon 4HBX) in 0.1 M 
carbonate buffer, pH = 9.6. Alternatively, 96 well plates were coated with cell lysates from VRP GD03-S, 
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VRP SZ16-S or VRP HA infected BHK cells that were used as GD03, SZ16 and HA antigen in the ELISA. 
Antigen-coupled plates were stored at 4ºC in a humid chamber overnight, or for up to 3 weeks.  Purified 
antigens were coupled to plates at a concentration of 1 µg/ml (100 ng/well, 100 µL/well). 
 On the day of the assay, the plates were washed 4x with ELISA wash buffer (EWB – phosphate 
buffered saline, pH = 7.4 with 0.01% Tween-20), excess medium was removed, and serum samples (diluted 
in EWB with 10% Sigma-Blok (Sigma-Aldrich) were added to the plate, 100 µL/well.  No pre-block step 
was necessary.  After 2 hours of incubation at 4ºC in a humid chamber, the plates were washed as above, 
and 100 µL of isotype-specific horseradish peroxidase- (HRP-) conjugated goat anti-mouse 
immunoglobulin was added to each well.  The plates were returned to the humid chamber for 2 hours. 
 The enzyme substrate was prepared immediately before use.  For each 10 ml of substrate needed, 
5 ml of 0.1 M acetic acid was mixed with 5 ml of 0.1 M sodium acetate, and 2 tablets of Sigma o-
Phenylenediamine dihydrochloride (OPD) substrate (catalog number P3804-50TAB) were added and 
dissolved.  After the OPD dissolved,  7.2 µL of 30% hydrogen peroxide was added for each 10 ml of 
substrate.  The plates were washed, a sheet of clear adhesive film was added to the top plate on the stack, 
and the stack of plates was inverted, shaken several times, and then washed as done above.  Extra medium 
was flicked off, the plates slapped onto paper towels, and 100 µL of substrate was added to each well.  The 
plates were incubated for 30 minutes in the dark at room temperature and the reaction was stopped by the 
addition of 100 µL of 0.1 M sodium fluoride.  The optical density of colored product was read immediately 
at 450 nm in an automated plate reader. 
 For analysis, every plate includes at least 4 wells that were antigen-coupled and received HRP-
conjugate, but no serum.  The average of these (background) values were subtracted from all of the OD 
readings, and these adjusted OD values were plotted for each serum sample versus  the log10 of the serum 
dilution A sigmoidal curve was then fit to these values using regression analysis and the half-max titer of 
that sample was derived: the serum dilution at which the OD is exactly half of the plateau maximum value.  
Comparisons between half-max titers derived from different experimental groups were statistically 
evaluated using the Mann-Whitney U test, a non-parametric method. 
Plaque reduction neutralization assay using post-boost sera. The percent neutralization for post boost 
serum samples was determined by a microneutralization assay as previously described(172).  Briefly, sera 
 105 
was serially diluted in twofold increments beginning at 1:25 and then mixed with 100pfu of rMA15-GD03 
and incubated for 1hr at 37˚C.  Virus and sera was then added to a 96-well plate of Vero E6 cells (5 x 103 
Vero E6/well). Each dilution of sera was plated in triplicate.  Wells were then assessed for the development 
of CPE at 4 to 5 days post infection. For each dilution of sera, the number of wells protected from CPE 
were scored.  The greatest dilution of sera with more than 2 wells of protection is the 50% neutralization 
titer. 
Statistical Analysis.  Statistical analysis was performed using Prism (Graphpad, San Diego, CA) software. 
Non-parametric Mann Whitney tests were performed to generate P values noted in the text. 
Results 
In vitro and in vivo characterization of the mouse adapted rMA15 GD03-S virus.  To increase the 
stringency of our senescent mouse vaccination and challenge model, we constructed a recombinant SARS-
CoV bearing a GD03 spike within the mouse adapted SARS-CoV infectious cDNA clone.  Recombinant 
rMA15 GD03-S virus was isolated, passaged twice and plaque purified. One amino acid mutation was 
found (S623Y) in the spike gene most likely resulting from passage while generating the virus stock.  
Interestingly, the recombinant icSARS GD03-S virus described in Deming et. al. developed a mutation 
(D613G) in a similar location of S during the process of virus stock generation(41).  To assess virus growth 
kinetics in vitro, Vero E6 cells were infected with rMA15, rMA15 GD03-S, icGD03-S or icSARS at an 
MOI of 0.01.  At 12 hpi, rMA15, rMA15 GD03-S and icSARS titers were 1 log superior to that of icGD03-
S (Fig. 1). At 24 hpi, rMA15 GD03 and icGD03-S titers are approximately 1 log inferior to rMA15 and 
icSARS. Though icGD03-S  and rMA15 GD03-S growth seemed to be depressed at earlier times, all 
viruses achieved similar peak titers (<108pfu/ml) at 36 hpi (Fig. 1).   
Age is a critical factor in determining mortality in BALB/c mice infected with rMA15 GD03-S.  After 
characterizing the in vitro growth kinetics of rMA15 GD03-S, we then wanted to evaluate the in vivo 
growth kinetics and pathogenesis of the novel virus.  First, we infected 10wk old BALB/c mice with 105 
pfu rMA15 GD03-S or rMA15.  rMA15 infection was uniformly fatal with mice losing 20% of their 
starting weight by 4 dpi and all mice succumbing to infection by 5 dpi (Fig 2A).  In contrast to rMA15 
infection,  rMA15 GD03-S infected mice all survived but did experience significant virus induced 
morbidity losing more than 10% of their starting weight by 4 dpi (Fig. 2A).  Interestingly, virus titers for 
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rMA15 and rMA15 GD03-S were similar on both 2 (rMA15 3.2x107 pfu/g, rMA15 GD03-S 1.5x107pfu/g) 
and 4 (rMA15 3.6x105 pfu/g, rMA15 GD03-S 9.3x105pfu/g) dpi (Fig. 2A). 
 Unlike infection of young adult mice, rMA15 and rMA15 GD03 infection of senescent mice was 
uniformly lethal. Infection of 12 month old BALB/c mice with either mouse adapted strain caused rapid 
weight loss (~20% starting weight) and 100% mortality by 4 dpi (Fig. 2B).  Mean virus lung titers in 
senescent mice were elevated as compared to young adult mice at early time points.  On 2 dpi, rMA15 and 
rMA15 GD03-S achieved mean titers approximately 1 log greater (rMA15 1.3x108 pfu/g, rMA15 GD03-S 
2.6x108 pfu/g) than titers in young adult mice at similar times post infection (Fig. 2B).  By 4 dpi, mean 
virus lung titers of both viruses had waned to similar levels (rMA15 9.7x105 pfu/g, rMA15 GD03-S 
3.5x105 pfu/g) seen in young adult mice at similar times post infection (Fig 2B). 
Morbidity and mortality is seen in all experimental groups of VRP vaccinated 15 month old rMA15 
GD03-S challenged BALB/c mice.  The SARS-CoV epidemic was most virulent in the elderly therefore it 
is imperative that vaccine therapies be effective in immune senescent populations. Senescent BALB/c mice 
were primed at 12 and boosted at 13 months of age with VRP expressing SARS Urbani-S, GD03-S, SZ16-
S or a pool of all three SARS-CoV S antigens (Pool-S).  Control mice were administered VRP expressing 
the influenza HA glycoprotein in the same manner. At 15 months of age, mice were intranasally challenged 
with 105 pfu of rMA15 GD03-S after which morbidity and mortality were monitored daily over 13 days.  
All vaccination groups exhibited significant morbidity and mortality after rMA15 GD03-S infection (Fig. 
3A, 3B).  All groups lost more than 20% of their starting weight by 4 dpi.  In addition, 100% of VRP HA 
and VRP SZ16-S vaccinated mice succumbed to infection by 5 and 6 dpi, respectively (Fig. 3B).  The 
groups receiving the VRP expressing the Urbani-S, GD03-S or Pool-S demonstrated varying degrees of 
survival with the groups receiving the homologous antigen experiencing the most protection (Percent 
survival: VRP Urbani-S 11%, VRP GD03-S 29%, VRP Pool-S 33%) (Fig. 3B).  Virus lung titers were very 
high 2 dpi (< 108pfu mean lung titer) in all vaccine groups (Fig. 4).  Regardless of the SARS vaccine 
antigen, most vaccinated animals died from virus infection demonstrating difficulties in priming the 
adaptive immune response through vaccination in aged animals. 
Levels of GD03-S specific IgG predict mortality in post boost sera.  The development of an adequate 
antibody response against the SARS S glycoprotein through vaccination is necessary to prevent SARS-CoV 
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replication after challenge.  To assess the SARS S specific IgG response in post prime and post boost sera, 
we performed several versions of ELISA.  The target antigen employed in the ELISA assay was varied 
(Urbani-S, SZ16-S, or GD03-S proteins) in order to gauge cross reactivity of the immune responses 
generated by each vaccine regimen.  For example, ELISA plates coated with Urbani-S antigen probed with 
sera from Urbani-S, SZ16-S or GD03-S vaccinated mice allow us to assess the quality of the homologous 
Urbani-S specific responses but also the heterologous and cross reactive SZ16-S and GD03-S specific 
responses.  When comparing peak IgG titers in each vaccine group, the titer of the greatest magnitude was 
typically against the cognate vaccine antigen.  Mean Log10 Half-Max IgG titers against the homologous 
vaccine antigen in the Urbani-S and GD03-S groups increased with boost while SZ16-S decreased slightly 
(Fig. 5A, B, C).  Not surprisingly, the mean Log10 Half-Max IgG responses within the Pool-S group were 
similar for each antigen in the cocktail(Fig. 5D).  Importantly, sera from control VRP HA animals did not 
significantly cross react with the SARS antigens and the magnitude of  HA specific responses were 
comparable to those seen in the SARS S groups (Fig. 5E).  Though the degree of mortality varied with each 
group, the magnitude of the mean Log10 Half-Max GD03 specific IgG titers in each group were similar 
(Fig. 5A, B, C, D).  Since mean GD03 specific IgG titer in each group did not seem to correlate well with 
mortality, animal serology data was stratified by mortality to create two groups: “protected” from mortality 
(n = 7) and “not protected” from mortality (n = 26). When comparing the protected and not protected 
cohorts that received VRP expressing SARS antigen, there is a statistically significant difference (p = 
0.0002) in the mean Log10 Half-Max GD03-S specific IgG titer (protected = 2.455, not protected = 1.233) 
(Fig. 5F).  We performed a microneutralization assay to generate 50% neutralization titers from post boost 
sera for each animal in the study.  One animal in the SZ16 group and one animal in the GD03 group had a 
reciprocal 50% neutralization titer of 25 while all other animals tested had titers below the limit of 
detection(Fig. 6). 
Discussion 
 Many respiratory viruses like influenza, RSV and SARS-CoV cause disproportionate burdens of 
disease in the immune senescent and it is important that vaccination be successful in this most vulnerable 
population(116, 202).  Prior to this report, most all SARS-CoV vaccine studies were performed within 
young animal models of SARS-CoV infection characterized by acute virus replication and deficient in 
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overt signs of clinical disease.  In 2006, Deming et al demonstrated that VRP expressing Urbani-S provided 
complete protection from heterologous challenge virus (icGD03-S) replication in young adult mice but 
provided variable protection in the senescent model(41). However, it was not clear whether variable 
protection from replication in this model would correlate with protection from lethal infection. To this end, 
we developed a recombinant mouse adapted SARS-CoV (rMA15) through the introduction of six amino 
acid changes into the epidemic strain infectious cDNA clone.  Within the rMA15 infectious cDNA clone, 
we constructed a recombinant mouse adapted virus bearing the S glycoprotein from the most divergent 
human strain (GD03).   The rationale for the construction of this virus is three-fold: First, we sought to 
investigate whether the mouse adapted mutations would universally enhance disease pathogenesis of 
recombinant viruses bearing zoonotic spike proteins.  Secondly, since the epidemic strain may no longer 
exist in nature and future epidemics might emerge from zoonotic pools, we sought to create a more relevant 
challenge virus to evaluate vaccine efficacy that was similar to the zoonotic SARS-CoV ancestors of the 
epidemic strain.  Lastly, we wanted to determine the feasibility of using the rMA15 molecular clone as a 
rapid and robust platform within which to construct lethal challenge viruses bearing S genes from future 
emergent SARS-CoV.   
 To rapidly construct the rMA15-GD03-S virus, the GD03 S gene cDNA was synthetically derived, 
the MA mutation was introduced into the S gene, the GD03 S containing the MA mutation (Y436H) was 
cloned into the rMA15 infectious clone, infectious genomic viral RNA was electroporated into Vero E6 
cells and recombinant virus was recovered.  Though rMA15 GD03-S in vitro growth is depressed 1 log as 
compared to rMA15 12 hpi, rMA15 GD03-S and rMA15 replicate to similar peak titers by 36hpi in Vero 
E6 cells.  Also, virus lung titers on 2 and 4 dpi in young BALB/c mice infected with rMA15 or rMA15 
GD03-S are similar but infection with rMA15 GD03-S is attenuated while rMA15 is uniformly lethal.  
These data suggest GD03 S glycoprotein and receptor ACE2 interactions are not as efficient as compared 
to those with rMA15 resulting in GD03 S mediated attenuation of virulence. Moreover, the Y436H MA 
mutation may lose its effect within GD03 S receptor binding domain architecture which may also 
contribute to attenuation in young mice.  Interestingly, virus titers in the lungs of rMA15 and rMA15 
GD03-S on 2 and 4 dpi were not statistically different.   Since rMA15 has a significant growth advantage 
over rMA15 GD03-S at early times within in vitro growth experiments, it is possible that increased 
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replication of rMA15 at early times during mouse infection and/or other times we did not evaluate set the 
stage for the lethal phenotype. Also, where rapid rMA15 growth within the lungs of young BALB/c mice 
most likely sets the course for lethal infection, delayed growth of rMA15 GD03-S in the lungs at early 
times post infection may make the virus to be more susceptible to the innate immune response contributing 
to virus clearance.   
 For the study of age related viral pathogenesis, the extreme differences seen in mortality between 
young and senescent BABL/c infected with rMA15 GD03-S may allow for the elucidation of age related 
mechanisms of severe SARS-CoV disease.  As compared to young mice, rMA15 GD03-S lung titers in 
senescent mice are elevated 1 log 2 dpi indicating the senescent animals on some level fail to control 
replication.  These data suggest that some protective components within young adult mice are absent in 
senescent mice or senescent mice are less resilient in handling acute lung damage but both scenarios could 
potentially explain mortality in senescent animals.  The innate immune system is debilitated in the 
senescent mouse and may account for the elevated virus lung titers and mortality seen with rMA15-GD03-
S infection.  Recent reports on the senescent immune system suggest that classical innate sentinels like 
macrophages and dendritic cells are defective in normal cytokine secretion after pathogen sensing, 
phagocytosis, and migration(31, 32, 60).  These defects in the innate response may have allowed for the 
elevated replication of the rMA15 GD03-S virus in senescent mice and resultant mortality.  The aged 
mouse lung might also be less resilient in acute lung injury caused by virus replication and the immune 
response.  The repair of tissue damage in the lung has been described as an inflammatory process very 
similar to wound healing in other tissues(66).  Deficiencies in the senescent inflammatory response whose 
coordination and function are necessary for appropriate wound healing have been demonstrated to delay 
wound healing and tissue repair(87).  As compared to young mice, the cytokine milieu and inflammatory 
cell infiltration and function at the site of tissue damage is altered possibly contributing to a delay in 
repair(87).  Detailed experiments exploring temporal virus lung titer and the associated inflammatory 
response in young and aged mice may help elucidate the mechanisms of the age related mortality seen in 
rMA15 GD03-S infection.  Moreover, it is possible that functional innate immune deficits observed in aged 
related mortality seen with rMA15 GD03-S infection may also mediate enhanced pathogenesis of other 
respiratory viruses (i.e. RSV, influenza etc.) in the immune senescent. Surprisingly, very few small animal 
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models exist to simultaneously study disproportionate viral disease in the immune senescent and age 
related effects on vaccine efficacy and to our knowledge, with rMA15 GD03-S we have developed the third 
SARS-CoV model with attenuated disease in young and lethal disease in old mice(172). Studies of vaccine 
efficacy in young adult mice using rMA15 GD03-S as a challenge virus are not as robust as senescent 
models due a lack of mortality though significant morbidity and replication could be used as metrics for 
therapeutic efficacy. 
 Due to the probable extinction of the epidemic strain, vaccine studies using the epidemic strain as 
both vaccine antigen and challenge virus most likely do not represent realistic scenarios of future SARS-
CoV emergence. So, rather than use a vaccine antigen that is homologous to antigen in the challenge virus, 
we constructed a panel of VRP vectors expressing an array of divergent SARS-CoV S glycoprotein 
antigens with the goal of inducing broadly cross reactive immune responses using an antigenic cocktail of 
vaccines.  VRP vaccines are safe replication incompetent vaccine vectors capable of inducing mucosal 
immunity from a peripheral route of inoculation(41, 201).  Previously, we demonstrated that vaccination of 
young adult mice with VRP expressing Urbani S provided complete protection from icGD03-S replication 
upon challenge and this protection was mediated by a very robust cross neutralizing antibody response(41).  
Using a prime and boost regimen, we vaccinated senescent BALB/c mice with VRP expressing S 
glycoproteins of Urbani, GD03 or SZ16 strains or a cocktail of all three VRPs. Both the GD03 and SZ16 S 
glycoproteins differ from the epidemic strain in 18 amino acids 16 of which reside in the target area of most 
neutralizing antibodies (S1 region).  Control mice were vaccinated with VRP expressing influenza HA.  
Our antigenically diverse SARS S expressing VRP panel coupled with our lethal rMA15 GD03-S challenge 
virus allows us to assess the efficacy of immune responses to both homologous (VRP GD03-S) and 
heterologous (VRP Urbani-S and VRP SZ16-S) antigens. Upon challenge with the rMA15 GD03-S, all 
groups demonstrated significant morbidity losing more than 20% of starting weight by 5 dpi and significant 
virus replication in the lung with mean titers exceeding 108 pfu/g.  Assessing protection from mortality, the 
HA and SZ16 groups uniformly succumbed to infection, the Urbani-S group demonstrated little protection 
from mortality while groups that received the homologous antigen demonstrated the most protection 
(GD03-S 29%, Pool-S 33% survival).  These data suggest that vaccination of senescent animals with VRP 
expressing antigens similar to the challenge virus provides the most protection against rMA15 GD03-S 
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infection though protecting only 30% of vaccinated animals is not an ideal outcome.  Prior to Deming et. 
al., SARS-CoV vaccination strategies had not been evaluated in aged mice(41).  Moreover, very few 
studies of influenza vaccine efficacy have been performed in aged mouse models. In 1993, Ben-Yehuda et 
al demonstrated that a recombinant vaccinia virus vaccine expressing influenza PR8 HA protected 
senescent mice from intranasal challenge by a homologous PR8 strain while conventional vaccines (killed 
virus vaccine) failed(14).  Similarly, Asanuma et. al. (2001) demonstrated partial protection of various 
strains (BALB/c, C57BL/6, C3H) of aged mice from PR8 challenge after conventional vaccination(9). 
Since effective vaccination strategies in the elderly have not yet been developed for influenza, West Nile 
virus and SARS-CoV, the development of small animals models to study vaccine efficacy in senescent 
populations may have broad public health application. 
 Our morbidity and mortality data suggested that the immune response to VRP vaccination may not 
have been robust since all vaccination groups experienced both morbidity and mortality.  Since the 
importance of an adequate IgG response has been demonstrated to be necessary for protection from SARS-
CoV infection, we assessed the magnitude and cross reactivity of the SARS S specific IgG responses by 
ELISA.  VRP vaccination of senescent animals induced robust homologous and heterologous SARS S 
specific serum IgG responses while sera from the HA control group did not cross react with SARS 
antigens.  Since the development of an adequate anti GD03-S IgG response would most likely be the most 
important in protection against the rMA15 GD03-S challenge, we sought to compare mean anti GD03-S 
IgG titers between groups.  Due to the variability in mean anti GD03-S IgG within each group, the means 
were not statistically different when comparing Urbani-S, GD03-S, SZ16-S or Pool-S groups. As a result, 
these data could not help to explain the differences seen in survival among the groups receiving VRP 
expressing SARS-CoV antigen.  Since comparing mean GD03 S specific IgG among vaccine groups was 
not particularly informative, we stratified the serology data into two groups: those that were protected from 
mortality and those that were not protected from mortality.  When organizing the data in this way, we now 
see that the animals that were protected from mortality had a superior GD03 S specific serum IgG titer as 
compared to those that were not protected and this difference was statistically significant.  Since 
neutralizing antibody would most likely be responsible for this protection from mortality, we assessed sera 
for neutralizing antibody by microneutralization assay using the rMA15 GD03-S as challenge virus.  Only 
 112 
two of our samples had reciprocal 50% neutralization titers of 25 while the remaining 57 samples were 
below the limit of detection (l.o.d. = 25) suggesting that low titers of neutralizing antibody are sufficient to 
protect from rMA15 GD03-S induced mortality. Since very few sera samples had neutralization titers 
above the limit of detection, we could not correlate survival to neutralizing antibody titers.  Nevertheless, 
there was a statistically significant difference in GD03 S specific IgG in comparing animals protected and 
not protected from mortality confirming the importance of the antibody response in protection from virus 
induced death.   
 Deming et al reported that vaccination with VRP expressing Urbani S provided complete 
protection from replication after a heterologous icGD03-S challenge(41). These data suggest that VRP 
based vaccines are quite capable of inducing an appropriate and sufficient cross protective immune 
response in immune competent young adult mice.  Interestingly, senescent animals seem unable to generate 
an adequate immune response by VRP Urbani-S vaccination and as a result we detect virus replication, 
morbidity and mortality.  Two possible explanations may help explain the differences seen in the vaccine 
efficacy when comparing young adult and senescent mice. The first explanation involves VRP cell tropism 
in vivo while the second explanation involves deficiencies in innate and adaptive immunity due to immune 
senescence. Since the VEE structural genes are replaced by a transgene of interest within VRP genomes, 
VEE structural genes provided in trans to “package” the replicon RNA and various VEE structural proteins 
can be utilized to enhance vector attenuation and safety(16, 41, 98, 201). While WT recombinant VEE 
V3000 infection is uniformly lethal in mice, VEE clones V3010, V3014, and V3533 are mutated in their 
viral glycoproteins and are completely attenuated in mice with all mice surviving infection(16).  A VRP 
packaged with wild-type VEE V3000 glycoproteins is targeted to the professional antigen presenting 
dendritic cell (DC) while the attenuated V3014 was found to have enhanced binding of heparan sulfate 
altering DC targeting/spread(130).  These data suggest that the alteration of the VRP coat can have 
profound effects on cell targeting which may affect the efficiency of antigen presentation and the resultant 
immune response.  On their major histocompatibility complexes (MHC), DCs can present endogenous (i.e. 
peptides from within the infected cell) or exogenous (peptides acquired from phagocytosis) antigen to 
prime cognate T cells for activation(82, 165, 231). DC priming of T cells using endogenous or exogenous 
(cross-priming) peptides can vary in efficiency resulting in differences in the quality and magnitude of the 
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immune response(231).  If VRP cell targeting differentially affects the pathway of antigen presentation 
(endogenous vs. exogenous), T cell activation may vary directly affecting the quality of the immune 
response.  
 Another possible explanation of why our vaccine failed to generate an adequate immune response 
in senescent animals may involve intrinsic deficiencies of the aged immune system.  Functional anomalies 
in both antigen presenting cells (DCs) and effector cells are seen in the senescent immune system 
complicating the process of vaccination.  As the immune system ages, DCs become less efficient at antigen 
sampling by phagocytosis and pinocytosis and their ability to migrate also becomes impaired(7).  If the 
antigen presenting cell is compromised in its ability to migrate and present antigen, the generation of an 
adaptive immune response may be compromised.  Cytokine secretion (IL-2) and key surface receptor 
expression (CD40L, CD28) on CD4+ Th cells declines as the immune system ages(3, 75).  Appropriate and 
adequate cytokine secretion and surface receptor expression are required for efficient CD8+ T cell and B 
cell activation(75).  Moreover, thymic involution and oligoclonal expansion of memory cells in response to 
chronic antigen exposure decrease the numbers and complexity of naïve T cells in the periphery of aged 
individuals(75, 77, 215).  The complications of the senescent immune system have plagued successful 
influenza vaccination of the elderly where 17- 53 % of individuals are protected(64).  Several experimental 
adjuvants like MF59 and CpG DNA have been able to overcome the apparent deficiencies of the senescent 
immune system enhancing the efficacy of vaccination and may prove to be an invaluable tool in 
vaccination of senescent populations(83, 131).  Unfortunately, our preliminary data suggest that CpG 
delivered with VRP-GD03 does not enhance protection from rMA15 GD03-S infection in senescent 
animals(Data not shown).  Rather than enhance the immune response of inactivated vaccines with 
adjuvants, an alternative approach might be to develop live attenuated virus vaccines.  
 Effective SARS-CoV vaccines should protect against future emergence of zoonotic strains and be 
effective in the immune senescent. We have developed a senescent mouse model of SARS-CoV disease 
and mortality using a mouse adapted SARS-CoV bearing a zoonotic GD03 S glycoprotein.  Vaccination of 
senescent BALB/c mice with VRP vectors expressing epidemic strain Urbani-S, GD03-S, SZ16-S or a pool 
of all three S expressing vaccines (Pool-S) did not protect against morbidity and provided variable 
protection against mortality.  Serum antibody specific for  GD03 S predicted survival in the GD03-S, Pool-
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S and Urbani-S groups suggesting that cross reactive epitopes exist between these antigen groups.  We 
postulate that the apparent failure to successfully vaccinate senescent mice might be due to either intrinsic 
vaccine or senescent immune factors or a complex mixture of the two.  
 115 
 
 
Figure 1: rMA15 GD03-S grows with slightly delayed kinetics as compared to rMA15 and icSARS in 
Vero E6 cells..  Vero E6 cells were infected at an MOI of 0.01 with rMA15, icSARS, or rMA15 GD03-S 
for 1hr at 37˚C after which monolayers were rinsed with DPBS and growth media was added. At various 
times post infection, cell media was sampled and frozen at -80˚C until titered by plaque assay on Vero E6 
cells.   
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Figure 2: Age is a critical factor in determining mortality in BALB/c mice infected with rMA15 
GD03-S. Ketamine anaesthetized 10wk (n = 10/virus) or 12 month old BALB/c (n = 6/virus) mice were 
infected with 105pfu/50µl of rMA15 or rMA15 GD03-S after which clinical signs of disease (weight) were 
monitored every dpi.  Animals found dead or that were at or below 80% of starting weight were sacrificed 
due to IACUC protocol. On days 2 and 4 post infection, groups of animals were sacrificed and lungs were 
removed for histology and virus lung titer. For virus titer, lungs were homogenized, clarified by 
centrifugation, and virus titer within lung supernatants were assessed via plaque assay in Vero E6 cells. (A) 
Percent weight loss, percent mortality and virus lung titer data for young mice. (B) Percent weight loss, 
percent mortality and virus lung titer data for old mice. 
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Figure 3: Morbidity and mortality is seen in all experimental groups of VRP vaccinated 15 month old 
rMA15 GD03-S challenged BALB/c mice. 12 month old Harlan Sprague Dawley (Indianapolis, IN) were 
vaccinated with 106 infectious units (IU)/10µl of either HA, SARS-S, GD03-S, SZ16-S VRP or a Pool of 
SARS S containing VRPs (Pool-S) in the left rear footpad.  At 13 months of age, mice received a secondary 
vaccination of equal dose and identity of their primary vaccination.  At 15 months of age, mice were 
infected with 105pfu/50µl rMA15 GD03-S. Mice were monitored for clinical signs (weight) every dpi. (A) 
Percent starting weight. (B) Percent Survival. (C) virus lung titer 2 dpi. 
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Figure 4: Virus lung titers are similar in all vaccinated groups 2 dpi.  To assess the degree of protection 
from replication, virus lung titers were assess in 3 mice per group on 2dpi.  Mean levels of replication are 
similar in each group. 
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Figure 5: Levels of GD03-S specific IgG predict mortality in post boost sera. Three weeks post primary 
vaccination and 8 weeks post boost, animals were bled and to assess SARS S specific serum IgG by 
ELISA. Plates were coated with Urbani S, GD03-S, SZ16-S or HA antigen and post prime or post boost 
serum samples were added as primary sera in ELISA. The average of background values were subtracted 
from all of the OD readings, and these adjusted OD values were plotted for each serum sample versus  the 
log10 of the serum dilution A sigmoidal curve is then fit to these values using regression analysis and the 
half-max titer of that sample is derived: the serum dilution at which the OD is exactly half of the plateau 
maximum value. (A) VRP-Urbani vaccine group responses (B) VRP-SZ16 vaccine group responses (C) 
VRP-GD03 vaccine group responses (D) VRP-Pool vaccine group responses (E) VRP-HA vaccine group 
responses (F) GD03-S specific IgG titers in animals that were protected and not protected from mortality. 
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Figure 6: Very low neutralization titers are needed to protect senescent animals from mortality. The 
percent neutralization for post boost serum samples was determined by a microneutralization assay as 
previously described.  Briefly, sera was serially diluted in two fold increments beginning at 1:25 and then 
mixed with 100pfu of rMA15-GD03 and incubated for 1hr at 37˚C.  Virus and sera was then added to a 96-
well plate of Vero E6 cells (5 x 103 Vero E6/well). Each dilution of sera was plated in triplicate.  Wells 
were then assessed for the development of CPE at 4 to 5 days post infection. For each dilution of sera, the 
number of wells protected from CPE were scored.  The greatest dilution of sera with more than 2 wells of 
protection is the 50% neutralization titer. 
 
 
 
  
 
Chapter VI 
CONCLUSION 
 
Through the study of viral pathogenesis, the mechanisms of disease can be elucidated providing 
specific targets for therapeutic intervention intended to prevent the development of disease.  We conducted 
four studies to gain a better understanding of SARS-CoV disease pathogenesis and therapeutic design.  
First, we two conducted studies to investigate SARS-CoV evolution and adaptation to the human host.  
Since efficient infection of a given host is necessary for virus propagation and the presentation of disease, 
host range expansion towards infection of a new host are integrative components of emerging disease 
pathogenesis.  Second, we have investigated the importance of innate immune adaptor protein (MyD88) 
signaling in protection from SARS-CoV disease.  Within a C57BL/6 model of SARS-CoV pathogenesis, 
we demonstrated that MyD88 is required for protection from lethal infection by recombinant mouse 
adapted SARS-CoV (rMA15).  Infection of mice deficient in MyD88 with rMA15 resulted in a delay in the 
lung inflammatory response (i.e. deficient cytokine response, delay in macrophage recruitment) ultimately 
resulting in mortality.  Lastly, we evaluated the protective efficacy of VRP vaccination in senescent mice 
challenged with a recombinant mouse adapted virus bearing a zoonotic GD03 S glycoprotein (rMA15 
GD03-S).  In order to induce broad cross neutralizing antibody responses, we vaccinated mice with VRP 
expressing three antigenically diverse SARS S glycoproteins (Urbani-S, GD03-S or SZ16-S) or a mixture 
of all three (Pool-S).  VRP vaccination provided little protection from lethal rMA15 GD03-S infection. We 
postulate that the apparent failure to successfully vaccinate senescent mice might be due to either intrinsic 
vaccine or senescent immune factors or a complex mixture of the two. 
 The plasticity of SARS-CoV S in host range expansion and a putative mechanism of 
epidemic strain evolution. Despite initial reports that civet strains SZ16 and SZ3 could be propagated in 
cell culture, subsequent studies have indicated that these viruses could not be successfully maintained in 
culture thereby hampering our understanding of their pathogenicity  and mechanisms of cross species 
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transmission in humans. Within the past four years, multiple newly emerging coronaviruses of human 
relevance have been identified highlighting the emerging disease potential of the coronavirus family. 
Moreover, viruses related to the SARS-CoV epidemic strain have recently been found in Chinese horseshoe 
bats during surveillance of wild animals in Hong Kong and as such, there is the potential for yet another 
reemergence. Since it is impossible to predict the antigenic identity of future SARS virus emergents, the 
development of highly cross reactive antibody, drug or vaccination therapies would provide the greatest 
potential benefit to public health.  Employing a panel of all known zoonotic and human tropic SARS-CoV 
strains may provide the most thorough and pertinent evaluation of antiviral therapies.   
 The prototypic civet SZ16 spike (S) gene was engineered into our epidemic strain infectious clone 
(icSARS) to create the recombinant icSZ16-S virus which could not be maintained through passage in Vero 
E6 cell cultures.  In order to promote the growth of icSZ16-S in vitro, we introduced a single point 
mutation in the RBD (K479N) which allowed for inefficient growth of the resultant recombinant virus 
(icSZ16-S K479N) in Vero E6 cells and in human airway epithelial cells (HAE).  Due to the poor growth 
fitness of icSZ16-S K479N, we postulated that we might enhance growth fitness through passage in HAE.  
Moreover, we hypothesized that enhanced growth fitness through passage in HAE might be mediated by 
mutation in the S glycoprotein that enhanced receptor binding. After icSZ16-S K479N passage in HAE, 
resultant “evolved” viruses (icSZ16-S K479N D8 and D22) were mutated in S enhancing interactions with 
the receptor (hACE2) thereby increasing their growth fitness in HAE.  Interestingly, the “evolved” virus 
mutations in S differed from those seen during the evolution of the epidemic strain.  The in vitro growth 
analysis of the “evolved” viruses was supported by predictive structural models which suggested that 
mutations acquired through passage in HAE remodeled the RBD architecture enhancing interactions with 
ACE2. These data demonstrate the plasticity of the RBD contact interface and its affinity for subtle 
remodeling to promote efficient entry and growth.  Clearly, multiple genetic pathways likely exist to allow 
for zoonotic SARS-CoV host range expansion and it will be interesting to determine if other mutations 
within the contact interface can enhance zoonotic virus infection of HAE cultures. Moreover, it will be 
interesting to test the limits of this S plasticity through passage in HAE.  icSZ16-S K479N HAE passage 
experiments could be set up in parallel resulting in the isolation of several “evolved” viral clones.  Through 
sequencing of isolated evolved clones, we could elucidate the genetic pathways that result in enhanced 
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infection of HAE.  These pathways may be similar to those seen in the past or may be completely novel.  
Regardless of which outcome proves to be true, the resultant data regarding the degree of S plasticity in 
adaptation to the human host will be invaluable.  Also, if future zoonotic SARS-CoV passage experiments 
in HAE produce several antigenically unique isolates, these viruses could be utilized to assess passive 
immunization and vaccine efficacy in current in vitro and in vivo models.  Previously, we have 
demonstrated that the mutations acquired that enhance growth of zoonotic viruses in HAE simultaneously 
make them more susceptible to neutralization by human monoclonal antibody(hu-mAb) S230.15.  Similar 
experiments could be performed with new in vitro evolved zoonotic SARS-CoV to assess their 
susceptibility to neutralization by hu-mAb.  Since it is impossible to predict the antigenic identity of future 
SARS-CoV like emergents, a panel of experimentally evolved zoonotic SARS-CoV could serve as a 
surrogate and provide insight in the potential protective efficacy of current passive immunization and 
vaccination therapies.   
 The prototypic civet epidemic strain of SARS-CoV, SZ16, was isolated from a palm civet but has 
not been successfully cultured in vitro. To promote the in vitro growth of the wild type icSZ16-S virus, we 
constructed cell lines expressing the civet ortholog (DBT-cACE2) of the SARS-CoV receptor (hACE2). 
Within in vitro growth assays, we demonstrated that SARS Urbani grows with similar kinetics in both 
DBT-cACE2 and DBT-hACE2 cells while icSZ16-S only grows within DBT-cACE2 cells. Within 
predictive structure models, we provide a structural explanation as to why the epidemic strain has retained 
dual species tropism.  Interestingly, in vitro “evolved” SZ16 S mutant viruses (icSZ16-S K479N and D22) 
with enhanced affinity for hACE2 exhibited severe growth defects in DBT-cACE2 cells suggesting that 
their mutational spectra promoting efficient hACE2 interactions, simultaneously abolished efficient 
interactions with cACE2. These data suggest that zoonotic viruses that evolved to more efficiently infect 
human cells in the absence of cACE2 lost their ability to efficient bind their native host receptor. It is 
hypothesized that zoonotic SARS Coronavirus (SARS-CoV) likely evolved to infect humans by a series of 
transmission events between humans and animals for sale in markets in China. Since dual species tropism 
is retained by the epidemic strain, it is likely that the 2003 epidemic virus retained high affinity interactions 
with cACE2/hACE2 receptors by evolving through repeated passage between human and civet hosts. This 
hypothesis is supported by serological surveys in Guangdong province in China where of SARS-CoV 
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specific IgG was found in animal traders (13%, n= 508), hospital workers (2.9% , n = 137), Guangdong 
CDC workers (1.6%, n = 63, and healthy adults at the clinic (1.2%, n = 84).  None of the subjects tested 
presented with symptomatic SARS.  If the subjects within the serological survey represent the population 
of Guangdong (est. population 100,000,000), there may have been many more subclinical cases of SARS-
CoV prior to the evolution of the more virulent human adaptive strains. These data are supported by other 
retrospective serological surveys in China which suggest that less serious or asymptomatic cases of SARS-
CoV existed at least 2 years prior to the beginning of the epidemic in various geographical locations in 
China.  Importantly, we demonstrated that icSZ16-S is susceptible to neutralization by hu-mAb S230.15 
providing further evidence of its efficacy and utility as a passive immunization therapy. We have also 
demonstrated that both icGD03-S and icSZ16-S are more resistant to S3.1 highlighting the utility of using 
an antigenically diverse SARS-CoV panel to assess sero therapy efficacy. The icSZ16-S virus is yet 
another antigenically divergent zoonotic S bearing SARS-CoV that will prove useful in evaluating future 
sero or vaccination therapies. 
 The innate immune response in SARS-CoV infection. The clinical course of SARS-CoV 
disease in humans is characterized by fever, non-productive cough, and malaise culminating in lung 
infiltrates visible by x-ray and an atypical pneumonia.  Immunologically, SARS-CoV infection of humans 
generates a cytokine storm where elevated levels of IP-10, MIP1-α, and MCP-1 are detected within the 
blood.  Histological examination of lung tissue in terminal SARS-CoV cases revealed SARS antigen within 
macrophages in the lung suggesting a role for these cells in SARS-CoV pathogenesis. Though clinical and 
epidemiological data from the epidemic and reemergence has provided insight into the molecular 
pathogenesis of SARS-CoV, thorough studies of virus and host interactions have been hampered by the 
lack of animal models that fully recapitulate human disease.  C57BL/6 mice infected with the epidemic 
strain, SARS Urbani, do not show any overt signs of disease but there is virus replication in the lung 
(107TCID50/g 3dpi), induction of MIP1α/MCP-1 and viral clearance even in the absence of T, B and NK 
cells suggesting that innate immunity alone is required for protection within this acute model of SARS-
CoV replication.  MA15 is a mouse adapted SARS-CoV strain that was generated by fifteen serial passages 
of the epidemic strain, SARS Urbani, in the lungs of BALB/c mice.  Infection of young or senescent 
BALB/c mice with either MA15 or recombinant MA15 (rMA15) results in high virus titers in the lung, 
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pulmonary pathology and mortality similar to those seen in severe and acute human cases of SARS-CoV 
disease. Toll-like receptors (TLRs) are cellular receptors that recognize molecular signatures of pathogens 
and initiate an inflammatory signaling cascade that is key to the innate immune response.  Myeloid 
differentiation primary response gene 88 (Myd88) is key adaptor protein within the inflammatory signaling 
pathways of most all TLRs as well as IL-1R, IL-18R and INFγR1. In animal models of viral pathogenesis, 
Myd88 signaling has been shown to be protective oftentimes providing instructions to innate immune cells 
shown to be important for viral clearance.  The role of Myd88 signaling in SARS-CoV pathogenesis has 
not yet been described. 
 We have demonstrated that mice deficient in MyD88 (MyD88-/-), an adapter protein that mediates 
Toll-like receptor (TLR), IL-1R, and IL-18R signaling, are far more susceptible to mouse adapted SARS-
CoV (rMA15) infection.  We find overwhelming evidence that suggests that mice deficient in Myd88 are 
unable to control virus replication early within the course of infection.  Compared to WT mice, virus titers 
are elevated in Myd88-/- mice at early times post infection and remain elevated until virus induced death.  
Despite increased viral loads, the expression of multiple proinflammatory cytokine and chemokine (e.g. 
MIP1α and MCP-1) genes within lung tissue was significantly reduced in MyD88-/- mice compared to 
wild-type mice. The recruitment of inflammatory monocytes into the infected lungs of WT mice is 
coincident with a reduction of virus replication as seen by in situ hybridization. The recruitment of these 
cells is severely delayed in MyD88-/- mice suggesting that MyD88-mediated innate immune signaling and 
inflammatory cell recruitment to the lung are required for protection from lethal rMA15 infection.   
 To further understand the  mechanism of MyD88-mediated protection in rMA15 infection of 
C57BL/6 mice, the molecules mediating the induction of the initial inflammatory response to virus 
infection should be elucidated.  We hypothesize that early inflammatory signaling events in WT mice 
recruit inflammatory macrophages to the lung resulting in a control of virus replication and survival.  To 
this end, we first set out to determine the contribution of alveolar macrophages in the recruitment of the 
inflammatory macrophages we hypothesize are important in controlling virus replication.  The depletion of 
alveolar macrophages did not affect the kinetics or magnitude of inflammatory macrophage recruitment 
during rMA15 infection of WT mice. These data suggest that alveolar macrophages are probably not the 
sentinel in the lung which initiate the inflammatory signaling cascade that ultimately controls virus 
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replication.  An alternative approach may be to create bone marrow chimeras between WT and MyD88-/- 
mice. By lethal irradiation, myeloid cells are depleted from WT and MyD88-/- mice and mice are 
subsequently injected with bone marrow cells (BM) derived from either WT or MyD88-/- mice creating WT 
and MyD88-/- mice that have been repopulated with either WT or MyD88-/- derived BM.  Infection of these 
bone marrow chimeras will allow us to deduce if myeloid or non-myeloid cells (i.e. ciliated epithelial cells 
in the lung) initiate the protective signal during rMA15 infection of WT mice.  If myeloid cells are the 
sentinel in the lung that signal through MyD88 to promote protection of WT mice, MyD88-/- mice 
repopulated with WT derived BM should survive the infection similar to WT mice.  If non-myeloid cells 
are the functional sentinel in the lung that promote protective MyD88 mediated inflammatory signaling 
events, WT mice repopulated with MyD88-/- derived BM infected with rMA15 should phenotypically look 
like WT mice. 
 MyD88 is a key signaling adaptor protein for most all TLRs, IL-1R, IL-18R and INFγ-R1.  As 
such, we will infect TLR, IL-1R, IL-18R and INFγR1deficient mice in hopes of recapitulating the MyD88 
phenotype.  Our preliminary data suggests that infection of IL-1R-/- and IL-18R-/- mice fail to reproduce the 
MyD88 phenotype suggesting that IL1-R and IL18-R signaling through MyD88 does not provide the 
protective signal during rMA15 infection.  Several TLR and intracellular PRRs have been shown to 
recognize viral RNA (TLR7, TLR8, RIG-I, MDA-5) and infection of mice deficient in these PRRs may 
demonstrate a MyD88-/- like phenotype.  If we are able to demonstrate a MyD88-/- like phenotype through 
the infection PRR deficient mice, it would suggest that that the PRR is responsible for the recognition of 
SARS-CoV and its signaling through MyD88 is protective during rMA15 infection of WT mice. 
 Viral pathogenesis is a complex process where the virus and host engage in a unintended 
collaboration to generate the clinical presentation of disease.  Being a newly emerged infectious disease, 
the pathogenic mechanisms of SARS-CoV disease remain unknown.  We have developed a mouse model 
of acute non-severe SARS-CoV pathogenesis characterized by a high titer virus replication in the lung 
followed by a robust innate immune response resulting in the recruitment of inflammatory macrophages to 
the lung that mostly likely responsible for viral clearance and convalescence.   We also demonstrate a key 
role for MyD88 dependent signaling events and associated inflammation/cell recruitment that serves to 
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protect WT mice from death while Myd88-/- mice succumb to infection.  These data suggest an important 
role for innate immunity in the control of SARS-CoV and prevention of virus induced mortality. 
 Models of age related susceptibility to SARS-CoV and vaccine efficacy in senescent 
populations. SARS-CoV disease is characterized by an atypical pneumonia where approximately 20% of 
cases progressed to acute respiratory distress syndrome (ARDS) requiring mechanical ventilation. The 
disease severity associated with SARS-CoV infection of humans was directly linked to increasing age with 
mortality rates exceeding 50% in people over 65 years of age. The successful vaccination of elderly 
populations is a difficult task due to the immunosenescence associated with ageing.  Current models predict 
that influenza vaccine efficacy in elderly populations ranges from 17-53% while the vaccine in young 
adults is 70-90% effective. Since influenza, West Nile Virus and SARS-CoV infection all produce a 
disproportionate amount of disease burden in the elderly, the development of robust model systems for the 
design of successful vaccine strategies in the elderly has a broad public health application especially given 
the increasing age of global human populations.  Besides vaccination of immune senescent populations, 
vaccine induced immunopotentiation of disease and antigen selection complicate the development of 
successful and safe SARS-CoV vaccines.   
 The successful vaccination of elderly populations is a difficult and unpredictable task due to 
immunosenescence with ageing and robust models are needed to evaluate and improve vaccines targeting 
infections that cause a disproportionate disease burden in the elderly. A mouse adapted SARS-CoV was 
created (MA15) through repeated passage of SARS Urbani in BALB/c mice.  We then constructed a 
molecular clone of MA15 (rMA15 ) by introducing the six amino acid changes found in MA15 into the 
infectious clone for SARS Urbani (icSARS).  When administered intranasally to young BALB/c mice, 
rMA15  causes significant weight loss by 4 days post infection (dpi) (~20 % of starting weight) infection is 
uniformly lethal by 5 dpi.  Infection of young adult mice with a recombinant mouse adapted SARS-CoV 
bearing a GD03 S glycoprotein (rMA15 GD03-S) attenuates the rMA15 lethal phenotype but rMA15 
GD03-S infection of senescent mice is uniformly lethal.  The age related mortality seen in BALB/c mice 
infected with rMA15 GD03-S mirrors the age related trends in SARS-CoV disease severity making it an 
attractive model within which to study age related susceptibility to SARS-CoV.  Future efforts will 
characterize the differences seen in infection of young adult and senescent BALB/c with rMA15 GD03-S.  
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Initially, a comprehensive evaluation of virus growth kinetics will be performed in order to elucidate the 
magnitude and spread of virus throughout the course infection of young and senescent animals.  Since 
previous experiments focused on virus replication and host pathology on 2 and 4 dpi, lungs of infected 
mice in future experiments will be harvested for virus titer, q-PCR, pathology and in situ hybridization 
every 24 hours post infection until senescent animals succumb to infection (~5 dpi).  These data will allow 
for the assessment of virus titer/spread, inflammatory gene transcription, and pathology in young and 
senescent mice.  Since rMA15 GD03-S lung titers in senescent mice are approximately one log greater than 
those in young mice on 2 dpi, the assessment of inflammatory gene transcription may suggest a defect in 
innate immune sensing rendering the aged mice less capable of controlling virus replication which 
ultimately results in their demise.  As we had done for our MyD88 experiments, we will also assess the 
kinetics of inflammatory cell recruitment in young and old mice infected with rMA15 GD03-S.  These data 
will allow us to determine if senescent mice are defective in inflammatory cell recruitment to the lung 
which may be necessary for protection in young mice.   
 Regardless of the mechanism of susceptibility in the aged mice, the rMA15 GD03-S BALB/c 
model of age related pathogenesis is a relevant model within which to study vaccine efficacy.  Inactivated 
whole virus and vectored SARS-CoV vaccine trials in a number of different animals models have 
demonstrated that the SARS-CoV spike glycoprotein (S) is the critical component of protective immunity 
and the passive transfer of SARS-CoV S specific sera and select human monoclonal antibodies is sufficient 
to provide protection from lethal and nonlethal infection by a homologous and select heterologous SARS-
CoV strains.  Since the epidemic strain may not exist in nature, vaccination with epidemic strain antigens 
followed by challenge with the epidemic strain may represent a biologically irrelevant design.  
Unfortunately, a difficult choice is presented in choosing SARS-CoV vaccine antigens in hopes of 
preventing disease by future emergents whose antigenic identity is unknown. Therefore, employing an 
antigenically diverse panel SARS-CoV antigens for vaccination coupled with the use of an similarly 
diverse lethal challenge virus panel may represent the most pertinent and relevant strategy to assess vaccine 
efficacy.  In 2003, Deming et al demonstrated that Venezuelan equine encephalitis virus replicon particles 
expressing SARS Urbani S (VRP-S) vaccine provided complete protection in young mice from replication 
of a SARS-CoV bearing a zoonotic heterologous GD03 S but protection was variable in senescent mice. 
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Due to the lack of significant morbidity and mortality in the SARS-CoV replication models, previous 
vaccine studies were unable to assess protection from disease or death and could only speculate that 
diminishing virus replication might result in reduced disease severity. We vaccinated senescent mice with 
Venezuelan equine encephalitis virus replicon particles (VRP) expressing Urbani-S, GD03-S, SZ16-S, a 
pool of all three S expressing VRPs  or control VRPs in a prime/boost regimen and all mice were 
subsequently infected with rMA15 GD03-S. Our antigenically diverse SARS S expressing VRP panel 
coupled with our lethal rMA15 GD03-S challenge virus allowed us to assess the efficacy of immune 
responses to both homologous (VRP GD03-S) and heterologous (VRP Urbani-S and VRP SZ16-S) 
antigens. Upon challenge with the rMA15 GD03-S, all groups demonstrated significant morbidity losing 
more than 20% of starting weight by 5 dpi.  Assessing protection from mortality, the HA and SZ16 groups 
uniformly succumbed to infection, the Urbani-S group demonstrated little protection from mortality while 
groups that received the homologous antigen demonstrated the most protection (GD03-S 29%, Pool-S 33% 
survival).  These data suggest that vaccination of senescent animals with VRP expressing antigens similar 
to the challenge virus provides the most protection. Through serological evaluation of post-boost sera from 
vaccinated mice, we deduced that levels of GD03-S specific sera predicted mortality.  Though our study 
outcome was not ideal, it provided us with a senescent animal vaccination and challenge model with much 
room for improvement.   
 Perhaps the most attractive aspect of viral vectored vaccine technology is that the same vaccine 
platform can be utilized to deliver a wide array of vaccine antigens. In theory, the same vector platform 
could be harnessed to deliver Influenza, SARS-CoV, or West Nile virus vaccine antigens.  Therefore, 
improving VRP efficacy in senescent animals could potentially lead to the development of successful 
vaccination strategies for multiple pathogens with disproportionate disease in the elderly.  To this end, 
future experiments will focus on increasing the protective efficacy of VRP vaccines in senescent mouse 
models.  Previous pilot experiments suggest that delivering the TLR agonist, CpG DNA, with the VRP 
GD03-S vaccine does not improve its protective efficacy with rMA15 GD03-S challenge. Rather than 
enhance vaccine efficacy through supplemental adjuvants like CpG DNA, we looked for alternative means 
of improving vaccine efficacy in the immune senescent.  This led us to hypothesize that the VEE 
glycoproteins coating the VRP vaccine may influence the quality of the immune response.  Since the VEE 
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structural genes are replaced by a transgene of interest within VRP genomes, VEE structural genes 
provided in trans to “package” the replicon RNA and various VEE structural proteins can be utilized to 
enhance vector attenuation and safety. While WT recombinant VEE V3000 infection is uniformly lethal in 
mice, VEE clones V3010, V3014, and V3533 are mutated in their viral glycoproteins and are completely 
attenuated in mice with all mice surviving infection.  A VRP packaged with wild-type VEE V3000 
glycoproteins is targeted to the professional antigen presenting dendritic cell (DC) while the attenuated 
V3014 was found to have enhanced binding of heparan sulfate altering DC targeting/spread.  These data 
suggest that the alteration of the VRP coat can have profound effects on cell targeting which may affect the 
efficiency of antigen presentation and the resultant immune response.  On their major histocompatibility 
complexes (MHC), DCs can present endogenous (i.e. peptides from within the infected cell) or exogenous 
(peptides acquired from phagocytosis) antigen to prime cognate T cells for activation. DC priming of T 
cells using endogenous or exogenous (cross-priming) peptides can vary in efficiency resulting in 
differences in the quality and magnitude of the immune response.  If VRP cell targeting differentially 
affects the pathway of antigen presentation (endogenous vs. exogenous), T cell activation may vary directly 
affecting the quality of the immune response. To address these concerns, we will vaccinate young adult and 
senescent mice with VRP GD03-S or influenza HA that have been packaged with either V3000 or V3014 
glycoproteins.  Post prime and boost sera will be harvested for to assess the magnitude of the SARS and 
HA specific antibody responses prior to challenge.  Mice will receive a lethal rMA15 or rMA15 GD03-S 
challenge which will allow us to look at homologous and heterologous immune protection.  Though 
infection of young mice with rMA15 GD03-S is not lethal, animals do experience a significant weight loss 
and this will be our metric in assessing protection.  Young animals vaccinated with HA should succumb to 
infection by rMA15 while rMA15 GD03-S infection will most likely experience weight loss and recover.  
Differences in morbidity or mortality between V3000 and V3014 vaccine groups would suggest that the 
VEE glycoproteins affect the quality of the immune response. If we are capable of increasing the efficacy 
of VRP vaccination in senescent populations, this improved vaccine platform technology might be adapted 
to develop vaccines for other disease with disproportionate disease in the elderly like influenza and West 
Nile virus. 
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 SARS-CoV pathogenesis is a complex process whose underlying mechanisms are not fully 
understood. Through the study of viral pathogenesis, the mechanisms of disease can be elucidated 
providing specific targets for therapeutic intervention intended to prevent the development of disease.  We 
have developed models for various aspects of SARS-CoV pathogenesis including virus evolution and host 
range expansion, innate immune regulation to protect from lethal disease, and age-related susceptibility to 
lethal disease.  Within these robust models of SARS-CoV pathogenesis, we assessed the protective efficacy 
of both passive immunization therapies and vaccination.  The models and molecular tools developed for 
this work will hopefully continue to advance the study of SARS-CoV pathogenesis and therapeutic design.  
Moreover, the improvement of platform vaccine technologies in senescent populations may promote the 
development of effective vaccines to treat multiple diseases currently causing disproportionate disease 
burdens in the elderly.   
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